<?xml version="1.0"?>


<!DOCTYPE Ontology [
    <!ENTITY xsd "http://www.w3.org/2001/XMLSchema#" >
    <!ENTITY xml "http://www.w3.org/XML/1998/namespace" >
    <!ENTITY rdfs "http://www.w3.org/2000/01/rdf-schema#" >
    <!ENTITY rdf "http://www.w3.org/1999/02/22-rdf-syntax-ns#" >
]>


<Ontology xmlns="http://www.w3.org/2002/07/owl#"
     xml:base="http://www.semanticweb.org/ontologies/2011/1/Ontology1296772722296.owl"
     xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
     xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:xml="http://www.w3.org/XML/1998/namespace"
     ontologyIRI="http://www.semanticweb.org/ontologies/2011/1/Ontology1296772722296.owl">
    <Prefix name="" IRI="http://www.semanticweb.org/ontologies/2011/1/Ontology1296772722296.owl#"/>
    <Prefix name="cre" IRI="http://www.semanticweb.org/ontologies/2011/1/Ontology1296772722296.owl#Slc6a3tm1(cre)"/>
    <Prefix name="owl" IRI="http://www.w3.org/2002/07/owl#"/>
    <Prefix name="rdf" IRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#"/>
    <Prefix name="xsd" IRI="http://www.w3.org/2001/XMLSchema#"/>
    <Prefix name="SNCA" IRI="http://www.semanticweb.org/ontologies/2011/1/Ontology1296772722296.owl#Gt(ROSA)26Sortm2(SNCA*119)"/>
    <Prefix name="rdfs" IRI="http://www.w3.org/2000/01/rdf-schema#"/>
    <Prefix name="owl2xml" IRI="http://www.w3.org/2006/12/owl2-xml#"/>
    <Prefix name="Ontology1296772722296" IRI="http://www.semanticweb.org/ontologies/2011/1/Ontology1296772722296.owl#"/>
    <Prefix name="Ontology12967727222962" IRI="http://www.semanticweb.org/ontologies/2011/1/Ontology1296772722296.owl#6-"/>
    <Declaration>
        <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Budipine"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#COMT_inhibitors"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Camptocormia"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Cinnerzin"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Constipation"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Depression"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Dopamine"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Dopamine_dysregulation_syndrome"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Emerging_etiology"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#End_of_dose"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Epidemiological_history"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Epigenetics"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Festination"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Fluctuation"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Flunarizin"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Hallucination"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Hereditary_forms_of_PD"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Hit_and_run_viral_infection"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#IPS_derived_model"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Incontinence"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Inflammation"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Lactacysteime"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Leaky_gut"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Lewy_body_dementia"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#MAO_inhibitors"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Memantine"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Models_of_Parkinson&apos;s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Mucuna_pruriens"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#NSAID"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Orthostatic_dysregulation"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#PANDA"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Pick&apos;s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Pisa-syndrome"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Protective_effect_of_nicotine_or_smoke"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Qigong"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Random_on_off"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Reserpin"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Sexual_dysfunction"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Smoke"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Solvent_exposure"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Surgical_therapy"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Synaptic_pathology"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Taichi"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Tetrabenazine"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Urinary_dysfunction"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Valproec_acid"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://protegeuserexample#Wearing_off"/>
    </Declaration>
    <Declaration>
        <Class IRI="#19-item_Wearing-off_Questionnaire"/>
    </Declaration>
    <Declaration>
        <Class IRI="#32-item_Wearing-off_Questionnaire"/>
    </Declaration>
    <Declaration>
        <Class IRI="#6-OHDA_model"/>
    </Declaration>
    <Declaration>
        <Class IRI="#9-item_Wearing-off_Questionnaire"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Abnormal_circadian_rhythm"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Abnormal_involuntary_movement_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Acquired_metabolic_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Action_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Adcy5tm1Yish"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Adh7tm1Gdu"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Adult_onset_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Aggregation_of_alpha-synuclein"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Aggregation_of_tau_protein"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Agraphia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Akathisia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Akinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Alcohol_consumption"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Alexander_technique"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Alpha-synuclein"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Alpha_synuclein_index"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Altered_tear_film"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Amyloid-beta"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Anal_sphincter_EMG"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Anhedonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Anismus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Anosmia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Anxiety"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Apathy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Apomorphine_test"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Apraxia_of_eyelid_opening"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Archimedes_spiral"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Arm_dystonia_disability_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Assistive_devices_for_gait"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Autonomic_dysfunction"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Autosomal_recessive_forms_of_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Autosomal_recessive_juvenile_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Axial_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#BDNF"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Beginning-of-dose_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Berg_balance_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Biophysical_biomarkers_of_Parkinson&apos;s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Blepharospasm"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Blood_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Bmpr1atm1Bhr"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Bmpr1atm2.1Bhr"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Body_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Borreliosis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Botulinum_toxin_A"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Botulinum_toxin_B"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Braak_staging_scheme_for_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Brachial_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Bradykinesia_symptom"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Bradyphrenia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Burning_sensation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#C-raclopride_PET"/>
    </Declaration>
    <Declaration>
        <Class IRI="#C._elegans_model_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#CSF_alpha_synuclein"/>
    </Declaration>
    <Declaration>
        <Class IRI="#CSF_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#CSF_osteopontin"/>
    </Declaration>
    <Declaration>
        <Class IRI="#CSM14.1"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Caffeine"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Caffeine_intake"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cancer"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Carbon_disulphide"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Carbon_monoxide-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cardiac_sympathetic_innervation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cell_therapy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Central_conduction_time"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Central_surgery"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Centralized_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Charnoly_body"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Chemodenervation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Childhood_onset_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Chlorpromazine-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cigarette_smoking"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Classical_essential_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Clinical_dyskinesia_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Clinical_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Clozapine_add-on"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Coenzyme_Q10"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cognitive_abnormality"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Columbia_university_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Communicating_hydrocephalus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Compulsive_foraging"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Compulsive_shopping"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Constipation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Continual_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Continuous_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Convergence_abnormality"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Core_assessment_program_for_intracerebral_transplantation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Core_assessment_program_for_surgical_interventional_therapies_in_Parkinsons_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cortical_excitability"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Corticobasal_degeneration"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Coxackie_B_virus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cranial_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Craving"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Creatine"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Criteria_for_definite_PD"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Criteria_for_possible_PD"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Criteria_for_probable_PD"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Crural_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cryprococcus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cyanide-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cyanide_poisoning"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cycle_ergometry"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Cytokines"/>
    </Declaration>
    <Declaration>
        <Class IRI="#DJ-1_concentration_in_CSF"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Daytime_sleepiness"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Deacreased_blink_rate"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Deafness"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Deep_brain_stimulation_for_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Delayed_gastric_emptying"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Delusion"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dementia_with_pallido-ponto-nigral_degeneration"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Depression"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Destination_hesitation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Diablotm1Mak"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Diagnosis_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Differential_diagnosis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Diffuse_pain"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Diphasic_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Donezepil_as_add-on_treatment"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dopamine_deficiency"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dopaminergic_cell_lines"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Drd2tm1Ebo"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Drd2tm1Low"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Drooling"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Drug-induced_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dysarthria"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dysexecutive_syndrome"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dysphagia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Dystonic_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000062"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000063"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000064"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000065"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000066"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000067"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000068"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000069"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000070"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000071"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000072"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000073"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000074"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000075"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000077"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000078"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000079"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000080"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000081"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000082"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000085"/>
    </Declaration>
    <Declaration>
        <Class IRI="#EPO_00000086"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Early-onset_Parkinson_s_disease_"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ecstasy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Electromyography_of_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#En1tm1Gld"/>
    </Declaration>
    <Declaration>
        <Class IRI="#En2tm1Alj"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Encephalitis_lethargica"/>
    </Declaration>
    <Declaration>
        <Class IRI="#End-of-dose_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Environmental_risk_factor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Epstein-Barr_virus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Epworth_sleepiness_sclae"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Essential_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Excessive_sweating"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Exertion-induced_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Exposure_to_copper"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Exposure_to_farming"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Exposure_to_herbicide"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Exposure_to_manganese"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Exposure_to_pesticide"/>
    </Declaration>
    <Declaration>
        <Class IRI="#F-dopa_PET"/>
    </Declaration>
    <Declaration>
        <Class IRI="#FDG_PET"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Fahn-Marsden_dystonia_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Fall_risk_factor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Falling"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Falls"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Familial_neurodegenerative_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Family_history_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Fat_intake"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Fatigue_Severity_Inventory"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Fatty_acid_intake"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ferritin"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Fluctuating_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Focal_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Foot_drag"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Foot_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Four-legged_cane"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Four-wheeled_walking_stabilizer"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Freezing"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Frequency_of_abnormal_movements_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Frontotemporal_dementia_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#GM-1_ganglioside"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Gait_disturbance"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Gastrointestinal_dysfunction"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Genetic_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Genetic_cause_of_parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Genetic_models_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Genital_pain"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Genomic_biomarker_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Glutathione"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Glycomic_biomarker_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Glyphosate_herbicide"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Graphic_tablet_analysis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Group_A_feature"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Group_B_feature"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Gt(ROSA)26Sortm2(SNCA*119)Djmo"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Guamanian_parkinsonism-dementia-ALS"/>
    </Declaration>
    <Declaration>
        <Class IRI="#HIV_encephalopathy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#H_magnetic_resonance_spectroscopy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Halogen"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Haloperidol-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Haloperidol_model"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hamilton_depression_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Head_trauma"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Heart_beat_frequency_modulation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hemiatrophy-hemiparkinsonism_syndrome"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Heroin_pyrolysate"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hesitation_in_tight_quarters"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hoehn_and_Yahr_stage_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Home_diaries"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hopkins_motor_and_vocal_tic_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hospital_anxiety_and_depression_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Htra2tm1Jdo"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Human_afult_stem_cell-based_therapy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Human_embryonic_stem_cell-based_therapy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Huntington_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hydrocephalus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hypersexuality"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hypnogenic_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hypoguesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hypokinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hypomimia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hypophonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Hypoxia-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#I-β-CIT_SPECT"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Idiopathic_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Immortalized_cell_line"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Immunulogical_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Impaired_handwriting"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Impulsive_behaviour"/>
    </Declaration>
    <Declaration>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Inconsistence"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Inherited_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Inherited_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Intention_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Intermediate_scale_for_assessment_of_Parkinsons_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Intrathecal_baclofen"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Iron_accumulation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Isolated_chin_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Isolated_voice_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Isometric_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Japanese_B_encephalitis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Juvenile_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Kinesia_paradoxica"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Kinesigenic_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Kinesigenic_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Kinetic_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#L-shaped_cane"/>
    </Declaration>
    <Declaration>
        <Class IRI="#LPS_model"/>
    </Declaration>
    <Declaration>
        <Class IRI="#LSVT_BIG"/>
    </Declaration>
    <Declaration>
        <Class IRI="#LSVT_LOUD"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Laser_cane"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Late-onset_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Lee-Silverman_Voice_Treatment"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Leg_dystonia_disability_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Levodopa_test"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Lewy_body"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Limitation_of_upward_gaze"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Lipidomic_biomarker_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Long_term_recordings_of_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Loss_of_hearing"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Loss_of_postural_reflex"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Loss_of_smell"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Loss_of_urinarry_bladder_control"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MAOB"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MAPT"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MDS-UPDRS"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MESC2.10"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MIBG_scintigraphy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MN9D"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MPTP"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MPTP-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#MPTP_model"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Machado-Joseph_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Malaria"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Maneb"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Manganese"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Manganese-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mapk10tm1Flv"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mapk9tm1Flv"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Marti_and_Tolosa_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Medical_risk_factor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Melatonin"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mercury_poisoning"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Metabolic_biomarker_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Metallothionein"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Methanol"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Metoclopramide-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Micrographia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mini-mental_parkinson"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mitochondrial_DNA_mutation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mitochondrial_DNA_polymerase_gamma_mutation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mitochondrial_complex_I_deficiency"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Monoamines"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Monocycline"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Monogenic_forms_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Montgomery-Asberg_depression_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Morphological_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Motor_features"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Motor_testing"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Motorized_scooter"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mouse_models_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mucormycosis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Multidimensional_fatigue_inventory"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Multifocal_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Multiple_system_atrophy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Muscle_action_potential"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Muscle_rigidity"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Mycoplasma_pneumonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Myectomy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Needle_electromyography"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuralgic_pain"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuroacanthocytosis_syndrome"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuroleptic-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuromelanin"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuromelanin_Ab"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuropathology_of_parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neurophysiological_testing"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Neurorestorative_treatment"/>
    </Declaration>
    <Declaration>
        <Class IRI="#New_York_University_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Nicotine"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Nigral_glutathione_deficiency"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Nigrostriatal_dopaminergic_loss"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Nocturia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Non-kinesigenic_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Non-motor_features"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Nonkinesigenic_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Normal_pressure_hydrocephalus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Northwestern_University_disability_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Nr4a2tm1Omc"/>
    </Declaration>
    <Declaration>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Obeso_dyskinesia_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Obessive_behaviour"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Obstructive_hydrocephalus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Occular_saccade_impairment"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ocular_surface_irritation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Off-period_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Olfaction"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Olfactory_dysfunction"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Open_space_hesitation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ophthalmological_measures"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Oral_pain"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Organophosphate"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Organotypic_culture"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Organotypic_slice_culture"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Oromandibular_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Oromandibular_dystonia_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Other_essential_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK10_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK11_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK1_mutation_induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK2_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK3_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK4_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK5_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK6_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PARK8_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PC12"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PET_biomarker"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PET_imaging_biomarker"/>
    </Declaration>
    <Declaration>
        <Class IRI="#PINK7_mutation_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pallidal_stimulation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pallidotomy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Paraquat"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Paresthesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Park2tm1Ccs"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Park2tm1Roo"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Park2tm1Shn"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Park2tm1Tmd"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Park2tm1Ykt"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Park7tm1Cai"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Park7tm1Shn"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Park7tm1Xz"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkin"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkinson_disease_dyskinesia_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkinson_fatigue_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkinson_psychosis_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkinsoniam_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkinsons_disease_cognitive_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkinsons_disease_dementia-short_screen"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Parkinsons_disease_questionnaire-39"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Paroxymal_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Paroxysmal_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pathological_gambling"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Peak_dose_dyskinesia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Peripheral_surgery"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Persistent_depression"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Physiological_biomarkers_od_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pink1tm1Aub"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pink1tm1Shn"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pittsburgh_sleep_quality_index"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Plasma_homocysteine"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Platelet_complex-1_activity"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Poliomyelitis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Polysomnography"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Position-specific_postural_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Position_specific_writing"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Post-traumatic_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Postencephalic_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Postural_instability"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Postural_irregularity"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Postural_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Power_wheelchair"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pramipexole"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Primary_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Primary_immature_dopaminergic_neuron"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Primary_midbrain_culture"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Primary_orthostatic_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Primary_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Primary_writing_tremot"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Prochlorperazine-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Progressive_pallidal_atrophy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Progressive_supranuclear_palsy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Promethazine-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Proteinopathy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Proteomic_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Psychosis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ptstm1Ich"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pulsion"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Punding"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Pyridoxal_kinase"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Quantitative_tremor_analysis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ramisectomy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Rapid-onset_dystonia-parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Rapid_eye_movement_sleep_behaviour_disorder"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Recessive_early-onset_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Reduced_CSF_gluthatione-SH"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Reserpine_model"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Rest_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Resting_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Restless_legs_syndrome"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Retropulsion"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Rigidity"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Risk_factors_for_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Rotenon_model"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Rotenone"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Rural_living"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Rush_dyskinesia_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#SCOPA-COG"/>
    </Declaration>
    <Declaration>
        <Class IRI="#SH-SY5Y"/>
    </Declaration>
    <Declaration>
        <Class IRI="#SPECT_biomarker"/>
    </Declaration>
    <Declaration>
        <Class IRI="#SPECT_imaging_biomarker"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Saint_Luis_encephalitis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Saliva_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Salsolinol"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Scales_for_outcomes_in_Parkinsons_disease-Motor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Schwab_and_England_activities_of_daily_living_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Secondary_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Secondary_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Segmental_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Selective_peripheral_denervation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sensory_symptom"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Shapiro_tourette_syndrome_severity_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Short_parkinsons_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Shuffling_gait"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Shy_Drager_syndrom"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sialorrhoea"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Simple_kinetic_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Slc6a3tm1(cre)Lrsn"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sleep_EEG"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sleep_attack"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sleep_disorder"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sleep_disturbance"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Slowness_of_movement"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sncatm1Nbm"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sncatm1Rosl"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sncatm1Sud"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sporadic_OPCA"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sporadic_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sporadic_parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Sporadic_tauopathy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Start_hesitation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Stem_cell_therapy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Striatal_iron"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Striatonigral_degeneration"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Strict_diet"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Structural_lesion-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Subthalamic_stimulation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Swallowing_disorder"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Symptom_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Symptomatic_skin_response"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Synucleinopathy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Syphilis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Syphilitic_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Targeted_gene"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Task-specific_kinetic_tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Task_specific_writing"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tauopathy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Testing_autonomic_nervous_system"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tfamtm1Lrsn"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Thalamotomy"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Three-wheeled_walking_stabilizer"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tightening_sensation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tingling_sensation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tnfrsf1atm1Imx"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tnfrsf1btm1Imx"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Toluene"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Toronto_western_spasmodic_torticollis_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Torsion_dystonia"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tourette_syndrome_global_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Toxin-induced_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Toxoplasma"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Transcranial_magnetic_stimulation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Transcranial_ultrasound_biomarker"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Transgenic_Drosohila_model_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Transgenic_mouse_model_of_Parkinsons_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tremor"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tremor-predominant_Parkinson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Tuberculosis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Turn_hesitation"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Turning"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Type_2_diabetes"/>
    </Declaration>
    <Declaration>
        <Class IRI="#U-shaped_walking_stabilizer"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ubiquinone_NADH_oxidoreductase"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ubiquitin"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Ultrasonography"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Unified_Parkinson_s_disease_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Unified_dystonia_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Unified_myoclonus_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#University_of_California_Los_Angeles_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Urinary_8-OH-2dG"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Urine_biomarkers_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Vascular_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Vesical_sphincter_EMG"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Visiospatial_and_color_discrimination"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Visiospatial_deficit"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Vitamin_intake"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Walking_difficulty"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Wearing-off_questionnaire"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Webster_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Well-water_drinking"/>
    </Declaration>
    <Declaration>
        <Class IRI="#West_Nile_virus"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Western_equine_encephalitis"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Wheeled_walker"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Wilson_s_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Writers_cramp_rating_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#X-linked_dystonia_parkinsonism"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Yale_global_tic_severity_scale"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Zebrafish_model_of_Parkinson_disease"/>
    </Declaration>
    <Declaration>
        <Class IRI="#n-hexane"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#Causes"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#adjacent_to"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#contained_in"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#derives_from_"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#describes"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#has_agent"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#has_participant"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#is_a"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#located_in"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#part_of"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#preceded_by"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="#targeted_in"/>
    </Declaration>
    <Declaration>
        <AnnotationProperty IRI="#BELcode"/>
    </Declaration>
    <Declaration>
        <AnnotationProperty IRI="#Context"/>
    </Declaration>
    <Declaration>
        <AnnotationProperty IRI="#Reference"/>
    </Declaration>
    <Declaration>
        <AnnotationProperty IRI="#Searchable"/>
    </Declaration>
    <Declaration>
        <AnnotationProperty IRI="#synonyms"/>
    </Declaration>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Budipine"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#COMT_inhibitors"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Camptocormia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Etiology_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Cinnerzin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#describes"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Constipation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autonomic_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Depression"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Dopamine"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Epidemiological_history"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Dopamine_dysregulation_syndrome"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Emerging_etiology"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Etiology_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#End_of_dose"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Epidemiological_history"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Etiology_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Epigenetics"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Neuropathology_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Festination"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Gait_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Fluctuation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Flunarizin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Hallucination"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Hereditary_forms_of_PD"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Canonical__etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Hit_and_run_viral_infection"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Emerging_etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#IPS_derived_model"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Incontinence"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Inflammation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Neuropathology_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Lactacysteime"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Leaky_gut"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Emerging_etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Lewy_body_dementia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Symptom_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#MAO_inhibitors"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Memantine"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Models_of_Parkinson&apos;s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#describes"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Mucuna_pruriens"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#NSAID"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Epidemiological_history"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Orthostatic_dysregulation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autonomic_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#PANDA"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Treatment_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Pick&apos;s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Pisa-syndrome"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Protective_effect_of_nicotine_or_smoke"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Emerging_etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Qigong"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Physical_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Random_on_off"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Reserpin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Sexual_dysfunction"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Smoke"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Epidemiological_history"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Solvent_exposure"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Emerging_etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Surgical_therapy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Treatment_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Synaptic_pathology"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Emerging_etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Taichi"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Physical_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Tetrabenazine"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Models_of_Parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Urinary_dysfunction"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autonomic_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Valproec_acid"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="http://protegeuserexample#Wearing_off"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#19-item_Wearing-off_Questionnaire"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Wearing-off_questionnaire"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#32-item_Wearing-off_Questionnaire"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Wearing-off_questionnaire"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#6-OHDA_model"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#9-item_Wearing-off_Questionnaire"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Wearing-off_questionnaire"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Abnormal_circadian_rhythm"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurobehavioral_biomarkers"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Abnormal_involuntary_movement_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Acquired_metabolic_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Action_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinsoniam_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Adcy5tm1Yish"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Adh7tm1Gdu"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Adult_onset_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Aggregation_of_alpha-synuclein"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Synucleinopathy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Aggregation_of_tau_protein"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Tauopathy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Agraphia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurobehavioral_biomarkers"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Akathisia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Akinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Alcohol_consumption"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Alexander_technique"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Physical_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Alpha-synuclein"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#has_participant"/>
            <Class IRI="#Aggregation_of_alpha-synuclein"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Alpha_synuclein_index"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Altered_tear_film"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Ophthalmological_measures"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Anal_sphincter_EMG"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Needle_electromyography"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Anhedonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Anismus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Gastrointestinal_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Anosmia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Anxiety"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Apathy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Apomorphine_test"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Apraxia_of_eyelid_opening"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Ophthalmological_measures"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Archimedes_spiral"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Arm_dystonia_disability_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Assistive_devices_for_gait"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Physical_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Autonomic_dysfunction"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Monogenic_forms_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Autosomal_recessive_forms_of_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Monogenic_forms_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Autosomal_recessive_juvenile_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_recessive_forms_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Axial_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Segmental_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#BDNF"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Beginning-of-dose_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Diphasic_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Berg_balance_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#contained_in"/>
            <Class IRI="#Diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Biophysical_biomarkers_of_Parkinson&apos;s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Blepharospasm"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Ophthalmological_measures"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Blood_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Bmpr1atm1Bhr"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Bmpr1atm2.1Bhr"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Body_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Borreliosis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Botulinum_toxin_A"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Chemodenervation"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Botulinum_toxin_B"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Chemodenervation"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Braak_staging_scheme_for_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Brachial_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Segmental_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Bradykinesia_symptom"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Bradyphrenia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Burning_sensation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sensory_symptom"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#C-raclopride_PET"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#PET_imaging_biomarker"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#C._elegans_model_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Genetic_models_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#CSF_alpha_synuclein"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#CSF_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#CSF_osteopontin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#CSM14.1"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dopaminergic_cell_lines"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Caffeine"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_agent_for_parkinson"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Caffeine_intake"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Strict_diet"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cancer"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Medical_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Carbon_disulphide"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Carbon_monoxide-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cardiac_sympathetic_innervation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Models_of_Parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cell_therapy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurorestorative_treatment"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Central_conduction_time"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Transcranial_magnetic_stimulation"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Central_surgery"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Surgical_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Centralized_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Charnoly_body"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Chemodenervation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Treatment_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Childhood_onset_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Chlorpromazine-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cigarette_smoking"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Classical_essential_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Essential_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Clinical_dyskinesia_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Clinical_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Clozapine_add-on"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Coenzyme_Q10"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cognitive_abnormality"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Columbia_university_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Communicating_hydrocephalus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Hydrocephalus"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Compulsive_foraging"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Compulsive_shopping"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Constipation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Gastrointestinal_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Continual_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Continuous_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Convergence_abnormality"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Ophthalmological_measures"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Core_assessment_program_for_intracerebral_transplantation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Core_assessment_program_for_surgical_interventional_therapies_in_Parkinsons_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cortical_excitability"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Transcranial_magnetic_stimulation"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Corticobasal_degeneration"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Coxackie_B_virus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cranial_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Segmental_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Craving"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Creatine"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_agent_for_parkinson"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Criteria_for_definite_PD"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Criteria_for_possible_PD"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Criteria_for_probable_PD"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Crural_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Segmental_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cryprococcus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cyanide-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cyanide_poisoning"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cycle_ergometry"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Physical_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Cytokines"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#DJ-1_concentration_in_CSF"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Daytime_sleepiness"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sleep_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Deacreased_blink_rate"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Ophthalmological_measures"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Deafness"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Deep_brain_stimulation_for_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Central_surgery"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Delayed_gastric_emptying"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Gastrointestinal_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Delusion"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dementia_with_pallido-ponto-nigral_degeneration"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Depression"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Medical_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Destination_hesitation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Freezing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Diablotm1Mak"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Diagnosis_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Differential_diagnosis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Diffuse_pain"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sensory_symptom"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Diphasic_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Donezepil_as_add-on_treatment"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dopamine_deficiency"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Canonical__etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dopaminergic_cell_lines"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Immortalized_cell_line"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Drd2tm1Ebo"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Drd2tm1Low"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Drooling"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Drug-induced_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Drug-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dysarthria"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dysexecutive_syndrome"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dysphagia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Dystonic_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Other_essential_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000062"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000063"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000064"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000065"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000066"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000067"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000068"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000069"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#COMT_inhibitors"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000070"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#COMT_inhibitors"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000071"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000072"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000073"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000074"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000075"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000077"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000078"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000079"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000080"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000081"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000082"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000085"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#MAO_inhibitors"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#EPO_00000086"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#MAO_inhibitors"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Early-onset_Parkinson_s_disease_"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ecstasy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Electromyography_of_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#En1tm1Gld"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#En2tm1Alj"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Encephalitis_lethargica"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#End-of-dose_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Diphasic_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Environmental_risk_factor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Risk_factors_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Epstein-Barr_virus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Epworth_sleepiness_sclae"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Essential_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#contained_in"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Excessive_sweating"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Exertion-induced_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Paroxymal_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Exposure_to_copper"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Exposure_to_farming"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Exposure_to_herbicide"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Exposure_to_manganese"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Exposure_to_pesticide"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#F-dopa_PET"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#PET_imaging_biomarker"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#FDG_PET"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#PET_imaging_biomarker"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Fahn-Marsden_dystonia_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Fall_risk_factor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Risk_factors_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Falling"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Falls"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Familial_neurodegenerative_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Family_history_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Risk_factors_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Fat_intake"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Strict_diet"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Fatigue_Severity_Inventory"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Fatty_acid_intake"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Strict_diet"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ferritin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Fluctuating_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Focal_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Foot_drag"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Gait_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Foot_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Focal_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Four-legged_cane"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Four-wheeled_walking_stabilizer"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Freezing"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Gait_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Frequency_of_abnormal_movements_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Frontotemporal_dementia_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#GM-1_ganglioside"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_agent_for_parkinson"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Gait_disturbance"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Akinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Gastrointestinal_dysfunction"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Genetic_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Genetic_cause_of_parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Etiology_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Genetic_models_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Models_of_Parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Genital_pain"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sensory_symptom"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Genomic_biomarker_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Glutathione"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Glycomic_biomarker_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Glyphosate_herbicide"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Graphic_tablet_analysis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Group_A_feature"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Group_B_feature"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Gt(ROSA)26Sortm2(SNCA*119)Djmo"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Guamanian_parkinsonism-dementia-ALS"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#HIV_encephalopathy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#H_magnetic_resonance_spectroscopy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Halogen"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Haloperidol-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Haloperidol_model"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hamilton_depression_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Head_trauma"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Medical_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Heart_beat_frequency_modulation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Testing_autonomic_nervous_system"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hemiatrophy-hemiparkinsonism_syndrome"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Heroin_pyrolysate"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hesitation_in_tight_quarters"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Freezing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hoehn_and_Yahr_stage_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Home_diaries"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hopkins_motor_and_vocal_tic_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hospital_anxiety_and_depression_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Htra2tm1Jdo"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Human_afult_stem_cell-based_therapy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Stem_cell_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Human_embryonic_stem_cell-based_therapy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Stem_cell_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Huntington_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Familial_neurodegenerative_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hydrocephalus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hypersexuality"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hypnogenic_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Paroxymal_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hypoguesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hypokinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hypomimia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hypophonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Hypoxia-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#I-β-CIT_SPECT"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#SPECT_imaging_biomarker"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Idiopathic_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Immortalized_cell_line"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Immunulogical_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Impaired_handwriting"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurobehavioral_biomarkers"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Impulsive_behaviour"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Inconsistence"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Etiology_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Inherited_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Inherited_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Intention_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Kinetic_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Intermediate_scale_for_assessment_of_Parkinsons_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Intrathecal_baclofen"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Peripheral_surgery"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Iron_accumulation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Isolated_chin_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Other_essential_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Isolated_voice_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Other_essential_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Isometric_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Postural_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Japanese_B_encephalitis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Juvenile_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Kinesia_paradoxica"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Kinesigenic_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Paroxymal_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Kinesigenic_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Paroxysmal_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Kinetic_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinsoniam_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#L-shaped_cane"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#LPS_model"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#LSVT_BIG"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Lee-Silverman_Voice_Treatment"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#LSVT_LOUD"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Lee-Silverman_Voice_Treatment"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Laser_cane"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Late-onset_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Lee-Silverman_Voice_Treatment"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Physical_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Leg_dystonia_disability_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Levodopa_test"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Lewy_body"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Limitation_of_upward_gaze"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Ophthalmological_measures"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Lipidomic_biomarker_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Long_term_recordings_of_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Loss_of_hearing"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurobehavioral_biomarkers"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Loss_of_postural_reflex"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Differential_diagnosis"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Loss_of_smell"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurobehavioral_biomarkers"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Loss_of_urinarry_bladder_control"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurobehavioral_biomarkers"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MAOB"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MAPT"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#has_participant"/>
            <Class IRI="#Aggregation_of_tau_protein"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MDS-UPDRS"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MESC2.10"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dopaminergic_cell_lines"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MIBG_scintigraphy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MN9D"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dopaminergic_cell_lines"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MPTP"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MPTP-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#MPTP_model"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Machado-Joseph_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Malaria"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Maneb"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Manganese"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Manganese-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mapk10tm1Flv"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mapk9tm1Flv"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Marti_and_Tolosa_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Medical_risk_factor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Risk_factors_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Melatonin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mercury_poisoning"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Metabolic_biomarker_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Metallothionein"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Methanol"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Metoclopramide-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Micrographia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurobehavioral_biomarkers"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mini-mental_parkinson"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mitochondrial_DNA_mutation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Canonical__etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mitochondrial_DNA_polymerase_gamma_mutation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Mitochondrial_DNA_mutation"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mitochondrial_complex_I_deficiency"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Canonical__etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Monoamines"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Monocycline"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_agent_for_parkinson"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Monogenic_forms_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Hereditary_forms_of_PD"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Montgomery-Asberg_depression_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Morphological_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Motor_features"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Symptom_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Motor_testing"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Motorized_scooter"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mouse_models_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Genetic_models_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mucormycosis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Multidimensional_fatigue_inventory"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Multifocal_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Segmental_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Multiple_system_atrophy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Muscle_action_potential"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Muscle_rigidity"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Mycoplasma_pneumonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Myectomy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Peripheral_surgery"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Needle_electromyography"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Neurophysiological_testing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuralgic_pain"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sensory_symptom"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuroacanthocytosis_syndrome"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Familial_neurodegenerative_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neurobehavioral_biomarkers"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuroleptic-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuromelanin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuromelanin_Ab"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuropathology_of_parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neurophysiological_testing"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Treatment_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Neurorestorative_treatment"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Treatment_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#New_York_University_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Nicotine"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_agent_for_parkinson"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Nigral_glutathione_deficiency"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Canonical__etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Nigrostriatal_dopaminergic_loss"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Nocturia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Non-kinesigenic_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Paroxymal_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Non-motor_features"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Symptom_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Nonkinesigenic_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Paroxysmal_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Normal_pressure_hydrocephalus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Communicating_hydrocephalus"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Northwestern_University_disability_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Nr4a2tm1Omc"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Obeso_dyskinesia_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Obessive_behaviour"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Obstructive_hydrocephalus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Hydrocephalus"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Occular_saccade_impairment"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Ophthalmological_measures"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ocular_surface_irritation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Ophthalmological_measures"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Off-period_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Olfaction"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Olfactory_dysfunction"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Open_space_hesitation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Freezing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ophthalmological_measures"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Oral_pain"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sensory_symptom"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Organophosphate"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Organotypic_culture"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Organotypic_slice_culture"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Organotypic_culture"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Oromandibular_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Focal_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Oromandibular_dystonia_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Other_essential_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Essential_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK10_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK11_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK1_mutation_induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK2_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK3_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK4_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK5_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK6_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PARK8_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PC12"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dopaminergic_cell_lines"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PET_biomarker"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PET_imaging_biomarker"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#PINK7_mutation_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pallidal_stimulation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Deep_brain_stimulation_for_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pallidotomy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Central_surgery"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Paraquat"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Paresthesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Park2tm1Ccs"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Park2tm1Roo"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Park2tm1Shn"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Park2tm1Tmd"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Park2tm1Ykt"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Park7tm1Cai"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Park7tm1Shn"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Park7tm1Xz"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkinson-Plus_syndrome"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkinson_disease_dyskinesia_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkinson_fatigue_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkinson_psychosis_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkinsoniam_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkinsons_disease_cognitive_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkinsons_disease_dementia-short_screen"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Parkinsons_disease_questionnaire-39"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Paroxymal_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Paroxysmal_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Fluctuating_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pathological_gambling"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Peak_dose_dyskinesia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_dyskinesia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Peripheral_surgery"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Surgical_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Persistent_depression"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neurobehavioral_biomarkers"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Treatment_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Physiological_biomarkers_od_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pink1tm1Aub"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pink1tm1Shn"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pittsburgh_sleep_quality_index"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Plasma_homocysteine"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Platelet_complex-1_activity"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Poliomyelitis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Polysomnography"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Position-specific_postural_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Postural_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Position_specific_writing"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_writing_tremot"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Post-traumatic_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Postencephalic_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Postural_instability"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Postural_irregularity"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Postural_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinsoniam_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Power_wheelchair"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pramipexole"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_agent_for_parkinson"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Primary_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Continual_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Primary_immature_dopaminergic_neuron"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Primary_midbrain_culture"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_immature_dopaminergic_neuron"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Primary_orthostatic_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Other_essential_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Primary_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Primary_writing_tremot"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Other_essential_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Prochlorperazine-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Progressive_pallidal_atrophy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Progressive_supranuclear_palsy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinson-Plus_syndrome"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Promethazine-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Drug-induced_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Proteinopathy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Neuropathology_of_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Proteomic_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Psychosis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuropsychiatric_dysfunction"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ptstm1Ich"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pulsion"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Gait_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Punding"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Pyridoxal_kinase"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Quantitative_tremor_analysis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ramisectomy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Peripheral_surgery"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Rapid-onset_dystonia-parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Rapid_eye_movement_sleep_behaviour_disorder"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sleep_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Recessive_early-onset_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Autosomal_recessive_forms_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Reduced_CSF_gluthatione-SH"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Reserpine_model"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Rest_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Differential_diagnosis"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Resting_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Parkinsoniam_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Restless_legs_syndrome"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sleep_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Retropulsion"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Gait_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Rigidity"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Risk_factors_for_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Etiology_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Rotenon_model"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Rotenone"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Rural_living"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Rush_dyskinesia_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#SCOPA-COG"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#SH-SY5Y"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Dopaminergic_cell_lines"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#SPECT_biomarker"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#SPECT_imaging_biomarker"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Saint_Luis_encephalitis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Saliva_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Salsolinol"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Scales_for_outcomes_in_Parkinsons_disease-Motor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Schwab_and_England_activities_of_daily_living_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Secondary_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Continual_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Secondary_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class abbreviatedIRI="owl:Thing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Segmental_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Selective_peripheral_denervation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Peripheral_surgery"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sensory_symptom"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Shapiro_tourette_syndrome_severity_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Short_parkinsons_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Shuffling_gait"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Gait_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Shy_Drager_syndrom"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Multiple_system_atrophy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sialorrhoea"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Simple_kinetic_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Kinetic_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Slc6a3tm1(cre)Lrsn"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sleep_EEG"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sleep_attack"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sleep_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sleep_disorder"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sleep_disturbance"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Slowness_of_movement"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sncatm1Nbm"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sncatm1Rosl"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sncatm1Sud"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sporadic_OPCA"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Multiple_system_atrophy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sporadic_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sporadic_parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Canonical__etiology"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Sporadic_tauopathy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Sporadic_parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Start_hesitation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Freezing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Stem_cell_therapy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Cell_therapy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Striatal_iron"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Striatonigral_degeneration"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Multiple_system_atrophy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Strict_diet"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Risk_factors_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Structural_lesion-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Subthalamic_stimulation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Deep_brain_stimulation_for_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Swallowing_disorder"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Non-motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Symptom_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Symptomatic_skin_response"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Testing_autonomic_nervous_system"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Synucleinopathy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Proteinopathy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Syphilis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Syphilitic_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Targeted_gene"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#targeted_in"/>
            <Class IRI="#Transgenic_mouse_model_of_Parkinsons_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Task-specific_kinetic_tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Kinetic_tremor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Task_specific_writing"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_writing_tremot"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tauopathy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Proteinopathy"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Testing_autonomic_nervous_system"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Neurophysiological_testing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tfamtm1Lrsn"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Thalamotomy"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Central_surgery"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Three-wheeled_walking_stabilizer"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tightening_sensation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sensory_symptom"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tingling_sensation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Sensory_symptom"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tnfrsf1atm1Imx"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tnfrsf1btm1Imx"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Targeted_gene"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Toluene"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Toronto_western_spasmodic_torticollis_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Torsion_dystonia"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Centralized_dystonia"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tourette_syndrome_global_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Toxin-induced_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Etiology_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Toxoplasma"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Transcranial_magnetic_stimulation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Neurophysiological_testing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Transcranial_ultrasound_biomarker"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Transgenic_Drosohila_model_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Genetic_models_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Transgenic_mouse_model_of_Parkinsons_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Mouse_models_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tremor"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Motor_features"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tremor-predominant_Parkinson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Primary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Tuberculosis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Turn_hesitation"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Freezing"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Turning"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#Causes"/>
            <Class IRI="#Gait_disturbance"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Type_2_diabetes"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Medical_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#U-shaped_walking_stabilizer"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ubiquinone_NADH_oxidoreductase"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ubiquitin"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Ultrasonography"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Unified_Parkinson_s_disease_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Unified_dystonia_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Unified_myoclonus_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#University_of_California_Los_Angeles_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Urinary_8-OH-2dG"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Urine_biomarkers_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Vascular_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Secondary_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Vesical_sphincter_EMG"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Needle_electromyography"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Visiospatial_and_color_discrimination"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Visiospatial_deficit"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Vitamin_intake"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Strict_diet"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Walking_difficulty"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Wearing-off_questionnaire"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#part_of"/>
            <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Webster_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Well-water_drinking"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Environmental_risk_factor"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#West_Nile_virus"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Western_equine_encephalitis"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Infectious_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Wheeled_walker"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Assistive_devices_for_gait"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Wilson_s_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Familial_neurodegenerative_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Writers_cramp_rating_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#X-linked_dystonia_parkinsonism"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Familial_neurodegenerative_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Yale_global_tic_severity_scale"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Clinical_rating_scale"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#Zebrafish_model_of_Parkinson_disease"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Genetic_models_of_Parkinson_disease"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <EquivalentClasses>
        <Class IRI="#n-hexane"/>
        <ObjectSomeValuesFrom>
            <ObjectProperty IRI="#is_a"/>
            <Class IRI="#Toxin_cause_of_parkinsonism"/>
        </ObjectSomeValuesFrom>
    </EquivalentClasses>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Budipine"/>
        <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#COMT_inhibitors"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Camptocormia"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Cinnerzin"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Constipation"/>
        <Class IRI="#Autonomic_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Depression"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Dopamine"/>
        <Class IRI="http://protegeuserexample#Epidemiological_history"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Dopamine_dysregulation_syndrome"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Emerging_etiology"/>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#End_of_dose"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Epidemiological_history"/>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Epigenetics"/>
        <Class IRI="#Neuropathology_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Festination"/>
        <Class IRI="#Gait_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Fluctuation"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Flunarizin"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Hallucination"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Hereditary_forms_of_PD"/>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Hit_and_run_viral_infection"/>
        <Class IRI="http://protegeuserexample#Emerging_etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#IPS_derived_model"/>
        <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Incontinence"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Inflammation"/>
        <Class IRI="#Neuropathology_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Lactacysteime"/>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Leaky_gut"/>
        <Class IRI="http://protegeuserexample#Emerging_etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Lewy_body_dementia"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
        <Class IRI="#Symptom_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#MAO_inhibitors"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Memantine"/>
        <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Mucuna_pruriens"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#NSAID"/>
        <Class IRI="http://protegeuserexample#Epidemiological_history"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Orthostatic_dysregulation"/>
        <Class IRI="#Autonomic_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#PANDA"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Pick&apos;s_disease"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Pisa-syndrome"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Protective_effect_of_nicotine_or_smoke"/>
        <Class IRI="http://protegeuserexample#Emerging_etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Qigong"/>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Random_on_off"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Reserpin"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Sexual_dysfunction"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Smoke"/>
        <Class IRI="http://protegeuserexample#Epidemiological_history"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Solvent_exposure"/>
        <Class IRI="http://protegeuserexample#Emerging_etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Surgical_therapy"/>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Synaptic_pathology"/>
        <Class IRI="http://protegeuserexample#Emerging_etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Taichi"/>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Tetrabenazine"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
        <Class IRI="http://protegeuserexample#Models_of_Parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Urinary_dysfunction"/>
        <Class IRI="#Autonomic_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Valproec_acid"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="http://protegeuserexample#Wearing_off"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#19-item_Wearing-off_Questionnaire"/>
        <Class IRI="#Wearing-off_questionnaire"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#32-item_Wearing-off_Questionnaire"/>
        <Class IRI="#Wearing-off_questionnaire"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#6-OHDA_model"/>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#9-item_Wearing-off_Questionnaire"/>
        <Class IRI="#Wearing-off_questionnaire"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Abnormal_circadian_rhythm"/>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Abnormal_involuntary_movement_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Acquired_metabolic_parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Action_tremor"/>
        <Class IRI="#Parkinsoniam_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Adcy5tm1Yish"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Adh7tm1Gdu"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Adult_onset_dystonia"/>
        <Class IRI="#Primary_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Aggregation_of_alpha-synuclein"/>
        <Class IRI="#Synucleinopathy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Aggregation_of_tau_protein"/>
        <Class IRI="#Tauopathy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Agraphia"/>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Akathisia"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Akinesia"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Alcohol_consumption"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Alexander_technique"/>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Alpha-synuclein"/>
        <Class IRI="#Aggregation_of_alpha-synuclein"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Alpha_synuclein_index"/>
        <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Altered_tear_film"/>
        <Class IRI="#Ophthalmological_measures"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Amyloid-beta"/>
        <Class IRI="#Aggregation_of_tau_protein"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Anal_sphincter_EMG"/>
        <Class IRI="#Needle_electromyography"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Anhedonia"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Anismus"/>
        <Class IRI="#Gastrointestinal_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Anosmia"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Anxiety"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Apathy"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Apomorphine_test"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Apraxia_of_eyelid_opening"/>
        <Class IRI="#Ophthalmological_measures"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Archimedes_spiral"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Arm_dystonia_disability_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Assistive_devices_for_gait"/>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Autonomic_dysfunction"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
        <Class IRI="#Monogenic_forms_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Autosomal_recessive_forms_of_parkinsonism"/>
        <Class IRI="#Monogenic_forms_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Autosomal_recessive_juvenile_parkinsonism"/>
        <Class IRI="#Autosomal_recessive_forms_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Axial_dystonia"/>
        <Class IRI="#Segmental_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#BDNF"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Beginning-of-dose_dyskinesia"/>
        <Class IRI="#Diphasic_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Berg_balance_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
        <Class IRI="#Diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Biophysical_biomarkers_of_Parkinson&apos;s_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Blepharospasm"/>
        <Class IRI="#Ophthalmological_measures"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Blood_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Bmpr1atm1Bhr"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Bmpr1atm2.1Bhr"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Body_tremor"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Borreliosis"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Botulinum_toxin_A"/>
        <Class IRI="#Chemodenervation"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Botulinum_toxin_B"/>
        <Class IRI="#Chemodenervation"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Braak_staging_scheme_for_Parkinson_s_disease"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Brachial_dystonia"/>
        <Class IRI="#Segmental_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Bradykinesia_symptom"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Bradyphrenia"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Burning_sensation"/>
        <Class IRI="#Sensory_symptom"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#C-raclopride_PET"/>
        <Class IRI="#PET_imaging_biomarker"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#C._elegans_model_of_Parkinson_disease"/>
        <Class IRI="#Genetic_models_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#CSF_alpha_synuclein"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#CSF_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#CSF_osteopontin"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#CSM14.1"/>
        <Class IRI="#Dopaminergic_cell_lines"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Caffeine"/>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Caffeine_intake"/>
        <Class IRI="#Strict_diet"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cancer"/>
        <Class IRI="#Medical_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Carbon_disulphide"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Carbon_monoxide-induced_parkinsonism"/>
        <Class IRI="#Toxin-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cardiac_sympathetic_innervation"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
        <Class IRI="http://protegeuserexample#Models_of_Parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cell_therapy"/>
        <Class IRI="#Neurorestorative_treatment"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Central_conduction_time"/>
        <Class IRI="#Transcranial_magnetic_stimulation"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Central_surgery"/>
        <Class IRI="http://protegeuserexample#Surgical_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Centralized_dystonia"/>
        <Class IRI="#Primary_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Charnoly_body"/>
        <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Chemodenervation"/>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Childhood_onset_dystonia"/>
        <Class IRI="#Primary_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Chlorpromazine-induced_parkinsonism"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cigarette_smoking"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Classical_essential_tremor"/>
        <Class IRI="#Essential_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Clinical_dyskinesia_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Clinical_rating_scale"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Clozapine_add-on"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Coenzyme_Q10"/>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cognitive_abnormality"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Columbia_university_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Communicating_hydrocephalus"/>
        <Class IRI="#Hydrocephalus"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Compulsive_foraging"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Compulsive_shopping"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Constipation"/>
        <Class IRI="#Gastrointestinal_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Continual_dystonia"/>
        <Class IRI="#Dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Continuous_dyskinesia"/>
        <Class IRI="#Dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Convergence_abnormality"/>
        <Class IRI="#Ophthalmological_measures"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Core_assessment_program_for_intracerebral_transplantation"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Core_assessment_program_for_surgical_interventional_therapies_in_Parkinsons_disease"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cortical_excitability"/>
        <Class IRI="#Transcranial_magnetic_stimulation"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Corticobasal_degeneration"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Coxackie_B_virus"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cranial_dystonia"/>
        <Class IRI="#Segmental_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Craving"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Creatine"/>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Criteria_for_definite_PD"/>
        <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Criteria_for_possible_PD"/>
        <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Criteria_for_probable_PD"/>
        <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Crural_dystonia"/>
        <Class IRI="#Segmental_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cryprococcus"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cyanide-induced_parkinsonism"/>
        <Class IRI="#Toxin-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cyanide_poisoning"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cycle_ergometry"/>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Cytokines"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#DJ-1_concentration_in_CSF"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Daytime_sleepiness"/>
        <Class IRI="#Sleep_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Deacreased_blink_rate"/>
        <Class IRI="#Ophthalmological_measures"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Deafness"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Deep_brain_stimulation_for_Parkinson_s_disease"/>
        <Class IRI="#Central_surgery"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Delayed_gastric_emptying"/>
        <Class IRI="#Gastrointestinal_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Delusion"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dementia_with_pallido-ponto-nigral_degeneration"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Depression"/>
        <Class IRI="#Medical_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Destination_hesitation"/>
        <Class IRI="#Freezing"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Diablotm1Mak"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Diagnosis_of_Parkinson_disease"/>
        <Class IRI="http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
        <Class IRI="#Diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Differential_diagnosis"/>
        <Class IRI="#Diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Diffuse_pain"/>
        <Class IRI="#Sensory_symptom"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Diphasic_dyskinesia"/>
        <Class IRI="#Drug-induced_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Donezepil_as_add-on_treatment"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dopamine_deficiency"/>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dopaminergic_cell_lines"/>
        <Class IRI="#Immortalized_cell_line"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Drd2tm1Ebo"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Drd2tm1Low"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Drooling"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Drug-induced_dyskinesia"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Drug-induced_parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dysarthria"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dysexecutive_syndrome"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dyskinesia"/>
        <Class IRI="http://protegeuserexample#Long_term_complication_of_medication"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dysphagia"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dystonia"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Dystonic_tremor"/>
        <Class IRI="#Other_essential_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000062"/>
        <Class IRI="http://protegeuserexample#NMDA_antagonist"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000063"/>
        <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000064"/>
        <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000065"/>
        <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000066"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000067"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000068"/>
        <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000069"/>
        <Class IRI="http://protegeuserexample#COMT_inhibitors"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000070"/>
        <Class IRI="http://protegeuserexample#COMT_inhibitors"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000071"/>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000072"/>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000073"/>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000074"/>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000075"/>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000077"/>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000078"/>
        <Class IRI="http://protegeuserexample#Anti-cholinergic_drugs"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000079"/>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000080"/>
        <Class IRI="http://protegeuserexample#Dopamine_agonists"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000081"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000082"/>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000085"/>
        <Class IRI="http://protegeuserexample#MAO_inhibitors"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#EPO_00000086"/>
        <Class IRI="http://protegeuserexample#MAO_inhibitors"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Early-onset_Parkinson_s_disease_"/>
        <Class IRI="#Primary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ecstasy"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Electromyography_of_tremor"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#En1tm1Gld"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#En2tm1Alj"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Encephalitis_lethargica"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#End-of-dose_dyskinesia"/>
        <Class IRI="#Diphasic_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Environmental_risk_factor"/>
        <Class IRI="#Risk_factors_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Epstein-Barr_virus"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Epworth_sleepiness_sclae"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Essential_tremor"/>
        <Class IRI="#Tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
        <Class IRI="#Diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Excessive_sweating"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Exertion-induced_dyskinesia"/>
        <Class IRI="#Paroxymal_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Exposure_to_copper"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Exposure_to_farming"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Exposure_to_herbicide"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Exposure_to_manganese"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Exposure_to_pesticide"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#F-dopa_PET"/>
        <Class IRI="#PET_imaging_biomarker"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#FDG_PET"/>
        <Class IRI="#PET_imaging_biomarker"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Fahn-Marsden_dystonia_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Fall_risk_factor"/>
        <Class IRI="#Risk_factors_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Falling"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Falls"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Family_history_of_Parkinson_disease"/>
        <Class IRI="#Risk_factors_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Fat_intake"/>
        <Class IRI="#Strict_diet"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Fatigue_Severity_Inventory"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Fatty_acid_intake"/>
        <Class IRI="#Strict_diet"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ferritin"/>
        <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Fluctuating_dystonia"/>
        <Class IRI="#Dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Focal_dystonia"/>
        <Class IRI="#Primary_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Foot_drag"/>
        <Class IRI="#Gait_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Foot_dystonia"/>
        <Class IRI="#Focal_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Four-legged_cane"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Four-wheeled_walking_stabilizer"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Freezing"/>
        <Class IRI="#Gait_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Frequency_of_abnormal_movements_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Frontotemporal_dementia_parkinsonism"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#GM-1_ganglioside"/>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Gait_disturbance"/>
        <Class IRI="#Akinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Gastrointestinal_dysfunction"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Genetic_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Genetic_cause_of_parkinson_disease"/>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Genetic_models_of_Parkinson_disease"/>
        <Class IRI="http://protegeuserexample#Models_of_Parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Genital_pain"/>
        <Class IRI="#Sensory_symptom"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Genomic_biomarker_of_Parkinson_disease"/>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Glutathione"/>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Glycomic_biomarker_of_Parkinson_disease"/>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Glyphosate_herbicide"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Graphic_tablet_analysis"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Group_A_feature"/>
        <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Group_B_feature"/>
        <Class IRI="#Diagnostic_criteria_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Gt(ROSA)26Sortm2(SNCA*119)Djmo"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Guamanian_parkinsonism-dementia-ALS"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#HIV_encephalopathy"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#H_magnetic_resonance_spectroscopy"/>
        <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Halogen"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Haloperidol-induced_parkinsonism"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Haloperidol_model"/>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hamilton_depression_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Head_trauma"/>
        <Class IRI="#Medical_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Heart_beat_frequency_modulation"/>
        <Class IRI="#Testing_autonomic_nervous_system"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hemiatrophy-hemiparkinsonism_syndrome"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Heroin_pyrolysate"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hesitation_in_tight_quarters"/>
        <Class IRI="#Freezing"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hoehn_and_Yahr_stage_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Home_diaries"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hopkins_motor_and_vocal_tic_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hospital_anxiety_and_depression_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Htra2tm1Jdo"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Human_afult_stem_cell-based_therapy"/>
        <Class IRI="#Stem_cell_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Human_embryonic_stem_cell-based_therapy"/>
        <Class IRI="#Stem_cell_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Huntington_disease"/>
        <Class IRI="#Familial_neurodegenerative_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hydrocephalus"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hypersexuality"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hypnogenic_dyskinesia"/>
        <Class IRI="#Paroxymal_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hypoguesia"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hypokinesia"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hypomimia"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hypophonia"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Hypoxia-induced_parkinsonism"/>
        <Class IRI="#Toxin-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#I-β-CIT_SPECT"/>
        <Class IRI="#SPECT_imaging_biomarker"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Immortalized_cell_line"/>
        <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Immunulogical_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Impaired_handwriting"/>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Impulsive_behaviour"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Inconsistence"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Inherited_Parkinson_s_disease"/>
        <Class IRI="#Primary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Inherited_dystonia"/>
        <Class IRI="#Primary_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Intention_tremor"/>
        <Class IRI="#Kinetic_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Intermediate_scale_for_assessment_of_Parkinsons_disease"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Intrathecal_baclofen"/>
        <Class IRI="#Peripheral_surgery"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Iron_accumulation"/>
        <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Isolated_chin_tremor"/>
        <Class IRI="#Other_essential_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Isolated_voice_tremor"/>
        <Class IRI="#Other_essential_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Isometric_tremor"/>
        <Class IRI="#Postural_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Japanese_B_encephalitis"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Juvenile_Parkinson_s_disease"/>
        <Class IRI="#Primary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Kinesia_paradoxica"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Kinesigenic_dyskinesia"/>
        <Class IRI="#Paroxymal_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Kinesigenic_dystonia"/>
        <Class IRI="#Paroxysmal_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Kinetic_tremor"/>
        <Class IRI="#Parkinsoniam_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#L-shaped_cane"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#LPS_model"/>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#LSVT_BIG"/>
        <Class IRI="#Lee-Silverman_Voice_Treatment"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#LSVT_LOUD"/>
        <Class IRI="#Lee-Silverman_Voice_Treatment"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Laser_cane"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Late-onset_Parkinson_s_disease"/>
        <Class IRI="#Primary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Lee-Silverman_Voice_Treatment"/>
        <Class IRI="http://protegeuserexample#Physical_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Leg_dystonia_disability_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Levodopa_test"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Lewy_body"/>
        <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Limitation_of_upward_gaze"/>
        <Class IRI="#Ophthalmological_measures"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Lipidomic_biomarker_of_Parkinson_disease"/>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Long_term_recordings_of_tremor"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Loss_of_hearing"/>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Loss_of_postural_reflex"/>
        <Class IRI="#Differential_diagnosis"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Loss_of_smell"/>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Loss_of_urinarry_bladder_control"/>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MAOB"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MAPT"/>
        <Class IRI="#Aggregation_of_tau_protein"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MDS-UPDRS"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MESC2.10"/>
        <Class IRI="#Dopaminergic_cell_lines"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MIBG_scintigraphy"/>
        <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MN9D"/>
        <Class IRI="#Dopaminergic_cell_lines"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MPTP"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MPTP-induced_parkinsonism"/>
        <Class IRI="#Toxin-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#MPTP_model"/>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Machado-Joseph_disease"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Malaria"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Maneb"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Manganese"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Manganese-induced_parkinsonism"/>
        <Class IRI="#Toxin-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mapk10tm1Flv"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mapk9tm1Flv"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Marti_and_Tolosa_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Medical_risk_factor"/>
        <Class IRI="#Risk_factors_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Melatonin"/>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mercury_poisoning"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Metabolic_biomarker_of_Parkinson_disease"/>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Metallothionein"/>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Methanol"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Metoclopramide-induced_parkinsonism"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Micrographia"/>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mini-mental_parkinson"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mitochondrial_DNA_mutation"/>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mitochondrial_DNA_polymerase_gamma_mutation"/>
        <Class IRI="#Mitochondrial_DNA_mutation"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mitochondrial_complex_I_deficiency"/>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Monoamines"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Monocycline"/>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Monogenic_forms_of_Parkinson_disease"/>
        <Class IRI="http://protegeuserexample#Hereditary_forms_of_PD"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Montgomery-Asberg_depression_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Morphological_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Motor_features"/>
        <Class IRI="#Symptom_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Motor_testing"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Motorized_scooter"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mouse_models_of_Parkinson_disease"/>
        <Class IRI="#Genetic_models_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mucormycosis"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Multidimensional_fatigue_inventory"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Multifocal_dystonia"/>
        <Class IRI="#Segmental_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Multiple_system_atrophy"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Muscle_action_potential"/>
        <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Muscle_rigidity"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Mycoplasma_pneumonia"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Myectomy"/>
        <Class IRI="#Peripheral_surgery"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Needle_electromyography"/>
        <Class IRI="#Neurophysiological_testing"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuralgic_pain"/>
        <Class IRI="#Sensory_symptom"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuroacanthocytosis_syndrome"/>
        <Class IRI="#Familial_neurodegenerative_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neurobehavioral_biomarkers"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuroleptic-induced_parkinsonism"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuromelanin"/>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuromelanin_Ab"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neurophysiological_testing"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Neurorestorative_treatment"/>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#New_York_University_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Nicotine"/>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Nigral_glutathione_deficiency"/>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Nigrostriatal_dopaminergic_loss"/>
        <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Nocturia"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Non-kinesigenic_dyskinesia"/>
        <Class IRI="#Paroxymal_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Non-motor_features"/>
        <Class IRI="#Symptom_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Nonkinesigenic_dystonia"/>
        <Class IRI="#Paroxysmal_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Normal_pressure_hydrocephalus"/>
        <Class IRI="#Communicating_hydrocephalus"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Northwestern_University_disability_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Nr4a2tm1Omc"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Obeso_dyskinesia_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Obessive_behaviour"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Obstructive_hydrocephalus"/>
        <Class IRI="#Hydrocephalus"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Occular_saccade_impairment"/>
        <Class IRI="#Ophthalmological_measures"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ocular_surface_irritation"/>
        <Class IRI="#Ophthalmological_measures"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Off-period_dystonia"/>
        <Class IRI="#Drug-induced_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Olfaction"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Olfactory_dysfunction"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Open_space_hesitation"/>
        <Class IRI="#Freezing"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ophthalmological_measures"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Oral_pain"/>
        <Class IRI="#Sensory_symptom"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Organophosphate"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Organotypic_culture"/>
        <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Organotypic_slice_culture"/>
        <Class IRI="#Organotypic_culture"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Oromandibular_dystonia"/>
        <Class IRI="#Focal_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Oromandibular_dystonia_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Other_essential_tremor"/>
        <Class IRI="#Essential_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK10_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK11_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK1_mutation_induced_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK2_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK3_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK4_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK5_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK6_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PARK8_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PC12"/>
        <Class IRI="#Dopaminergic_cell_lines"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PET_biomarker"/>
        <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PET_imaging_biomarker"/>
        <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#PINK7_mutation_parkinsonism"/>
        <Class IRI="#Autosomal_dominant_form_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pallidal_stimulation"/>
        <Class IRI="#Deep_brain_stimulation_for_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pallidotomy"/>
        <Class IRI="#Central_surgery"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Paraquat"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Paresthesia"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Park2tm1Ccs"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Park2tm1Roo"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Park2tm1Shn"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Park2tm1Tmd"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Park2tm1Ykt"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Park7tm1Cai"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Park7tm1Shn"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Park7tm1Xz"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Parkin"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Parkinson_disease_dyskinesia_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Parkinson_fatigue_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Parkinson_psychosis_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Parkinsoniam_tremor"/>
        <Class IRI="#Tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Parkinsons_disease_cognitive_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Parkinsons_disease_dementia-short_screen"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Parkinsons_disease_questionnaire-39"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Paroxymal_dyskinesia"/>
        <Class IRI="#Dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Paroxysmal_dystonia"/>
        <Class IRI="#Fluctuating_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pathological_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pathological_gambling"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Peak_dose_dyskinesia"/>
        <Class IRI="#Drug-induced_dyskinesia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Peripheral_surgery"/>
        <Class IRI="http://protegeuserexample#Surgical_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Persistent_depression"/>
        <Class IRI="#Neurobehavioral_biomarkers"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pharmacological_management_of_parkinson_disease"/>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Physiological_biomarkers_od_Parkinson_disease"/>
        <Class IRI="#Biomarkers_in_the_diagnosis_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pink1tm1Aub"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pink1tm1Shn"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pittsburgh_sleep_quality_index"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Plasma_homocysteine"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Platelet_complex-1_activity"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Poliomyelitis"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Polysomnography"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Position-specific_postural_tremor"/>
        <Class IRI="#Postural_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Position_specific_writing"/>
        <Class IRI="#Primary_writing_tremot"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Post-traumatic_parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Postencephalic_parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Postural_instability"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Postural_irregularity"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Postural_tremor"/>
        <Class IRI="#Parkinsoniam_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Power_wheelchair"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pramipexole"/>
        <Class IRI="#Neuroprotective_agent_for_parkinson"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Primary_dystonia"/>
        <Class IRI="#Continual_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Primary_immature_dopaminergic_neuron"/>
        <Class IRI="#Cell_culture_models_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Primary_midbrain_culture"/>
        <Class IRI="#Primary_immature_dopaminergic_neuron"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Primary_orthostatic_tremor"/>
        <Class IRI="#Other_essential_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Primary_writing_tremot"/>
        <Class IRI="#Other_essential_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Prochlorperazine-induced_parkinsonism"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Progressive_pallidal_atrophy"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Progressive_supranuclear_palsy"/>
        <Class IRI="#Parkinson-Plus_syndrome"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Promethazine-induced_parkinsonism"/>
        <Class IRI="#Drug-induced_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Proteinopathy"/>
        <Class IRI="#Neuropathology_of_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Proteomic_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#OMICS_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Psychosis"/>
        <Class IRI="#Neuropsychiatric_dysfunction"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ptstm1Ich"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pulsion"/>
        <Class IRI="#Gait_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Punding"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Pyridoxal_kinase"/>
        <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Quantitative_tremor_analysis"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ramisectomy"/>
        <Class IRI="#Peripheral_surgery"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Rapid-onset_dystonia-parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Rapid_eye_movement_sleep_behaviour_disorder"/>
        <Class IRI="#Sleep_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Recessive_early-onset_parkinsonism"/>
        <Class IRI="#Autosomal_recessive_forms_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Reduced_CSF_gluthatione-SH"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Reserpine_model"/>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Rest_tremor"/>
        <Class IRI="#Differential_diagnosis"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Resting_tremor"/>
        <Class IRI="#Parkinsoniam_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Restless_legs_syndrome"/>
        <Class IRI="#Sleep_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Retropulsion"/>
        <Class IRI="#Gait_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Rigidity"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Risk_factors_for_Parkinson_disease"/>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Rotenon_model"/>
        <Class IRI="http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Rotenone"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Rural_living"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Rush_dyskinesia_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#SCOPA-COG"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#SH-SY5Y"/>
        <Class IRI="#Dopaminergic_cell_lines"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#SPECT_biomarker"/>
        <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#SPECT_imaging_biomarker"/>
        <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Saint_Luis_encephalitis"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Saliva_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Salsolinol"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Scales_for_outcomes_in_Parkinsons_disease-Motor"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Schwab_and_England_activities_of_daily_living_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Secondary_dystonia"/>
        <Class IRI="#Continual_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Segmental_dystonia"/>
        <Class IRI="#Primary_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Selective_peripheral_denervation"/>
        <Class IRI="#Peripheral_surgery"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sensory_symptom"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Shapiro_tourette_syndrome_severity_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Short_parkinsons_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Shuffling_gait"/>
        <Class IRI="#Gait_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Shy_Drager_syndrom"/>
        <Class IRI="#Multiple_system_atrophy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sialorrhoea"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Simple_kinetic_tremor"/>
        <Class IRI="#Kinetic_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Slc6a3tm1(cre)Lrsn"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sleep_EEG"/>
        <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sleep_attack"/>
        <Class IRI="#Sleep_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sleep_disorder"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sleep_disturbance"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Slowness_of_movement"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sncatm1Nbm"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sncatm1Rosl"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sncatm1Sud"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sporadic_OPCA"/>
        <Class IRI="#Multiple_system_atrophy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sporadic_dystonia"/>
        <Class IRI="#Primary_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sporadic_parkinson_disease"/>
        <Class IRI="http://protegeuserexample#Canonical__etiology"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Sporadic_tauopathy"/>
        <Class IRI="#Sporadic_parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Start_hesitation"/>
        <Class IRI="#Freezing"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Stem_cell_therapy"/>
        <Class IRI="#Cell_therapy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Striatal_iron"/>
        <Class IRI="#Miscellaneous_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Striatonigral_degeneration"/>
        <Class IRI="#Multiple_system_atrophy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Strict_diet"/>
        <Class IRI="#Risk_factors_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Structural_lesion-induced_parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Subthalamic_stimulation"/>
        <Class IRI="#Deep_brain_stimulation_for_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Swallowing_disorder"/>
        <Class IRI="#Non-motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Symptom_of_Parkinson_disease"/>
        <Class IRI="http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Symptomatic_skin_response"/>
        <Class IRI="#Testing_autonomic_nervous_system"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Synucleinopathy"/>
        <Class IRI="#Proteinopathy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Syphilis"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Syphilitic_parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Targeted_gene"/>
        <Class IRI="#Transgenic_mouse_model_of_Parkinsons_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Task-specific_kinetic_tremor"/>
        <Class IRI="#Kinetic_tremor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Task_specific_writing"/>
        <Class IRI="#Primary_writing_tremot"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tauopathy"/>
        <Class IRI="#Proteinopathy"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Testing_autonomic_nervous_system"/>
        <Class IRI="#Neurophysiological_testing"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tfamtm1Lrsn"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Thalamotomy"/>
        <Class IRI="#Central_surgery"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Three-wheeled_walking_stabilizer"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tightening_sensation"/>
        <Class IRI="#Sensory_symptom"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tingling_sensation"/>
        <Class IRI="#Sensory_symptom"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tnfrsf1atm1Imx"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tnfrsf1btm1Imx"/>
        <Class IRI="#Targeted_gene"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Toluene"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Toronto_western_spasmodic_torticollis_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Torsion_dystonia"/>
        <Class IRI="#Centralized_dystonia"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tourette_syndrome_global_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Toxin-induced_parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
        <Class IRI="#Etiology_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Toxoplasma"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Transcranial_magnetic_stimulation"/>
        <Class IRI="#Neurophysiological_testing"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Transcranial_ultrasound_biomarker"/>
        <Class IRI="#Neuroimaging_biomarkers_for_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Transgenic_Drosohila_model_of_Parkinson_disease"/>
        <Class IRI="#Genetic_models_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Transgenic_mouse_model_of_Parkinsons_disease"/>
        <Class IRI="#Mouse_models_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Treatment_of_Parkinson_s_disease"/>
        <Class IRI="http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tremor"/>
        <Class IRI="#Motor_features"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tremor-predominant_Parkinson_s_disease"/>
        <Class IRI="#Primary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Tuberculosis"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Turn_hesitation"/>
        <Class IRI="#Freezing"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Turning"/>
        <Class IRI="#Gait_disturbance"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Type_2_diabetes"/>
        <Class IRI="#Medical_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#U-shaped_walking_stabilizer"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ubiquinone_NADH_oxidoreductase"/>
        <Class IRI="#Neuroprotective_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ubiquitin"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Ultrasonography"/>
        <Class IRI="#In-vivo_biomarker_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Unified_Parkinson_s_disease_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Unified_dystonia_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Unified_myoclonus_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#University_of_California_Los_Angeles_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Urinary_8-OH-2dG"/>
        <Class IRI="#In-vitro_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Urine_biomarkers_of_Parkinson_disease"/>
        <Class IRI="#Biochemical_biomarkers_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Vascular_parkinsonism"/>
        <Class IRI="#Secondary_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Vesical_sphincter_EMG"/>
        <Class IRI="#Needle_electromyography"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Visiospatial_and_color_discrimination"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Visiospatial_deficit"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Vitamin_intake"/>
        <Class IRI="#Strict_diet"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Walking_difficulty"/>
        <Class IRI="#Clinical_markers_associated_with_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Wearing-off_questionnaire"/>
        <Class IRI="#Evaluation_of_Parkinson_s_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Webster_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Well-water_drinking"/>
        <Class IRI="#Environmental_risk_factor"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#West_Nile_virus"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Western_equine_encephalitis"/>
        <Class IRI="#Infectious_cause_of_parkinsonism"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Wheeled_walker"/>
        <Class IRI="#Assistive_devices_for_gait"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Wilson_s_disease"/>
        <Class IRI="#Familial_neurodegenerative_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Writers_cramp_rating_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#X-linked_dystonia_parkinsonism"/>
        <Class IRI="#Familial_neurodegenerative_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Yale_global_tic_severity_scale"/>
        <Class IRI="#Clinical_rating_scale"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Zebrafish_model_of_Parkinson_disease"/>
        <Class IRI="#Genetic_models_of_Parkinson_disease"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#n-hexane"/>
        <Class IRI="#Toxin_cause_of_parkinsonism"/>
    </SubClassOf>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Anti-cholinergic_drugs</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">anticholinergic medication</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Anti-cholinergic_drugs</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anti-cholinergic drug</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Budipine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Budipine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#COMT_inhibitors</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">COMT inhibitor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Camptocormia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bloch, F., Houeto, J. L., du Montcel, S. T., Bonneville, F., Etchepare, F., Welter, M. L., ... &amp; Agid, Y. (2006). Parkinson’s disease with camptocormia. Journal of Neurology, Neurosurgery &amp; Psychiatry, 77(11), 1223-1228.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Camptocormia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Camptocormia is defined as an abnormal flexion of the trunk that appears when standing or walking and disappears in the supine position. The origin of the disorder is unknown, but it is usually attributed either to a primary or a secondary paravertebral muscle myopathy or a motor neurone disorder. Camptocormia is also observed in a minority of patients with parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Camptocormia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Camptocormia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Canonical__etiology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Canonical__etiology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Important and main causes of Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Canonical__etiology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Canonical  etiology</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Cinnerzin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sethi K.D. (2004) Drug-induced Movement Disorders. Marcel Dekker, Inc.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Cinnerzin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">cinnarizine-induced extrapyramidal reactions</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Cinnerzin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Drug-induced parkinsonism due to the use of the vestibular sedative cinnarizine, which inhibits lipid peroxidation and blocks postsynaptic striatal dopamine receptors.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Cinnerzin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cinnarizine-induced Parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Clinical characteristics of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">clinical features of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">A broad spectrum of motor and non-motor features manifested by patienst with Parkinson&apos;s disease. The natural progression of PD is variable but is usually more rapid in patients with late onset and with the PIGD form of PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Clinical_view_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Clinical aspects of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Constipation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Constipation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Difficulty and delay in bowel movements. Constipation is an early but inconclusive symptom of Parkinson’s that tends to become more severe as the disease progresses.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Constipation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Constipation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Depression</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Depression</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A prolonged or intense state in which a person feels deep sadness, hopelessness, helplessness worthlessness, or guilt. Depression can be a response to external situations or events, such as the diagnosis or symptoms of Parkinson’s disease. Depression also can be an integral element of the overall presentation of symptoms in Parkinson’s disease, in which case it is called an endogenous depression.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Depression</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Depression</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Dopamine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://www.psychologytoday.com/basics/dopamine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Dopamine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dopamine is a neurotransmitter that helps control the brain&apos;s reward and pleasure centers. Dopamine also helps regulate movement and emotional responses, and it enables us not only to see rewards, but to take action to move toward them. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Dopamine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dopamine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Dopamine_agonists</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dopamine agonist</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Dopamine_dysregulation_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">O’Sullivan, S. S., Evans, A. H., &amp; Lees, A. J. (2009). Dopamine Dysregulation Syndrome. CNS drugs, 23(2), 157-170.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Dopamine_dysregulation_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DDS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Dopamine_dysregulation_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dopamine dysregulation syndrome (DDS) is a relatively recently described iatrogenic disturbance that may complicate long-term symptomatic therapy of Parkinson&apos;s disease. Patients with DDS develop an addictive pattern of dopamine replacement therapy (DRT) use, administering doses in excess of those required to control their motor symptoms. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Dopamine_dysregulation_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dopamine dysregulation syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Emerging_etiology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jenner, P., Schapira, A. H. V., &amp; Marsden, C. D. (1992). New insights into the cause of Parkinson&apos;s disease. Neurology, 42(12), 2241-2241.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Emerging_etiology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">New insights into the cause of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Emerging_etiology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Emerging etiology</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#End_of_dose</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">en.wikipedia.org/wiki/L-DOPA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#End_of_dose</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Effects of chronic levodopa administration in the treatment of Parkinson disease indicating deterioration of function.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#End_of_dose</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">End of dose</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Epidemiological_history</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">de Lau, L. M., &amp; Breteler, M. (2006). Epidemiology of Parkinson&apos;s disease. The Lancet Neurology, 5(6), 525-535.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Epidemiological_history</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">epidemiology of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Epidemiological_history</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral"> What is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Epidemiological_history</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Epidemiological history</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Epigenetics</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dupont, C., Armant, D. R., &amp; Brenner, C. A. (2009, September). Epigenetics: definition, mechanisms and clinical perspective. In Seminars in reproductive medicine (Vol. 27, No. 5, p. 351). NIH Public Access.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Epigenetics</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The study of changes in gene function that are mitotically and/or meiotically heritable and that do not entail a change in DNA sequence.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Epigenetics</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Epigenetics</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Festination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Festination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The Latin origin of the word festination means “to hasten,” as a person with this gait disturbance appears to do. A festinating gait consists of short, increasingly rapid steps with a marked forward lean, as though the person is about to break into a run.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Festination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Festination</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Fluctuation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. (2005). Motor fluctuations and dyskinesias in Parkinson&apos;s disease: clinical manifestations. Movement Disorders, 20(S11), S11-S16.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Fluctuation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">luctuations in the symptoms of Parkinson&apos;s disease (PD), such as wearing-off and on-off effects, and dyskinesias are related to a variety of factors, including duration and dosage of levodopa, age at onset, stress, sleep, food intake, and other pharmacokinetic and pharmacodynamic mechanisms. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Fluctuation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fluctuation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Flunarizin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Litvan, I. (Ed.). (2005). Atypical parkinsonian disorders: clinical and research aspects. Humana Press Incorporated.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Flunarizin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A calcium channel blocker which can cause drug-induced parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Flunarizin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Flunarizine-induced Parkinson</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Hallucination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Hallucination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A sensory perception of an event that is not really occurring. Hallucinations can affect any or all of the five physical senses (sight, hearing, touch, taste, smell). Hallucinations, usually visual, are common in Parkinson’s and can be side effects of ANTI-PARKINSON’S MEDICATIONS, particularly DOPAMINERGIC MEDICATIONS such as LEVODOPA and DOPAMINE AGONIST MEDICATIONS such as BROMOCRIPTINE and ROPINIROLE. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Hallucination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hallucination</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Hereditary_forms_of_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Facts on Files, Inc.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Hereditary_forms_of_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hereditary form of parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Hereditary_forms_of_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">genetic forms of Parkinson&apos;s</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Hereditary_forms_of_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hereditary forms of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Hereditary_forms_of_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Some forms of Parkinson&apos;s clearly are hereditary, appearing in gneration after generation in certain families.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Hereditary_forms_of_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hereditary form of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Hit_and_run_viral_infection</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://www.bvd-info.ch/veterinarians/types_of_infection.html</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Hit_and_run_viral_infection</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The hit and run strategy means that the viruses make use of a relatively short period of susceptibility to infection in their host population in order to multiply and thus for survival. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Hit_and_run_viral_infection</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hit and run viral infection</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#IPS_derived_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Byers, B., Lee, H. L., &amp; Pera, R. R. (2012). Modeling Parkinson’s disease using induced pluripotent stem cells. Current neurology and neuroscience reports, 12(3), 237-242.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#IPS_derived_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Induced Pluripotent Stem Cell-Derived Neural Cells</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#IPS_derived_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">iPSC-derived DA neurons</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#IPS_derived_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">iPSC-derived neurons</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#IPS_derived_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Stable pluripotent lines from patients with inherited forms of disease, with their endogenous genome and its transcriptional feedbacks largely intact.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#IPS_derived_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">IPS derived model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Incontinence</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Incontinence</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The inability to retain urine or feces. In the person with Parkinson’s, this usually results from the loss of muscle control of the sphincter muscles in the bladder and rectum, typically in later stages of the disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Incontinence</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Incontinence</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Inflammation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Inflammation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Significant glial reaction in the SNpc.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Inflammation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Inflammation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Lactacysteime</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Factor S.A., Weiner J.W. (2008) Parkinson&apos;s Disease-Diagnosis and Clinical Management. Demos Medical Publishing, LLC. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Lactacysteime</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A proteasomal inhibitor model that causes acute degeneration of dopaminergic neurons when injected stereotacticly into the nigra.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Lactacysteime</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lactacystin model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Leaky_gut</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">en.wikipedia.org/wiki/Leaky_gut‎</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Leaky_gut</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Leaky gut is a name used to describe intestinal or bowel hyperpermeability.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Leaky_gut</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Leaky gut</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Lewy_body_dementia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Facts on Files, Inc.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Lewy_body_dementia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DLB</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Lewy_body_dementia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lewy body disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Lewy_body_dementia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dementia with Lewy bodies</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Lewy_body_dementia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">diffuse Lewy body disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Lewy_body_dementia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A form of dementia, the symptoms of which resemble those of Alzheimer&apos;s disease, that results from lewy body infiltration of brain tissue and in which there are components motor function impairment similar to the symptoms of Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Lewy_body_dementia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lewy body dementia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Long_term_complication_of_medication</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Marsden, C. D. (1994). Problems with long-term levodopa therapy for Parkinson&apos;s disease. Clinical neuropharmacology.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Long_term_complication_of_medication</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">long-term complications of treatment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Long_term_complication_of_medication</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Problems with long-term levodopa therapy for Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Long_term_complication_of_medication</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Long term complication of medication</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#MAO_inhibitors</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MAO inhibitor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Memantine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Memantine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Models_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Nass, R., &amp; Przedborski, S. (Eds.). (2011). Parkinson&apos;s Disease: molecular and therapeutic insights from model systems. Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Models_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s disease model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Models_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">model for parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Models_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Non-human organisms that reproduce one or several phenotypic or biochemical characteristics of the PD pathogenesis.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Models_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Model of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Mucuna_pruriens</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Velvel bean</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Mucuna_pruriens</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mucuna pruriens</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#NMDA_antagonist</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">NMDA antagonist</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#NSAID</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://en.wikipedia.org/wiki/Non-steroidal_anti-inflammatory_drug</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#NSAID</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Aspirin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#NSAID</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Nonsteroidal anti-inflammatory drugs, usually abbreviated to NSAIDs —but also referred to as nonsteroidal anti-inflammatory agents/analgesics (NSAIAs) or nonsteroidal anti-inflammatory medicines (NSAIMs)—are a class of drugs that provide analgesic and antipyretic (fever-reducing) effects, and, in higher doses, anti-inflammatory effects.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#NSAID</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">NSAID</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Orthostatic_dysregulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Orthostatic_dysregulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A drop in blood pressure that occurs with a change in position, most commonly from lying down to standing up and sometimes from sitting to standing. Orthostatic HYPOTENSION is a common side effect of many ANTIPARKINSON’S MEDICATIONS, and can be caused by Parkinson’s.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Orthostatic_dysregulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Orthostatic hypotension</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#PANDA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kalbe, E., Calabrese, P., Kohn, N., Hilker, R., Riedel, O., Wittchen, H. U., ... &amp; Kessler, J. (2008). Screening for cognitive deficits in Parkinson&apos;s disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism &amp; related disorders, 14(2), 93-101.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#PANDA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PANDA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#PANDA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The PANDA is an economical, easy-to-use and sensitive tool to detect neuropsychological dysfunctions in PD patients in clinical practice. It comprises of five cognitive tasks and a short depression questionnaire. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#PANDA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson neuropsychometric dementia assessment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Physical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Physical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A specialty of health care that focuses on improving and restoring physical function after injury or disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Physical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Physical therapy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Pick&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Adler, C. H., &amp; Ahlskog, J. E. (Eds.). (2000). Parkinson&apos;s disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Springer.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Pick&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The classic features of Pick&apos;s disease are personality changes and dementia but several reports describe patients with findings similar to those of CBD including assymetric dystonia, myoclonus as well as cortical atrophy and Pick bodies.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Pick&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pick&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Pisa-syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Doherty, K. M., Davagnanam, I., Molloy, S., Silveira-Moriyama, L., &amp; Lees, A. J. (2013). Pisa syndrome in Parkinson&apos;s disease: a mobile or fixed deformity?. Journal of Neurology, Neurosurgery &amp; Psychiatry.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Pisa-syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pisa syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Pisa-syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pisa syndrome is defined as &gt;10° lateral flexion in the standing position,1 and it has been suggested that in the context of Parkinson&apos;s disease (PD) it is an axial dystonia analogous to that seen as a rare consequence of neuroleptic therapy.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Pisa-syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pisa-syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Protective_effect_of_nicotine_or_smoke</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Miller R.Leah, Das K Salil, Cigarette smoking and Parkinson’s disease, EXCLI Journal 2007;6:93-99.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Protective_effect_of_nicotine_or_smoke</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Several epidemiological studies have found a negative association between cigarette smoking and PD. It is reported that patients who smoke are 50% less likely to have PD when compared to their non-smoking counterparts. This suggests that cigarette smoking might exert a neuroprotective effect.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Protective_effect_of_nicotine_or_smoke</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Protective effect of smoking</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Qigong</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schmitz-Hübsch, T., Pyfer, D., Kielwein, K., Fimmers, R., Klockgether, T. and Wüllner, U. (2006), Qigong exercise for the symptoms of Parkinson&apos;s disease: A randomized, controlled pilot study. Mov. Disord., 21: 543–548. doi: 10.1002/mds.20705</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Qigong</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Qigong (pronounced “chi kung”) is a general term for a large variety of traditional Chinese energy exercises and therapies. Its immediate and sustained effects of Qigong on motor and nonmotor symptoms of PD has been shown.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Qigong</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Qigong</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Random_on_off</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fernandez, H. H. (2012). Updates in the medical management of Parkinson disease. Cleveland Clinic journal of medicine, 79(1), 28-35.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Random_on_off</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Random fluctuations between the &apos;off&apos; state and the &apos;on&apos; state.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Random_on_off</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Random on off</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pahwa, R., Lyons, K. E., &amp; Koller, W. (Eds.). (2003). Handbook of Parkinson&apos;s disease. CRC Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reserpine (RE)-induced oral dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hypokinesia induced by reserpine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">reserpine-induced catalepsy </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">reserpine-induced hypokinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">reserpine-induced motor disturbances</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">reserpine-induced rigidity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">reserpine-induced rorfacial dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">reserpine-induced tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reserpine is a catecholamine-depleting agent that blocks vesicular storage of monoamines and induces the akinetic state.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Reserpin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reserpine-induced Parkinson</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Sexual_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tuite, P. J. (2009). Parkinson&apos;s Disease: A Guide to Patient Care. Springer Publishing Company.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Sexual_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">genitourinary dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Sexual_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sexual dysfunction may involve a reduction in sex drive with difficulty becoming aroused, difficulty achieving and sustaining an erection, inability to reach orgasm, or pain with sexual activity. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Sexual_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sexual dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Smoke</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://www.merriam-webster.com/medical/smoke?show=0&amp;t=1380277934</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Smoke</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral"> to inhale and exhale the fumes of burning plant material and especially tobacco; especially : to smoke tobacco habitually .</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Smoke</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Smoke</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Solvent_exposure</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Goldman, S. M., Quinlan, P. J., Ross, G. W., Marras, C., Meng, C., Bhudhikanok, G. S., Comyns, K., Korell, M., Chade, A. R., Kasten, M., Priestley, B., Chou, K. L., Fernandez, H. H., Cambi, F., Langston, J. W. and Tanner, C. M. (2012), Solvent exposures and parkinson disease risk in twins. Ann Neurol., 71: 776–784. doi: 10.1002/ana.22629</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Solvent_exposure</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to specific solvents may increase risk of PD. TCE is the most common organic contaminant in groundwater, and PERC and CCl4 are also ubiquitous in the environment. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Solvent_exposure</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Solvent exposure</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Surgical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Surgical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">surgical interventional therapies in Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Surgical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">surgical therapy of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Surgical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">surgical treatment of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Surgical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Invasive intervention to alter the functions of brain structures involved in movement that become dysfunctional in Parkinson’s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Surgical_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Surgical therapy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Synaptic_pathology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Picconi, B., Piccoli, G., &amp; Calabresi, P. (2012). Synaptic dysfunction in Parkinson’s disease. In Synaptic Plasticity (pp. 553-572). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Synaptic_pathology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">synaptic dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Synaptic_pathology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The pathological events occurring precociously at the synapses of PD patients.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Synaptic_pathology</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Synaptic pathology</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Taichi</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Li, F., Harmer, P., Fitzgerald, K., Eckstrom, E., Stock, R., Galver, J., ... &amp; Batya, S. S. (2012). Tai chi and postural stability in patients with Parkinson&apos;s disease. New England Journal of Medicine, 366(6), 511-519.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Taichi</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tai chi, a balance-based exercise, has been shown to improve strength, balance, and physical function and to prevent falls in older adults.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Taichi</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Taichi</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Tetrabenazine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hardiman O. (2011) Neurodegenerative Disorders: A Clinical Guide. Springer</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Tetrabenazine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">TBZ induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Tetrabenazine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">tremor induced by tetrabenazine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Tetrabenazine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tetrabenazine administration depletes dopamine and can also cause parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Tetrabenazine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tetrabenazine-induced Parkinson</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Duty, S., &amp; Jenner, P. (2011). Animal models of Parkinson&apos;s disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology, 164(4), 1357-1391.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lesion model of parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pharmacological model of parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">toxin-based models</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">toxin-induced animal model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">toxin-induced rodent models of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Toxin-based models of nigro-striatal tract degeneration.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Toxic_model_of_parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Toxin-induced model of parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Urinary_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Urinary_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Urinary symptoms are very common in Parkinson&apos;s disease (PD). They are primarily irritative (frequency, urgency, urge incontinence) and correlate with the urodynamic finding of involuntary detrusor contractions at early stages of bladder filling (detrusor hyperreflexia).</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Urinary_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Urinary dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Valproec_acid</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti K. and verhagen L. (2010) Encyclopedia of Movement Disorders (Vol. 1). Academic Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Valproec_acid</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">VPA-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Valproec_acid</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism induced by valporate</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Valproec_acid</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">valporate-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Valproec_acid</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">valproic acid and parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>http://protegeuserexample#Valproec_acid</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">valproic-acid-induced tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Valproec_acid</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A non-neuroleptic which induces parkinsonism through unknown mechanisms. It does not affect dopamine receptors. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Valproec_acid</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Valproic acid-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>http://protegeuserexample#Wearing_off</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>http://protegeuserexample#Wearing_off</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A period during which dosage of one of the ANTI-PARKINSON’S MEDICATIONS should still be effective but is not. Wearing-off is an indication that LEVODOPA is losing its ability to meet the brain’s DOPAMINE needs.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>http://protegeuserexample#Wearing_off</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Wearing off</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#19-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#19-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Patient Card Questionnaire</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#19-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Quick Questionnaire</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#19-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">19-item Wearing-off Questionnaire</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#32-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#32-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">WOQ-32</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#32-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">32-item Wearing-off Questionnaire</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#6-OHDA_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Duty, S., &amp; Jenner, P. (2011). Animal models of Parkinson&apos;s disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology, 164(4), 1357-1391.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#6-OHDA_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">6-OHDA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#6-OHDA_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The 6-OHDA model mimics many of biochemical features of PD, including reduced levels of striatal dopamine and tyrosine hydroxylase. 6-OHDA produces a dose-dependent degeneration of the nigro-striatal tract.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#6-OHDA_model</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">6 OHDA model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#9-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#9-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">WOQ-9</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#9-item_Wearing-off_Questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">9-item Wearing-off Questionnaire</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Abnormal_circadian_rhythm</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Abnormal_circadian_rhythm</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Abnormal circadian rhythm</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Abnormal_involuntary_movement_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Abnormal_involuntary_movement_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A purely objective scale that rates dyskinesia across body parts by severity.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Abnormal_involuntary_movement_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Abnormal involuntary movement scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Acquired_metabolic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Adler C.H. &amp; Ahlskog J.E. (2000) Parkinson&apos;s disease and movement disorders. HUMANA PRESS.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Acquired_metabolic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism due to metabolic disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Acquired_metabolic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Metabolic disorders can result in parkinsonism or produce symptoms that may resemble parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Acquired_metabolic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Acquired metabolic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Action_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Action_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Type III tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Action_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Action tremor is any tremor occuring on voluntary contraction of muscle.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Action_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Action tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Adcy5tm1Yish</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Adcy5tm1Yish</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Adh7tm1Gdu</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Adh7tm1Gdu</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Adult_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Adult_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">late onset dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Adult_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A category of dystonia in which the symptoms begin in adulthood, typically after the age of 30. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Adult_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Adult onset dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Aggregation_of_alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Iwatsubo, T. (2003). Aggregation of α-synuclein in the pathogenesis of Parkinson’s disease. Journal of neurology, 250(3), iii11-iii14.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Aggregation_of_alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">alpha-synuclein aggregation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Aggregation_of_alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">deposition of alpha-synuclein</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Aggregation_of_alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The deposition of α-synuclein, an abundant presynaptic brain protein, as fibrillary aggregates in affected neurons or glial cells.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Aggregation_of_alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Aggregation of alpha-synuclein</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Aggregation_of_tau_protein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">amyloidosis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Aggregation_of_tau_protein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">deposition of tau</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Aggregation_of_tau_protein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">protein aggregation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Aggregation_of_tau_protein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">tau aggregation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Aggregation_of_tau_protein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pathological aggregation of tau protein in the human brain leads to tauopathy, a class of neurodegenerative diseases, in which tau protein is deposited within neurons in the form of neurofibrillary tangles.  </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Aggregation_of_tau_protein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Aggregation of tau protein</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Agraphia</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Agraphia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Agraphia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Akathisia</IRI>
        <Literal datatypeIRI="&xsd;string">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Akathisia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An inability to sit still, typically as an aspect of AGITATION or ANXIETY. In people with Parkinson’s disease, akathisia is relatively rare and when it does occur is often an adverse reaction to a medication used to treat the disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Akathisia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Akathisia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Akinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Akinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">akinetic</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Akinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Is defined as the loss of movement.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Akinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Akinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Alcohol_consumption</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Liu, R., Guo, X., Park, Y., Wang, J., Huang, X., Hollenbeck, A., ... &amp; Chen, H. (2013). Alcohol Consumption, Types of Alcohol, and Parkinson’s Disease. PloS one, 8(6), e66452.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Alcohol_consumption</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Beer and liquor consumption may have opposite associations with PD: low to moderate beer consumption with lower PD risk and greater liquor consumption with higher risk.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Alcohol_consumption</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Alcohol consumption</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Alexander_technique</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://en.wikipedia.org/wiki/Alexander_technique</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Alexander_technique</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral"> The Alexander technique teaches people how to stop using unnecessary levels of muscular and mental tension during their everyday activities. It is an educational process rather than a relaxation technique or form of exercise. The Alexander technique has been shown to be helpful for back pain and Parkinson&apos;s.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Alexander_technique</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Alexander technique</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Recchia, A., Debetto, P., Negro, A., GUIDOLIN, D., SKAPER, S. D., &amp; GIUSTI, P. (2004). α-Synuclein and Parkinson’s disease. The FASEB journal, 18(6), 617-626.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">aSyn</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">alpha-syn</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Alpha-synuclein (α-syn) is a small soluble protein expressed primarily at presynaptic terminals in the central nervous system.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Alpha-synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Alpha-synuclein</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Alpha_synuclein_index</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Alpha_synuclein_index</IRI>
        <Literal datatypeIRI="&xsd;string">The α-Syn index is the ratio of nitrative α-Syn vs. native α-Syn and provides an sensitive and accurate estimate of nitrative as well as oxidative stress to α-Syn implicated in Lewy body pathogenesis.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Alpha_synuclein_index</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Alpha synuclein index</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Altered_tear_film</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Altered tear film</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Amyloid-beta</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., ... &amp; Ward, P. J. (1990). Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science, 248(4959), 1122-1124.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Amyloid-beta</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A-beta</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Amyloid-beta</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">APP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Amyloid-beta</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Abeta</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Amyloid-beta</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">amyloid</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Amyloid-beta</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">beta-amyloid</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Amyloid-beta</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The amyloid beta peptide (A beta P) is a small fragment of the much larger, broadly distributed amyloid precursor protein (APP). </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Amyloid-beta</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Amyloid-beta</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Anal_sphincter_EMG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anal sphincter EMG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Anhedonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Anhedonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anhedonia is the inability to experience physical or social pleasure. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Anhedonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anhedonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Anismus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anismus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Anosmia</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Anosmia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anosmia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Anxiety</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Anxiety</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Intense feelings of fear and worry. In people with Parkinson’s disease, anxiety is both a symptom and a reaction.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Anxiety</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anxiety</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Apathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Apathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A lack of motivation, interest, and energy. Apathy is an early and progressive symptom of DEMENTIA in Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Apathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Apathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Apomorphine_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Apomorphine_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">apomorphine challenge test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Apomorphine_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">response to apomorphine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Apomorphine_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A test to determine responsiveness and to establish effective doses and to observe for side effects in parkinsonian patients.  </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Apomorphine_test</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Apomorphine test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Apraxia_of_eyelid_opening</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Apraxia of eyelid opening</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Archimedes_spiral</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Saunders‐Pullman, R., Derby, C., Stanley, K., Floyd, A., Bressman, S., Lipton, R. B., ... &amp; Pullman, S. L. (2008). Validity of spiral analysis in early Parkinson&apos;s disease. Movement disorders, 23(4), 531-537.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Archimedes_spiral</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Archimedes spirals</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Archimedes_spiral</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">spiral analysis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Archimedes_spiral</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">spirography</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Archimedes_spiral</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Spiral analysis is an objective, easy to administer noninvasive test that has been proposed to measure motor dysfunction in Parkinson disease. Spiral analysis is a noninvasive system of quantifying motor function based on kinematic and physiologic features derived from handwritten spirals. Spiral analysis provides computer-generated measures of force, speed, time, tightness and uniformity of the spiral to record position, force, and time measurements.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Archimedes_spiral</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Archimedes spiral</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Arm_dystonia_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Arm_dystonia_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ADDS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Arm_dystonia_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The ADDS evaluates functional impairment of the dystonic hand on a 7-item scale, scored from 0 to 3.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Arm_dystonia_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Arm dystonia disability scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Assistive_devices_for_gait</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pahwa, R., Lyons, K. E., &amp; Koller, W. (Eds.). (2003). Handbook of Parkinson&apos;s disease. CRC Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Assistive_devices_for_gait</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gait-assistive devices</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Assistive_devices_for_gait</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Devices which can help improve balance, reduce joint stress, and enhance feelings of security when moving about.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Assistive_devices_for_gait</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Assistive device</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Autonomic_dysfunction</IRI>
        <Literal datatypeIRI="&xsd;string">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Autonomic_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Changes to body functions regulated by the autonomic NERVOUS SYSTEM that are the result of injury or disease. As Parkinson’s disease progresses, the NEUROTRANSMITTER imbalances affect other organ systems in addition to the SUBSTANTIA NIGRA and affect motor movement processes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Autonomic_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Autonomic dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Autosomal_dominant_form_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Autosomal_dominant_form_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">raditional linkage studies followed by gene sequencing have identified genes with definitive evidence for pathogenicity causing autosomal dominant PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Autosomal_dominant_form_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Autosomal dominant form of parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Autosomal_recessive_forms_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Autosomal_recessive_forms_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Recessive loci can be found by linkage mapping in small families or through autozygosity mapping. Using these methods, a relativela high proportion of patients with early Parkinson&apos;s disease have been found to be caused by recessive mutations in several genes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Autosomal_recessive_forms_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Autosomal recessive form of parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Autosomal_recessive_juvenile_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Saito, M., Maruyama, M., Ikeuchi, K., Kondo, H., Ishikawa, A., Yuasa, T., &amp; Tsuji, S. (2000). Autosomal recessive juvenile parkinsonism. Brain and Development, 22, 115-117.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Autosomal_recessive_juvenile_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">AR-JP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Autosomal_recessive_juvenile_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">autosomal recessive form of juvenile Parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Autosomal_recessive_juvenile_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Autosomal recessive juvenile parkinsonism (AR-JP) is a hereditary neurodegenerative disorder characterized by levodopa-responsive parkinsonism with onset before age 40 years and a slowly progressive course.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Autosomal_recessive_juvenile_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Autosomal recessive juvenile parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Axial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Axial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dystonia that affects the &apos;midline&apos; of the body—chest, abdominal, and back muscles</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Axial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Axial dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#BDNF</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#BDNF</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">BDNF</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#BELcode</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">BELcode</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Beginning-of-dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schapira A.H.V. (2010) Parkinson&apos;s disease. Oxford University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Beginning-of-dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">beginning-of-dose</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Beginning-of-dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dyskinesias that occur at the beginning of dose, when plasma concentrations of dopaminergic medications are increasing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Beginning-of-dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Beginning-of-dose dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Berg_balance_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Blum, L., &amp; Korner-Bitensky, N. (2008). Usefulness of the Berg Balance Scale in stroke rehabilitation: a systematic review. Physical Therapy, 88(5), 559-566.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Berg_balance_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">BBS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Berg_balance_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Berg balance test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Berg_balance_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A widely used clinical test of a person&apos;s static and dynamic balance abilities.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Berg_balance_scale</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Berg balance scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Biochemical_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Biochemical_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">The ideal biochemical biomarker would need to be easily measured and to reflect accurately the ongoing degenerative process in the basal ganglia. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Biochemical_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Biochemical biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Biomarkers_in_the_diagnosis_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Biomarkers_in_the_diagnosis_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">The presence of a biomarker makes it possible to diagnose conclusively, and sometimes even screen for, the condition. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Biomarkers_in_the_diagnosis_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Biomarkers in the diagnosis of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Biophysical_biomarkers_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Biophysical_biomarkers_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Nonimaging biomarkers that have biophysical properties, which permit their measurement in biological samples.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Biophysical_biomarkers_of_Parkinson&apos;s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Biophysical biomarker of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Blepharospasm</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Blepharospasm</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Blood_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Blood_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Platelets have been used for a long time to model serotonergic and dopaminergic neuron behaviour (Da Prada et al., 1988), and since they are easily collected they make appealing candidates as peripheral biomarkers of oxidative stress, rather than other sources such as skeletal muscle .</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Blood_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Blood biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Bmpr1atm1Bhr</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Bmpr1atm1Bhr</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Bmpr1atm2.1Bhr</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Bmpr1atm2.1Bhr</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Body_tremor</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Body_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Body tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Borreliosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Borreliosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lime disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Borreliosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Borreliosis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Botulinum_toxin_A</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Botulinum_toxin_A</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Botulinum toxin A</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Botulinum_toxin_B</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Botulinum_toxin_B</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Botulinum toxin B</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Braak_staging_scheme_for_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Burke, R. E. (2010). Evaluation of the Braak staging scheme for Parkinson&apos;s disease: Introduction to a panel presentation. Movement Disorders, 25(S1), S76-S77.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Braak_staging_scheme_for_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Braak Parkinson disease (PD) stage</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Braak_staging_scheme_for_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Braak stage</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Braak_staging_scheme_for_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Braak stages</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Braak_staging_scheme_for_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Braak and colleagues have proposed a staging scheme for Parkinson&apos;s disease (PD) based on patterns of abnormal immunostaining for alpha-synuclein. They have proposed a temporal sequence in which the appearance of Lewy bodies and neurites in brainstem structures represent the earliest manifestations of the disease, and that this involvement of non-dopaminergic structures long antedates involvement of the substantia nigra and the appearance of the cardinal motor signs that are now required for diagnosis.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Braak_staging_scheme_for_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Braak staging</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Brachial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Brachial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dystonia in one arm and trunk or both arms.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Brachial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Brachial dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Bradykinesia_symptom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Bradykinesia_symptom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bradykinesia refers to slowness of movement and is the most characteristic clinical feature of PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Bradykinesia_symptom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bradykinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Bradyphrenia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Bradyphrenia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">BRADYPHRENIA is a slowness of the thought process.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Bradyphrenia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bradyphrenia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Burning_sensation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Burning_sensation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Burning sensation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#C-raclopride_PET</IRI>
        <Literal datatypeIRI="&xsd;string">It provids an indirect estimate of synaptic dopamine levels from changes in tracer D2 receptor binding potentials</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#C-raclopride_PET</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#C-raclopride_PET</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">C-raclopride PET</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#C._elegans_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Duty, S., &amp; Jenner, P. (2011). Animal models of Parkinson&apos;s disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology, 164(4), 1357-1391.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#C._elegans_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A genetic model with many of the PD-associated genes and molecular pathways involved in PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#C._elegans_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">C. elegans model of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#CSF_alpha_synuclein</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#CSF_alpha_synuclein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">CSF alpha synuclein</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#CSF_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#CSF_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Chemical composition of CSF in Parkinson&apos;s disease, especially in relation to potential markers of oxidative stress has been used as a potential source of biomarkers.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#CSF_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">CSF biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#CSF_osteopontin</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#CSF_osteopontin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">CSF osteopontin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#CSM14.1</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#CSM14.1</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cell lines originated from rat embryonal mesencephalon presenting TH phenotype.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#CSM14.1</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">CSM14.1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Caffeine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Caffeine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Caffeine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Caffeine_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., &amp; Willett, W. C. (2001). Prospective study of caffeine consumption and risk of Parkinson&apos;s disease in men and women. Annals of neurology, 50(1), 56-63.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Caffeine_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Experimental findings suggest that caffeine intake may reduce the risk of Parkinson&apos;s disease. In fact, inverse associations between consumption of coffee or caffeine and risk of Parkinson&apos;s disease have been found in case-control studies in Germany and Sweden, whereas a nonsignificant inverse association was found in a third study in Spain. These results are consistent with a protective effect of caffeine but could also reflect an effect of symptoms of Parkinson&apos;s disease on caffeine consumption.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Caffeine_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Caffeine intake</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cancer</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Elbaz, A., Peterson, B. J., Bower, J. H., Yang, P., Maraganore, D. M., McDonnell, S. K., ... &amp; Rocca, W. A. (2005). Risk of cancer after the diagnosis of Parkinson&apos;s disease: a historical cohort study. Movement disorders, 20(6), 719-725.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cancer</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Increased risk of cancer in the presence of PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cancer</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cancer</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Carbon_disulphide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Carbon_disulphide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Carbon disulfide, usually in solvents or pesticides, can cause Parkinson&apos;s disease that is associated with other neurological symptoms. The toxic effects can persist for years after exposure to the carbon disulfide has ceased. Potential sources include pesticides used as fumigants, disulfiram (a drug used in the treatment of chronic alcoholism), industrial solvents, solvents used in the production of viscose rayon and cellophane film. Means of toxicity is not established. However, carbon disulphide interferes with pyridoxal 5-phosphate. Pyridoxal 5-phosphate is essential for the formation of dopamine from L-dopa. So carbon disulphide may cause Parkinson&apos;s disease symptoms by reducing the formation of L-dopa.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Carbon_disulphide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Carbon disulphide</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Carbon_monoxide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ringel, S. P., &amp; Klawans, H. L. (1972). Carbon monoxide-induced parkinsonism. Journal of the neurological sciences, 16(3), 245-251.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Carbon_monoxide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonian syndrome following acute carbon monoxide intoxication</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Carbon_monoxide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism after carbon monoxide poisoning</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Carbon_monoxide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Severe, rapidly progressive Parkinsonism that develops after prolonged exposure to carbon monoxide.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Carbon_monoxide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Carbon monoxide-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cardiac_sympathetic_innervation</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cardiac_sympathetic_innervation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cardiac sympathetic innervation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cell_culture_models_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Journal of Neural Transmission. Supplementa Volume 70, 2006, pp 261-268 .</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cell_culture_models_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cell-based models of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cell_culture_models_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cellular models of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cell_culture_models_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cellular models in which most new experimental therapeutic strategies for Parkinson&apos;s disease are first evaluated.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cell_culture_models_of_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Cell culture model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cell_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cell_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">cell replacement therapy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cell_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cell replacement therapy using the tissues of fetal ventral mesencephalon has proven to be beneficial for treating PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cell_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cell therapy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Central_conduction_time</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Central conduction time</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Central_surgery</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Central_surgery</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Opposite to peripheral surgery, it points to surgery on the brain for deep brain stimulation. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Central_surgery</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Central surgery</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Centralized_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Centralized_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Generalized dystonia affects most or all of the body. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Centralized_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Centralized dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Charnoly_body</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sharma, S., Rais, A., Sandhu, R., Nel, W., &amp; Ebadi, M. (2013). Clinical significance of metallothioneins in cell therapy and nanomedicine. International journal of nanomedicine, 8, 1477.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Charnoly_body</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Aggregation of multilamellar electron-dense membrane stacks (Charnoly body) due to mitochondrial degeneration.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Charnoly_body</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Charnoly body</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Chemodenervation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Elovic, E. P., Esquenazi, A., Alter, K. E., Lin, J. L., Alfaro, A., &amp; Kaelin, D. L. (2009). Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. PM&amp;R, 1(9), 842-851.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Chemodenervation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">chemo-denervation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Chemodenervation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A process used by clinicians to manage focal muscle overactivity through the use of an established agent such as phenol or alcohol or one of the newer Botolinum toxins. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Chemodenervation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Chemodenervation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Childhood_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Childhood_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">childhood onset symptomatic dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Childhood_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">childhood-onset dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Childhood_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">childhood-onset generalized dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Childhood_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">early onset dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Childhood_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Early-onset generalized dystonia is characterized by the twisting of the limbs, specifically the foot and leg or hand and arm. The spasms may spread to involve twisting contractions of other parts of the body.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Childhood_onset_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Childhood onset dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Chlorpromazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Adler C.H. &amp; Ahlskog J.E. (2000) Parkinson&apos;s disease and movement disorders. HUMANA PRESS.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Chlorpromazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsonism induced by classic neuroleptic agent chlorpromazine.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Chlorpromazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Chlorpromazine-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cigarette_smoking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fratiglioni, L., &amp; Wang, H. X. (2000). Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies. Behavioural brain research, 113(1), 117-120.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cigarette_smoking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PD and smoking</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cigarette_smoking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PD with smoking</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cigarette_smoking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s disease risks associated with cigarette smoking</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cigarette_smoking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">cigarette smoking, and the risk of Parkinson&apos;s</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cigarette_smoking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">smoking and Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cigarette_smoking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">There is a consistent negative association between PD and smoking.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cigarette_smoking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cigarette smoking</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Classical_essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Classical_essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">classical ET</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Classical_essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A monosymptomatic, predominant postural and action tremor that is usually slowly progressive over time. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Classical_essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Classical essential tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Clinical_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Clinical_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">CDRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Clinical_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">This consists of independent evaluations for hyperkinesia and dystonic posture in seven body parts, scored from 0 to 4.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Clinical_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Clinical dyskinesia rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Clinical_markers_associated_with_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Clinical_markers_associated_with_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Clinical features and symptoms that have been investigated for their potential roles in diagnosis during early premotor stages and/or in motor stages of PD. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Clinical_markers_associated_with_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Clinical biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Clinical_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Clinical_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Assignment of numerals to symptoms, behaviors, or clinical signs according to agreed-upon rules. Scales are the means used in clinical medicine for assigning numbers to observable qualities.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Clinical_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Clinical rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#Clozapine_add-on</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000356</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Clozapine_add-on</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Clozapine add-on</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Clozapine_add-on</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Clozapine add on</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Coenzyme_Q10</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Coenzyme_Q10</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Coenzyme Q10</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cognitive_abnormality</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cognitive_abnormality</IRI>
        <Literal datatypeIRI="&xsd;string">Parkinson&apos;s dementia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cognitive_abnormality</IRI>
        <Literal datatypeIRI="&xsd;string">Parkinson&apos;s disease dementia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cognitive_abnormality</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">cognitive impairment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cognitive_abnormality</IRI>
        <Literal datatypeIRI="&xsd;string">dementia associated with Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cognitive_abnormality</IRI>
        <Literal datatypeIRI="&xsd;string">dementia in Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cognitive_abnormality</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">COGNITIVE IMPAIRMENT severe enough to interfere with everyday activities and functions. Dementia includes dysfunctions of memory, logic, reasoning, and analytical thinking.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cognitive_abnormality</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cognitive decline</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Columbia_university_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Columbia_university_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">This scale assessed facial expression, seborrhea, salivation, speech, tremor, rigidity, various limb specific bradykinesia items, etc. , each on a 0-4 scale, with 0 representing normal.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Columbia_university_rating_scale</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Columbia university rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Communicating_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Communicating_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Poos CSF absorption back into the venous system.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Communicating_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Communicating hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Compulsive_foraging</IRI>
        <Literal datatypeIRI="&xsd;string">Factor, S. A. (2008). Parkinson&apos;s disease: diagnosis and clinical management. W. J. Weiner (Ed.). New York: Demos.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Compulsive_foraging</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">binge eating</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Compulsive_foraging</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">compulsive foraging</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Compulsive_foraging</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An uncontrollable consumption of a larger amount of food than normal in excess of than necessary to alleviate hunger. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Compulsive_foraging</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Compulsive eating</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Compulsive_shopping</IRI>
        <Literal datatypeIRI="&xsd;string">Factor, S. A. (2008). Parkinson&apos;s disease: diagnosis and clinical management. W. J. Weiner (Ed.). New York: Demos.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Compulsive_shopping</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Maladaptive shopping behaviors that result in negative consequences.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Compulsive_shopping</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Compulsive shopping</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Constipation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Constipation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Continual_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Continual_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">continual muscle contractions that cause twisting and repetitive motions.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Continual_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Continual dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Continuous_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hankey, G. J., &amp; Wardlaw, J. M. (2008). Clinical neurology. Manson publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Continuous_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Continuous dyskinesias characterized by repetitive, involuntary, purposeless movements that are neuroleptic-induced.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Continuous_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tardive dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Convergence_abnormality</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Convergence abnormality</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Core_assessment_program_for_intracerebral_transplantation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Core_assessment_program_for_intracerebral_transplantation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">CAPIT</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Core_assessment_program_for_intracerebral_transplantation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Conglomeration of different scales, including the UPDRS and HY, developed by international investigators to capture the essential elements to test efficacy of neurotransplantation surgery in PD. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Core_assessment_program_for_intracerebral_transplantation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Core assessment program for intracerebral transplantation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Core_assessment_program_for_surgical_interventional_therapies_in_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Core_assessment_program_for_surgical_interventional_therapies_in_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">CAPSIT</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Core_assessment_program_for_surgical_interventional_therapies_in_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is a more recent modification that added additional cognitive and behavioral assessments along with some modifications in the CAPIT protocol. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Core_assessment_program_for_surgical_interventional_therapies_in_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Core assessment program for surgical interventional therapies in Parkinsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cortical_excitability</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cortical excitability</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Corticobasal_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Corticobasal_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">CBD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Corticobasal_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">cortical-basal ganglionic degeneration</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Corticobasal_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A rare and serious degenerative brain disease that, in its early stages, mimics Parkinson’s disease. CBD may begin
with mild TREMOR and BRADYKINESIA in one limb, often an arm, but stiffness seems to be more pronounced than is typical for nonyoung onset Parkinson’s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Corticobasal_degeneration</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Corticobasal degeneration</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Coxackie_B_virus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Coxackie_B_virus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Coxackie B virus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cranial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cranial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cranial dystonia is a broad description for dystonia that affects any part of the head. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cranial_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cranial dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Craving</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Craving</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Impulse control problem with eating or consuming medications.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Craving</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Craving</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Creatine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Creatine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Creatine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Criteria_for_definite_PD</IRI>
        <Literal datatypeIRI="&xsd;string"> Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Criteria_for_definite_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">definite PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Criteria_for_definite_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Criteria for clinically probable PD and definitive response to antiparkinsonian medications.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Criteria_for_definite_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Criteria for definite PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Criteria_for_possible_PD</IRI>
        <Literal datatypeIRI="&xsd;string">Factor, S. A. (2008). Parkinson&apos;s disease: diagnosis and clinical management. W. J. Weiner (Ed.). New York: Demos.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Criteria_for_possible_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Criteria for diagnosis of PD when one of the following is present: assymetric resting tremor, assymetric rigidity, or assymetric bradykinesia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Criteria_for_possible_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Criteria for possible PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Criteria_for_probable_PD</IRI>
        <Literal datatypeIRI="&xsd;string">Factor, S. A. (2008). Parkinson&apos;s disease: diagnosis and clinical management. W. J. Weiner (Ed.). New York: Demos.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Criteria_for_probable_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">probable PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Criteria_for_probable_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Diagnosis of PD when any two of the following is present: assymetric rigidity. assymetric resting tremor, or assymetric bradykinesia. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Criteria_for_probable_PD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Criteria for probable PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Crural_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Crural_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dystonia in one leg plus trunk or both legs.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Crural_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Crural dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cryprococcus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cryprococcus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cryprococcus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cyanide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Functional impairment of dopaminergic nigrostriatal neurons related to direct toxicity of cyanide.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cyanide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rosenberg et al. Cyanide-induced parkinsonism: clinical, MRI, and 6-fluorodopa PET studies. Neurology 1989, 39:142. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cyanide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cyanide-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cyanide_poisoning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cyanide_poisoning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cyanide, usually from the consumption of potassium cyanide or sodium cyanide can result in Parkinsonism. Cyanide is also produced by certain bacteria, fungi, and algae, and are found in a number of foods and plants, such as unprocessed cassava, cherry pits, apricot pits, bitter almonds. Hydrogen cyanide is contained in vehicle exhaust and in tobacco smoke, as does burning plastic. Cyanides are also found in gold processing. Cyanide interrupts the electron transport chain in the inner membrane of the mitochondrion. Cyanide also occupies the place of oxygen in hemoglobin (which transports oxygen). Oxygen is required for the formation of L-dopa. So carbon monoxide may cause Parkinson&apos;s disease symptoms by interfering with the availability of oxygen to the brain. However, the precise toxic means by which it causes Parkinson&apos;s disease has still not been proven.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cyanide_poisoning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cyanide poisoning</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cycle_ergometry</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reuter, I., Martin Engelhardt, M. D., Freiwaldt, J., &amp; Horst Baas, M. D. (1999). Exercise test in Parkinson&apos;s disease. Clinical Autonomic Research, 9(3), 129-134.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cycle_ergometry</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bicycle ergometric test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cycle_ergometry</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bicycle ergometry</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cycle_ergometry</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">cycle ergometer test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Cycle_ergometry</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ergometric exercise</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Cycle_ergometry</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An exercise test using a cycle ergometer.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cycle_ergometry</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Cycle ergometry</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Cytokines</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Cytokines</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cytokine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#DJ-1_concentration_in_CSF</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#DJ-1_concentration_in_CSF</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DJ-1 concentration in CSF</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Daytime_sleepiness</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Knie, B., Mitra, M. T., Logishetty, K., &amp; Chaudhuri, K. R. (2011). Excessive daytime sleepiness in patients with Parkinson’s disease. CNS drugs, 25(3), 203-212.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Daytime_sleepiness</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">EDS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Daytime_sleepiness</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">daytime somnolence</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Daytime_sleepiness</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">excessive daytime sleepiness</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Daytime_sleepiness</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">somnolence</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Daytime_sleepiness</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Inappropriate and undesirable sleepiness during waking hours and ia a common non-motor symptom in Parkinson&apos;s disease, affecting up to 50% of patients.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Daytime_sleepiness</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Daytime sleepiness</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Deacreased_blink_rate</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Decreased blink rate</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Deafness</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Deafness</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Deafness</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Deep_brain_stimulation_for_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Deep_brain_stimulation_for_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DBS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Deep_brain_stimulation_for_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A procedure for treating TREMORS in which implanted electrodes deliver electrical stimulation to structures of the brain that are responsible for movement.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Deep_brain_stimulation_for_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Deep brain stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Delayed_gastric_emptying</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Delayed gastric emptying</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Delusion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Delusion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A false belief that something is real although in fact it is untrue or imagined.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Delusion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Delusion</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dementia_with_pallido-ponto-nigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dementia with pallido-ponto-nigral degeneration</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dementia_with_pallido-ponto-nigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PPND</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dementia_with_pallido-ponto-nigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pallido-ponto-nigral degeneration</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dementia_with_pallido-ponto-nigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">One of genetic forms of parkinsonism associated to the gene for the microtubule-associated protein tau (MAPT) on chromosome 17q.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dementia_with_pallido-ponto-nigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dementia_with_pallido-ponto-nigral_degeneration</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Dementia with pallido ponto nigral degeneration</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Depression</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lieberman, A. (2006). Depression in Parkinson&apos;s disease–a review. Acta Neurologica Scandinavica, 113(1), 1-8.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Depression</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Major depression is present, at any given time, in 20–40% of Parkinson&apos;s disease (PD) patients, several times the prevalence in the general population. In addition, depression may precede the diagnosis of PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Depression</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Depression</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Destination_hesitation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Destination hesitation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Diablotm1Mak</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Diablotm1Mak</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Diagnosis_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Diagnosis_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">The process of diagnosing Parkinson’s is a challenge for both physicians and those who have the disease. As there is no definitive clinical test either to confirm or rule out Parkinson’s, for many people diagnosis is a painstaking assessment of symptoms and circumstances. Because the symptoms and the course of the disease are highly variable, the doctor may suspect Parkinson’s immediately or not even consider it until other potential explanations for the symptoms turn out to be false leads.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Diagnosis_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Diagnosis of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Diagnostic_criteria_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Diagnostic_criteria_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">PD is diagnosed on clinical criteria; there is no definitive test for diagnosis. Historically, pathological confirmation of the hallmark Lewy body on autopsy has been considered the criterion standard for diagnosis. In clinical practice, diagnosis is typically based on the presence of a combination of cardinal motor features, associated and exclusionary symptoms, and response to levodopa.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Diagnostic_criteria_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Diagnostic criteria for Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Differential_diagnosis</IRI>
        <Literal datatypeIRI="&xsd;string">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Differential_diagnosis</IRI>
        <Literal datatypeIRI="&xsd;string">Diagnosis among a number of diseases that can mimic Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Differential_diagnosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Differential diagnosis of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Diffuse_pain</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Diffuse_pain</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Diffuse pain</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Diphasic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pahwa, R., Lyons, K. E., &amp; Koller, W. (Eds.). (2003). Handbook of Parkinson&apos;s disease. CRC Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Diphasic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Biphasic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Diphasic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">biphasic dyskinesias</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Diphasic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">biphasic pattern of dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Diphasic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">diphasic dyskinesias</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Diphasic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dyskinesias at the beginning and enf of dose</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Diphasic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Streotyped, ballistic or dystonic movements that occur at onset or wearing off (or both) of clinical benefit from a dose of levodopa.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Diphasic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Diphasic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#Donezepil_as_add-on_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000836</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Donezepil_as_add-on_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">donezepil as add-on</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Donezepil_as_add-on_treatment</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Donezepil as add on</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Dopamine_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Willis, G. L., Moore, C., &amp; Armstrong, S. M. (2012). Breaking away from dopamine deficiency: an essential new direction for Parkinson’s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dopamine_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dopaminergic deficiency</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dopamine_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">depletion of dopamine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dopamine_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">depletion of stratial dopamine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dopamine_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dopamine loss</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dopamine_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s disease (PD) has been intrinsically associated with dopamine (DA) deficiency of the nigrostriatal DA system.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dopamine_deficiency</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Dopamine deficiency</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dopaminergic_cell_lines</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Dopaminergic cell line</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Drd2tm1Ebo</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Drd2tm1Ebo</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Drd2tm1Low</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Drd2tm1Low</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Drooling</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Drooling</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Saliva fails of being directed to the back part of the fauces, and hence is continually draining from the mouth.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Drooling</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Drooling</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Drug-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Factor, S., Lang, A., &amp; Weiner, W. (Eds.). (2008). Drug induced movement disorders. Wiley. com.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Drug-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Levodopa-induced dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Drug-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Drug-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Drug-induced dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Drug-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Drug-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DIP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Drug-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Drug-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Drug-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">drug induced Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Drug-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">drug induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Drug-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">iatrogenic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Drug-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson’s symptoms that are side effects of medications, particularly ANTIPSYCHOTIC DRUGS.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Drug-induced_parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Drug induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Dysarthria</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dysarthria</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Difficulties with speech that are the result of BRADYKINESIA involving the muscles of the mouth, throat, and chest.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dysarthria</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dysarthria</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Dysexecutive_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ceravolo, R., Pagni, C., Tognoni, G., &amp; Bonuccelli, U. (2012). The epidemiology and clinical manifestations of dysexecutive syndrome in Parkinson’s disease. Frontiers in neurology, 3.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dysexecutive_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A poorly defined nosological entity, which may be caused by various diseases. According to diagnostic criteria proposed by Godefroy et al. (2010), dysexecutive syndrome includes cognitive (e.g., deficits in response inhibition, set-shifting, and information generation) and/or behavioral (e.g., apathy, distractibility, perseverative behavior) alterations. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dysexecutive_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dysexecutive syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hankey, G. J., &amp; Wardlaw, J. M. (2008). Clinical neurology. Manson publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dyskinesias</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dyskinetic movements</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Abnormal dystonic and choreoathetoid involuntary movements that may occur spontaneously after a sudden voluntary movement, after prolonged physical exertion, or during sleep.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dyskinesia</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Dysphagia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dysphagia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">swallowing difficulty</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Dysphagia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">swallowing disorder</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dysphagia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dysphagia is defined as impaired swallowing, which can occur any where from the mouth to the stomach. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dysphagia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dysphagia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dystonia is defined as a neurological syndrome characterized by involuntary, sustained, patterned and often repetitive muscle contractions of opposing muscles causing twisting movements or abnormal postures. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Dystonic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Dystonic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is defined as a postural/kinetic tremor usually not seen during complete rest and occuring in an extremity or body part that is affected by dystonia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Dystonic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dystonic tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000062</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000907</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000062</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Amantadine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000063</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000565</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000063</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Atropine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000064</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000239</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000064</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Benztropine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000065</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000803</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000065</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Biperiden</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000066</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000385</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000066</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ethopropazine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000067</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000380</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000067</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Procyclidine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000068</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000369</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000068</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Trihexyphenidyl</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000069</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000487</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000069</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Entacapone</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000070</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000317</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000070</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tolcapone</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000071</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000707</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000071</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Apomorphine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000072</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA001189</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000072</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bromocriptine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000073</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000242</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000073</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cabergoline</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000074</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000582</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000074</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lisuride</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000075</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA001175</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000075</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pergolide</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000077</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA004761</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000077</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rotigotine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000078</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000843</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000078</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Perphenazine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000079</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000406</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000079</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pramipexole</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000080</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000262</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000080</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ropinirole</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#EPO_00000081</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">L-dopa</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000081</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Levodopa</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000082</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA000184</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#EPO_00000082</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Benserazide</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000082</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Carbidopa</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000085</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA001333</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000085</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rasagiline</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Context"/>
        <IRI>#EPO_00000086</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DrugBank:DBA001028</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#EPO_00000086</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Selegiline</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hof P.R. &amp; Mobbs C.V. (2001) Functional Neurobiology of Aging. Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Early-onset Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">early onset Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">early onset of parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">early-onset Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">early-onset Parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">young-onset Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Patients with onset age below 45 years progress at a slower rate and show motor fluctuations, diskinesias and dystonia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Early-onset_Parkinson_s_disease_</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Early onset Parkinsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Ecstasy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ecstasy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ecstasy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Electromyography_of_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Electromyography_of_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">EMG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Electromyography_of_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Electromyography is the best method to identify those muscles and limb segments that are involved in tremor.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Electromyography_of_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Electromyography of tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#En1tm1Gld</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">En1tm1Gld</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#En2tm1Alj</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">En2tm1Alj</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Encephalitis_lethargica</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Encephalitis_lethargica</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Encephalitis lethargica</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#End-of-dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schapira A.H.V. (2010) Parkinson&apos;s disease. Oxford University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#End-of-dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">end-of-dose</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#End-of-dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dyskinesias that occur at the end of dose, when plasma concentrations of dopaminergic medications are decreasing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#End-of-dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">End-of-dose dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Environmental_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Logroscino, G. (2005). The role of early life environmental risk factors in Parkinson disease: what is the evidence?. Environmental health perspectives, 113(9), 1234.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Environmental_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to environmental neurotoxicants can determine progressive damage in the substantia nigra many years before the onset of clinical parkinsonism. Therefore, PD, like other neurologic diseases related to aging, may be determined by exposures present in the environment early during the life span or even during pregnancy.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Environmental_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Environmental risk factor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Epstein-Barr_virus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Epstein-Barr_virus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Epstein-Barr virus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Epworth_sleepiness_sclae</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Epworth_sleepiness_sclae</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ESS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Epworth_sleepiness_sclae</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">This scale is recommended to assess daytime sleepiness.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Epworth_sleepiness_sclae</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Epworth sleepiness sclae</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ET</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A tremor syndrome that is classically defined by an often hereditary monosymptomic tremor.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Essential tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Etiology_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schapira, A. H. (2006). Etiology of Parkinson’s disease. Neurology, 66(10 suppl 4), S10-S23.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Etiology_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pathogenesis of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Etiology_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">cause of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Etiology_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">etiology and pathogenesis of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Etiology_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The etiology of Parkinson&apos;s disease (PD) has long been thought to involve both genetic and environmental factors.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Etiology_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Etiology of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Evaluation_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Evaluation_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">evaluation of motor impairment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Evaluation_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&xsd;string">The evauation of motor impairment and disability in patients with PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Evaluation_of_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Evaluation of parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Excessive_sweating</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Excessive_sweating</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Excessive and even drenching episodes of sweating are common in Parkinson’s, particularly in mid to late stages of the disease, when OFFSTATES begin to occur. Excessive sweating can be a consequence of damage to the autonomic NERVOUS SYSTEM as Parkinson’s progresses or a side effect of ANTI-PARKINSON’S MEDICATIONS.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Excessive_sweating</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Excessive sweating</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Exertion-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Attacks of abnormal involuntary movements precipitated by prolonged physical exertion.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Exertion-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hankey, G. J., &amp; Wardlaw, J. M. (2008). Clinical neurology. Manson publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Exertion-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PED</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Exertion-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">exercise induced dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Exertion-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">exercise-induced dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Exertion-induced_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exertion-induced dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Exposure_to_copper</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Kortsha, G. X., Brown, G. G., &amp; Richardson, R. J. (1998). Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson&apos;s disease. Neurotoxicology, 20(2-3), 239-247.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Exposure_to_copper</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Chronic exposure to copper is associated with PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Exposure_to_copper</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to copper</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Exposure_to_farming</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., &amp; Richardson, R. J. (1998). The risk of Parkinson&apos;s disease with exposure to pesticides, farming, well water, and rural living. Neurology, 50(5), 1346-1350.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Exposure_to_farming</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">farming</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Exposure_to_farming</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PD is associated with occupational exposure to farming and the risk of farming can not be accounted for by pesticide exposure alone.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Exposure_to_farming</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to farming</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Exposure_to_herbicide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Peng, J., Mao, X. O., Stevenson, F. F., Hsu, M., &amp; Andersen, J. K. (2004). The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. Journal of Biological Chemistry, 279(31), 32626-32632.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Exposure_to_herbicide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Environmental exposure to the oxidant-producing herbicide paraquat has been implicated as a risk factor in Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Exposure_to_herbicide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to herbicide</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Exposure_to_manganese</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Kortsha, G. X., Brown, G. G., &amp; Richardson, R. J. (1998). Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson&apos;s disease. Neurotoxicology, 20(2-3), 239-247.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Exposure_to_manganese</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Chronic occupational exposure to manganese individually or combined with lead, iron and copper is associated with PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Exposure_to_manganese</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to manganese</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Exposure_to_pesticide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ascherio, A., Chen, H., Weisskopf, M. G., O&apos;Reilly, E., McCullough, M. L., Calle, E. E., ... &amp; Thun, M. J. (2006). Pesticide exposure and risk for Parkinson&apos;s disease. Annals of neurology, 60(2), 197-203.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Exposure_to_pesticide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pesticide exposure</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Exposure_to_pesticide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pesticide use</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Exposure_to_pesticide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to pesticides may increase risk for PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Exposure_to_pesticide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to pesticide</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#F-dopa_PET</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#F-dopa_PET</IRI>
        <Literal datatypeIRI="&xsd;string">It is used for assessment of dopaminergic function of the caudate and putamen</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#F-dopa_PET</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">F-dopa PET</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#FDG_PET</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#FDG_PET</IRI>
        <Literal datatypeIRI="&xsd;string">18-fluorodeoxyglucose PET</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#FDG_PET</IRI>
        <Literal datatypeIRI="&xsd;string">A PET imaging biomarker for monitoring metabolic activity.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#FDG_PET</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FDG PET</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Fahn-Marsden_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fahn-Marsden_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">F-M</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Fahn-Marsden_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">This scale is used to assess the severity of generalized dystonia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Fahn-Marsden_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fahn-Marsden dystonia rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Fall_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gray, P., &amp; Hildebrand, K. (2000). Fall risk factors in Parkinson&apos;s disease. Journal of Neuroscience Nursing, 32(4), 222-228.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Fall_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Risk factors associated with falls for PD patients.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Fall_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fall risk factor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Falling</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Falling</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falling</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Falls</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Falls</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falls are most likely to occur during changes in position— from sitting to standing, from standing to walking, when changing direction during movement, and from walking to sitting.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Falls</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falls</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Familial_neurodegenerative_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Y. Mizuno, Donald B. Calne, R. Horowski, W. H. Poewe, Peter Riederer. (2000) Advances in Research on Neurodegeneration: Volume 7. Springer-Verlag.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Familial_neurodegenerative_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hereditary neurodegenerative diseases</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Familial_neurodegenerative_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A genetic contribution to the etiology of Parkinson&apos;s disease based on the demonstration of a familial aggregation of the disease, as demonstrated by several case-control and twin studies.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Familial_neurodegenerative_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Familial neurodegenerative disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Family_history_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Taylor, C. A., Saint‐Hilaire, M. H., Cupples, L. A., Thomas, C. A., Burchard, A. E., Feldman, R. G., &amp; Myers, R. H. (1999). Environmental, medical, and family history risk factors for Parkinson&apos;s disease: A New England‐based case control study. American journal of medical genetics, 88(6), 742-749.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Family_history_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">family history of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Family_history_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The effects of family history on PD risk. Family history of PD among first-degree relatives (parents and siblings) has been reported in 6.8 to 16% of PD cases.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Family_history_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Family history of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Fat_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth Jr, W. T., Swanson, P. D., &amp; Checkoway, H. (2009). Dietary fats, cholesterol and iron as risk factors for Parkinson&apos;s disease. Parkinsonism &amp; related disorders, 15(1), 47-52.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fat_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dietary fat intake</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fat_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dietary intakes of fat</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fat_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dietary lipids</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Fat_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A low intake of cholestrol may be associated with an increased risk for PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Fat_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fat intake</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Fatigue_Severity_Inventory</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dittner, A. J., Wessely, S. C., &amp; Brown, R. G. (2004). The assessment of fatigue: a practical guide for clinicians and researchers. Journal of psychosomatic research, 56(2), 157-170.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fatigue_Severity_Inventory</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FAI</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fatigue_Severity_Inventory</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FSI</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Fatigue_Severity_Inventory</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The FSS principally measures the impact of fatigue on specific types of functioning rather than the intensity of fatigue-related symptoms.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Fatigue_Severity_Inventory</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fatigue Severity Inventory</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Fatty_acid_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">De Lau, L. M. L., Bornebroek, M. M. D. P., Witteman, J. C. M., Hofman, A. M. D. P., Koudstaal, P. J., &amp; Breteler, M. M. B. (2005). Dietary fatty acids and the risk of Parkinson disease The Rotterdam Study. Neurology, 64(12), 2040-2045.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fatty_acid_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dietary fatty acids</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fatty_acid_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">unsaturated fatty acids</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Fatty_acid_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">High intake of unsaturated fatty acids might protect against PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Fatty_acid_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fatty acid intake</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Ferritin</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ferritin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ferritin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Fluctuating_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Fluctuating_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">diurnal fluctuation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Fluctuating_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Variation in the severity of dystonia in the course of the day.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Fluctuating_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fluctuating dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Focal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://www.dystonia-foundation.org/</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Focal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Focal dystonias are adult-onset forms that affects a specific area of the body.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Focal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Focal dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Foot_drag</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Foot_drag</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">People with Parkinson’s often drag one foot or sometimes both feet, depending on whether movement dysfunctions are unilateral (primarily affect one side) or bilateral (affect both sides). Foot drag involves both MOTOR and PROPRIOCEPTION dysfunctions.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Foot_drag</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Foot drag</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Foot_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Foot_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Foot dystonia is uncontrollable and often painful muscle contractions in the foot which causes a twisting or turning in of the foot.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Foot_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Foot dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Four-legged_cane</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Duvoisin, R. C., &amp; Sage, J. (2001). Parkinson&apos;s disease: A guide for patient and family. Wolters Kluwer Health.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Four-legged_cane</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Four-legged (quad) cane</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Four-legged_cane</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">quad cane</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Four-legged_cane</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A cane with wide or narrow base where four legs are attached and is helpful to patients with poor equilibrium.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Four-legged_cane</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Four-legged cane</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Four-wheeled_walking_stabilizer</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">4 wheel rollator</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Four-wheeled_walking_stabilizer</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">four wheel rollator</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Four-wheeled_walking_stabilizer</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Four-wheeled walking stabilizer</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FOG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">freezing of gait</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gait and freezing</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gait freezing</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gait-related mobility</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">magnetic feet</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">motor blocks</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Freezing is a form of akinesia and is one of the most disabling symptoms of PD and has five subtypes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Freezing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Freezing</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Frequency_of_abnormal_movements_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Frequency_of_abnormal_movements_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FAM</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Frequency_of_abnormal_movements_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It was developed to assess musician&apos;s dystonia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Frequency_of_abnormal_movements_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Frequency of abnormal movements scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://en.wikipedia.org/wiki/Frontotemporal_dementia_and_parkinsonism_linked_to_chromosome_17</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FTD with parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FTDP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FTDP17</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Frontotemporal dementia with parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">frontotemporal dementia (FTD) with parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">frontotemporal dementia and parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">FTDP-17 is an autosomal dominant neurodegenerative disorder, which has three cardinal features: behavioral and personality changes, cognitive impairment, and motor symptoms.  </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Frontotemporal_dementia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Frontotemporal dementia parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#GM-1_ganglioside</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#GM-1_ganglioside</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">GM-1 ganglioside</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Gait_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Gait_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gait biomechanics</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Gait_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gait difficulty</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Gait_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gait disturbances</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Gait_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gait dynamics</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Gait_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is a deviation from the normal pattern of movement in walking.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Gait_disturbance</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Gait disturbance</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Gastrointestinal_dysfunction</IRI>
        <Literal datatypeIRI="&xsd;string">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Gastrointestinal_dysfunction</IRI>
        <Literal datatypeIRI="&xsd;string">gastric motility</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Gastrointestinal_dysfunction</IRI>
        <Literal datatypeIRI="&xsd;string">Parkinson’s disease affects the action of smooth (involuntary) muscle tissue such as that of the digestive system.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Gastrointestinal_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gastrointestinal dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Genetic_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Genetic_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">These biomarkers establish the link between genotype and the development of Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Genetic_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Genetic biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Genetic_cause_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Genetic_cause_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Genetics of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Genetic_cause_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">genetic causes of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Genetic_cause_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Genetic factors that are found in a minority of patients with the typical clinical picture of PD and positive family history compatible with Mendelian inheritance.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Genetic_cause_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Genetic cause of parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Genetic_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dawson, T. M., Ko, H. S., &amp; Dawson, V. L. (2010). Genetic animal models of Parkinson&apos;s disease. Neuron, 66(5), 646-661.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Genetic_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">gene-based models</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Genetic_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">genetci animal models of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Genetic_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Modeling PD in animals or cellular systems using genetic manipulation, that is transgenic overexpression of mutant genes. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Genetic_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Genetic model of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Genital_pain</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Genital_pain</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Genital pain</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Genomic_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Genomic_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Genomic biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Glutathione</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Glutathione</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Glutathione</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Glycomic_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Glycomic_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Glycomic biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Glyphosate_herbicide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Glyphosate_herbicide</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Glyphosate herbicide</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Graphic_tablet_analysis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Graphic_tablet_analysis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Graphic tablets have been introduced for the analysis of writing tremor and to measure the severity of action and intention tremor.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Graphic_tablet_analysis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Graphic tablet analysis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Group_A_feature</IRI>
        <Literal datatypeIRI="&xsd;string">Waters, C. H. (2008). Diagnosis and management of Parkinson&apos;s disease. Professional Communications.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Group_A_feature</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">group A</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Group_A_feature</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gelb and colleagues divided the clinical features of PD into two c´roups according to their diagnostic utility. Group A includes features characteristic of PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Group_A_feature</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Group A feature</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Group_B_feature</IRI>
        <Literal datatypeIRI="&xsd;string">Waters, C. H. (2008). Diagnosis and management of Parkinson&apos;s disease. Professional Communications.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Group_B_feature</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gelb and colleagues divided the clinical features of PD into two groups according to their diagnostic utility. Group B are features suggestive of alternate diagnoses.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Group_B_feature</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Group B feature</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Gt(ROSA)26Sortm2(SNCA*119)Djmo</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gt(ROSA)26Sortm2(SNCA*119)Djmo</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Gt(ROSA)26Sortm2(SNCA*119)Djmo</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Gt(ROSA)26Sortm2(SNCA119)Djmo</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">(ALS)/parkinsonism-dementia of Guam</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ALS-P-D</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ALS/PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ALS/PDC</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ALS/parkinsonism-dementia complex of Guam</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Guamanian ALS and parkinsonism-dementia complex</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lytico-Bodig</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PDACG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">amyotrophic lateral sclerosis/parkinsonism-dementia complex in Guam</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A neurodegenerative disease that affects up to one percent of native residents of Guam (the indigenous Chamorro population), typically manifested in late midlife. In Guam ALS-PDC the person has parkinsonism, dementia, and ALS concurrently and typically eventually shows symptoms of all three. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Guamanian_parkinsonism-dementia-ALS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Guamanian parkinsonism-dementia-ALS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#HIV_encephalopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#HIV_encephalopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">HIV encephalopathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#H_magnetic_resonance_spectroscopy</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#H_magnetic_resonance_spectroscopy</IRI>
        <Literal datatypeIRI="&xsd;string">H MRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#H_magnetic_resonance_spectroscopy</IRI>
        <Literal datatypeIRI="&xsd;string">An imaging biomarker used to study cerebral metabolites including NAA, Cr, Cho amd ml. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#H_magnetic_resonance_spectroscopy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">H magnetic resonance spectroscopy biomarker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Halogen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Halogen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Halogen</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Haloperidol-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Charney D.S. and Nestler E.J. (2004) Neurobiology of Mental Illness. Oxford University Press, Inc.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Haloperidol-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Haloperidol has a high affinity for the D2 family of dopamine receptors and its pharmacological actions have been linked with the ability of haloperidol to induce parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Haloperidol-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Haloperidol-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Haloperidol_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Duty, S., &amp; Jenner, P. (2011). Animal models of Parkinson&apos;s disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology, 164(4), 1357-1391.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Haloperidol_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A pharmacological model of PD is haloperidol-treated rats in which haloperidol works by antagonizing dopamine D2 and to a lesser extent D1 receptors in medium spiny neurons that comprise the indirect and direct pathways of the motor circuit respectively. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Haloperidol_model</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Haloperidol model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hamilton_depression_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hamilton_depression_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Recommended for the assessment of depression.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hamilton_depression_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hamilton depression scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Head_trauma</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Goldman, S. M., Tanner, C. M., Oakes, D., Bhudhikanok, G. S., Gupta, A., &amp; Langston, J. W. (2006). Head injury and Parkinson&apos;s disease risk in twins. Annals of neurology, 60(1), 65-72.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Head_trauma</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">head injury</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Head_trauma</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mild-to-moderate closed head injury may increase PD risk decades later.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Head_trauma</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Head trauma</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Heart_beat_frequency_modulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Heart beat frequency modulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">HP-HA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">HPHA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hemiparkinsonism and hemiatrophy syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hemiparkinsonism as a late complication of hemiatrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hemiparkinsonism in association with ipsilateral body hemiatrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hemiparkinsonism-hemiatrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hemiparkinsonism-somatic hemiatrophy syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hemiparkinsonism/hemiatrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">the syndrome of hemiparkinsonism-hemiatrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A rare syndrome showing atrophy of one side of the body present from childhood. Ipsilateral parkinsonism develops years later and can be associated with dystonia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hemiatrophy-hemiparkinsonism_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hemiatrophy-hemiparkinsonism syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Heroin_pyrolysate</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Heroin_pyrolysate</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Heroin pyrolysate</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hesitation_in_tight_quarters</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hesitation in tight quarters</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hoehn and Yahr Index</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hoehn and Yahr Scale score</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hoehn and Yahr scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hoehn and Yahr scale grades</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hoehn and Yahr&apos;s classification</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hoehn- Yahr scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hoehn/Yahr scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal datatypeIRI="&xsd;string">The Hoehn and Yahr scale is commonly used to compare groups of patients and to provide gross assessment of disease progression, ranging from stage 0 (no signs of disease) to stage 5 (wheelchair bound or bedridden unless assisted). </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hoehn_and_Yahr_stage_scale</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Hoehn and Yahr stage scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Home_diaries</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Home_diaries</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Useful tools for obtaining valuable information on PD motor complications. A diversity of diaries exists but in essence they capture the patient&apos;s situation throughout the day, at scheduled intervals.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Home_diaries</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Home diaries</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hopkins_motor_and_vocal_tic_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hopkins_motor_and_vocal_tic_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">HMVTS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hopkins_motor_and_vocal_tic_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It consists of a series of visual analogue scales on which both patient and physician separately rank each tic.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hopkins_motor_and_vocal_tic_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hopkins motor and vocal tic scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hospital_anxiety_and_depression_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hospital_anxiety_and_depression_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A scale used for the assessment of depression.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hospital_anxiety_and_depression_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hospital anxiety and depression scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Htra2tm1Jdo</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Htra2tm1Jdo</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Human_afult_stem_cell-based_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Human_afult_stem_cell-based_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Adult stem cells are currently considered a potential source of newly formed DAergic neurons.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Human_afult_stem_cell-based_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Human adult stem cell-based therapy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Human_embryonic_stem_cell-based_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Human_embryonic_stem_cell-based_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Human embryonic stem cells are pluripotent and able to differentiate into various cell types, including DAergic neurons.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Human_embryonic_stem_cell-based_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Human embryonic stem cell-based therapy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Huntington_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schapira H.V.A. (2010) parkinson&apos;s Disease. Oxford University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Huntington_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">HD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Huntington_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Huntington&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Huntington_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An sutosomal-dominant trinucleotide repeat disorder with cognitive and neurophyschiatric problems. HD can present as a mainly bradykinetic disorder in those under age 20 and rarely in adults. The possibility of HD should be considered in the evaluation of juvenile parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Huntington_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Huntington disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hydrocephalic tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hydrocephalus parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hydrocephalus with parkinsonian symptomatology</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hydrocephalus-parkinsonism complex</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonian syndrome associated with hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism associated with secondary hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism due to hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism secondary to hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism with hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hydrocephalus results from increased CDF production or impairment of CSF outflow.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hypersexuality</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hypersexuality</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hypersexuality includes increased libido, increase in erection frequency, and increased sexually demanding behavior.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hypersexuality</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hypersexuality</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hypnogenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hankey, G. J., &amp; Wardlaw, J. M. (2008). Clinical neurology. Manson publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hypnogenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PHD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hypnogenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">paroxysmal hypnogenic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hypnogenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Attacks of abnormal involuntary movements occuring only during sleep.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hypnogenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hypnogenic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hypoguesia</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hypoguesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hypoguesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hypokinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dauer, W., &amp; Przedborski, S. (2003). Parkinson&apos;s disease: mechanisms and models. Neuron, 39(6), 889-909.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hypokinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">hypokinesis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hypokinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reduction in movement amplitude.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hypokinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hypokinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hypomimia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Hypomimia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">impairment of facial expression</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hypomimia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The clinical term for the composite of symptoms that includes reduced facial movements, slowed eye movements, slowed blinking, and reduced facial expression.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hypomimia</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Hypomimia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hypophonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hypophonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reduced VOICE volume and strength that develops when Parkinson’s disease affects the muscles that control the vocal cords.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hypophonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hypophonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Hypoxia-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Hypoxia-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hypoxia induced by carbon monoxide poisoning can cause bilateral globus pallidus necrosis and subsequent parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Hypoxia-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hypoxia-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#I-β-CIT_SPECT</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#I-β-CIT_SPECT</IRI>
        <Literal datatypeIRI="&xsd;string">It is used to study the integrity of the dopaminergic system (reuptake of dopamine into axons via the DAT) in patients treated with pramipexole versus levodopa.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#I-β-CIT_SPECT</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">I-beta-CIT SPECT</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Idiopathic_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Facts on Files, Inc.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Idiopathic_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Idiopathic Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Idiopathic_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sporadic Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Idiopathic_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">idiopathic parkinson&apos;s syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Idiopathic_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It indicates that the reason for development of Parkinson&apos;s disease is unknown.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Idiopathic_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Idiopathic Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Immortalized_cell_line</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Immortalized_cell_line</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">They represent homogenous populations of continuously proliferating cells. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Immortalized_cell_line</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Immortalized cell line</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Immunulogical_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Immunulogical_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Immunulogical biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Impaired_handwriting</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Impaired_handwriting</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Impaired handwriting</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Impulsive_behaviour</IRI>
        <Literal datatypeIRI="&xsd;string">1.Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.
2.Parashos, S. A., Parashos, S., &amp; Wichman, R. (2012). Navigating Life with Parkinson&apos;s Disease. Oxford University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Impulsive_behaviour</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Trying to move too quickly or engage in unsafe behaviors like climbing and overreaching.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Impulsive_behaviour</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Impulsive behaviour</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#In-vitro_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#In-vitro_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Biomarkers that measure molecular concentrations in biological samples of PD patients.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#In-vitro_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">In-vitro biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#In-vivo_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#In-vivo_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">In-vivo biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Inconsistence</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Inconsistence</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Inconsistence</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Infectious_cause_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Infectious_cause_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">infection as a cause of idiopathic parkinson</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Infectious_cause_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">infections in the etiology of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Infectious_cause_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s disease caused by exposure to infectious agents.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Infectious_cause_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Infectious cause of parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schiesling, C., Kieper, N., Seidel, K., &amp; Krüger, R. (2008). Review: Familial Parkinson&apos;s disease–genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathology and applied neurobiology, 34(3), 255-271.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Familial Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Inherited Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">familial PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">familial occurrence of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">inherited form of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">inherited forms of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">inherited forms of parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Genetic forms of Parkinsonism with clinical features indistinguishable from idiopathic parkinsonism but different neuropathological features not consistent with idiopathic PD. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Inherited_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Inherited Parkinsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Inherited_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Inherited_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dystonia that is passed on genetically from parent or ancestor to a child.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Inherited_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Inherited dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Intention_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Intention_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Intention tremor is present when the amplitude increases during visually guided movements toward a target.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Intention_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Intention tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Intermediate_scale_for_assessment_of_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Intermediate_scale_for_assessment_of_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ISAPD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Intermediate_scale_for_assessment_of_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">This is a short scale for use in clinical practice and in research, composed of a 13-item section that assesses functional aspects, and a 4-item section that assesses dyskinesias and fluctuations.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Intermediate_scale_for_assessment_of_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Intermediate scale for assessment of Parkinsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Intrathecal_baclofen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Intrathecal_baclofen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Intrathecal baclofen therapy (IBT) is a method of infusing injectable baclofen directly into the thecal sac.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Intrathecal_baclofen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Intrathecal baclofen</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Iron_accumulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mochizuki, H., &amp; Yasuda, T. (2012). Iron accumulation in Parkinson’s disease. Journal of Neural Transmission, 119(12), 1511-1514.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Iron_accumulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">accumulation of iron</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Iron_accumulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">iron overload</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Iron_accumulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral"> A selective and significant elevation in iron which occurs in the substantia nigra of patients with PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Iron_accumulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Iron accumulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Isolated_chin_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Isolated_chin_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is a rare, autosomal dominant hereditary tremor syndrome characterized by attacks of high-frequency tremor of the mentalis muscles or of the chin. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Isolated_chin_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Isolated chin tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Isolated_voice_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Isolated_voice_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A tremor which is limited to the voice.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Isolated_voice_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Isolated voice tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Isometric_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Isometric_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Occurs as a result of muscle contraction against a rigid stationary object.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Isometric_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Isometric tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Japanese_B_encephalitis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Japanese_B_encephalitis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Japanese B encephalitis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Juvenile_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Menkes J.H., Sarnat H.B., Maria B.L. (2006) Child Neurology. Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Juvenile_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Juvenile Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Juvenile_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Juvenile onset Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Juvenile_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Juvenile parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Juvenile_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">juvenile variant of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Juvenile_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Juvenile PD refers to a condition in which symptoms of Parkinson&apos;s disease make their appearance before age 20 years.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Juvenile_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Juvenile Parkinsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Kinesia_paradoxica</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Kinesia_paradoxica</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">paradoxical kinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Kinesia_paradoxica</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Immobile patients who become excited may be able to make quick movement.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Kinesia_paradoxica</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kinesia paradoxica</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hankey, G. J., &amp; Wardlaw, J. M. (2008). Clinical neurology. Manson publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PKD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">paroxysmal kinesigenic choreoathetosis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">paroxysmal kinesigenic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Abrupt onset of episodes of abnormal involuntary movements after a sudden voluntary movement. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kinesigenic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Kinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Kinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PKD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Kinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An autosomal-dominant disorder with a significant variable expressivity and an apparent male predominance.The paroxysms are triggered by sudden movement and are usually short and can occur hundreds of times each day.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Kinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kinesigenic dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Occurs during any voluntary movement.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kinetic tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#L-shaped_cane</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Seymour stick</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#L-shaped_cane</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">L-shaped cane</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#LPS_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Facts on Files, Inc.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#LPS_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">LPS-induced animal model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#LPS_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">lipopolysaccharide (LPS) model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#LPS_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Animal models that show conditions of parkisnon&apos;s disease after injecting lipopolysaccharides into substantia nigra  and striatum. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#LPS_model</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">LPS model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#LSVT_BIG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fox, C., Ebersbach, G., Ramig, L., &amp; Sapir, S. (2012). LSVT LOUD and LSVT BIG: behavioral treatment programs for speech and body movement in Parkinson disease. Parkinson&apos;s disease, 2012.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#LSVT_BIG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">LSVT program to address limb motor systems.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#LSVT_BIG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">LSVT BIG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#LSVT_LOUD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fox, C., Ebersbach, G., Ramig, L., &amp; Sapir, S. (2012). LSVT LOUD and LSVT BIG: behavioral treatment programs for speech and body movement in Parkinson disease. Parkinson&apos;s disease, 2012.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#LSVT_LOUD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">LSVT program with a focus on the speech motor system.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#LSVT_LOUD</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">LSVT LOUD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Laser_cane</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Laser cane</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hof P.R. &amp; Mobbs C.V. (2001) Functional Neurobiology of Aging. Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Late-onset Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">late onset Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">late-onset PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">late-onset Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">late-onset sporadic Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">later onset Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">old-onset Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Patients with onset age of symptoms above 70 years have a more agressive form of PD with faster progression and more severe motor disability.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Late-onset_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Late-onset Parkinsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Lee-Silverman_Voice_Treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://en.wikipedia.org/wiki/Lee_Silverman_voice_treatment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Lee-Silverman_Voice_Treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lee-Silverman Voice Treatment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Lee-Silverman_Voice_Treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">voice treatment (LSVT)</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Lee-Silverman_Voice_Treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The Lee Silverman Voice Treatment - LOUD (LSVT LOUD) is one of the most widely practiced treatment for speech disorders associated with Parkinson&apos;s disease (PD). It focuses on increasing vocal loudness and has an intensive approach of one month. Speech therapy and specifically LSVT LOUD may improve voice and speech function in PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Lee-Silverman_Voice_Treatment</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Lee Silverman Voice Treatment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Leg_dystonia_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Leg_dystonia_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Assessment of functional impairment caused by the dystonic leg in walking, standing, and other activities. It consists of 7 items with the final total score expressed as percentage.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Leg_dystonia_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Leg dystonia disability scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Levodopa_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pahwa, R., Lyons, K. E., &amp; Koller, W. (Eds.). (2003). Handbook of Parkinson&apos;s disease. CRC Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Levodopa_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Levodopa challenge test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Levodopa_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">levodopa administration as a test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Levodopa_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">levodopa challenge</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Levodopa_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">levodopa challenges</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Levodopa_test</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Administration of levodopa for diagnostic purposes as PD patients respond more frequently and robustly to levodopa compared with other forms of parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Levodopa_test</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Levodopa test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Lewy_body</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Wakabayashi, K., Tanji, K., Mori, F., &amp; Takahashi, H. (2007). The Lewy body in Parkinson&apos;s disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates. Neuropathology, 27(5), 494-506.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Lewy_body</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">lewy body like</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Lewy_body</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">lewy body-like</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Lewy_body</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The presence of fibrillar aggregates called Lewy bodies (LBs) which is the histological hallmark of Parkinson&apos;s disease. LB formation has been considered to be a marker for neuronal degeneration, because neuronal loss is found in the predilection sites for LBs.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Lewy_body</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lewy body</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Limitation_of_upward_gaze</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Limitation of upward gaze</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Lipidomic_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Lipidomic_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lipidomic biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Long_term_recordings_of_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Long_term_recordings_of_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Long-term recordings of tremor EMG have been made for one or several days to study drug effects.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Long_term_recordings_of_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Long term recordings of tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Loss_of_hearing</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Loss_of_hearing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Loss of hearing</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Loss_of_postural_reflex</IRI>
        <Literal datatypeIRI="&xsd;string">Pahwa, R., Lyons, K. E., &amp; Koller, W. (Eds.). (2003). Handbook of Parkinson&apos;s disease. CRC Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Loss_of_postural_reflex</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Loss of postural reflexes usually occurs in more advanced stages of PD and, along with freezing, is the most common cause of falls, often resulting in hip fractures.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Loss_of_postural_reflex</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Loss of postural reflex</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Loss_of_smell</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Loss_of_smell</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Loss of smell</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Loss_of_urinarry_bladder_control</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Loss_of_urinarry_bladder_control</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Loss of urinary bladder control</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MAOB</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MAOB</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MAOB</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MAPT</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., ... &amp; Hirokawa, N. (1994). Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature, 369(6480), 488-491.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MAPT</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MAPT</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MAPT</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">microtobule-associated protein</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#MAPT</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The tau gene encodes a protein that is a major neuronal microtubule-associated protein localized mostly in axons.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MAPT</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tau protein</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MDS-UPDRS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MDS-UPDRS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">UPDRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#MDS-UPDRS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The Movement Disorder Sociaty-sponsored revision of the United Parkinson&apos;s Disease Rating Scale.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MDS-UPDRS</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MDS-UPDRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MESC2.10</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#MESC2.10</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cell lines originated from 8 week old human mesencephalon presenting TH, DAT, DA release and electrical activity phenotypes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MESC2.10</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MESC2.10</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MIBG_scintigraphy</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MIBG_scintigraphy</IRI>
        <Literal datatypeIRI="&xsd;string">Cardiac metaiodobenzylguanidine scintigraphy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#MIBG_scintigraphy</IRI>
        <Literal datatypeIRI="&xsd;string">MIBG is an analogue of noradrenaline that is transported into sympathetic neurons and can act as a tracer of catecholaminergic neurons if labelled with radiolabelled iodine and detected by scintigraphy. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MIBG_scintigraphy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MIBG scintigraphy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MN9D</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#MN9D</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cell lines originated from mouse hybrid mesencephalic cells presenting no DAT but D2R, DA, and TH phenotypes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MN9D</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">MN9D</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MPTP</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#MPTP</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MPTP (1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine) is a chemical that may be produced accidentally during illicit manufacture of the recreational drug MPPP, which is a synthetic heroin substitute. The neurotoxicity of MPTP was discovered in 1976 after a chemistry graduate student synthesized MPPP incorrectly and injected the result. It was contaminated with MPTP, and within three days he began exhibiting symptoms of acute Parkinson&apos;s disease. It was also developed but unused as a herbicide and was distributed on the streets as a synthetic opioid-like drug. MPTP inhibits tyrosine hydroxylation, which is essential for the formation of dopamine. So MPTP causes acute Parkinson&apos;s disease by lowering dopamine levels.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MPTP</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MPTP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MPTP-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MPTP-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">(MPTP)-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MPTP-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MPTP-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MPTP induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MPTP-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MPTP-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MPTP-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MPTP-induced_parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">MPTP induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#MPTP_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MPTP_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MPTP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MPTP_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MPTP-lesioned mouse model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#MPTP_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MPTP-treated mouse model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#MPTP_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MPTP-administered mouse models showing degeneration of SNpc neurons and striatal dopamine depletion.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#MPTP_model</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">MPTP model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Machado-Joseph_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bettencourt, C., Santos, C., Coutinho, P., Rizzu, P., Vasconcelos, J., Kay, T., ... &amp; Lima, M. (2011). Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report. BMC neurology, 11(1), 131.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Machado-Joseph_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Machado-Joseph disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Machado-Joseph_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SCA3</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Machado-Joseph_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">spinocerebellar ataxia type 3</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Machado-Joseph_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A neurodegenerative disorder that presents extrapyramidal motor signs (EPS) more frequently than the other subtypes of ataxias.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Machado-Joseph_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Machado Joseph disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Malaria</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Malaria</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Malaria</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Maneb</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://viartis.net/parkinsons.disease/toxic.causes.htm</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Maneb</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Maneb is a fungicide that contains manganese. The major active element of Maneb is manganese ethylene-bis-dithiocarbamate. Pesticides are known to be associated with an increased rate of Parkinson&apos;s disease, so there is a greatly increased likelihood of developing toxic symptoms by people involved in horticulture and agriculture. As Maneb contains manganese it is possible that it causes Parkinson&apos;s Disease symptoms via the same means as manganese, which is by inhibiting tyrosine hydroxylation, which is essential for the formation of dopamine. The effects of Maneb are potentiated when there is also exposure to the pesticide Paraquat.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Maneb</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Maneb</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Manganese</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Manganese</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Manganese can cause manganism, an irreversible neurological disorder similar to Parkinson&apos;s disease. Occupational exposures occur mainly in welding, mining as miners are surrounded by manganese dust and airborne manganese particles, alloy production, processing, ferro-manganese operations especially in which manganese ore or manganese compounds are turned into steel, and work with agrochemicals. The towns and communities surrounding the areas of manganese heavy industry could also become affected by toxic exposure to manganese. It is also hypothesized that long-term exposure to the naturally-occurring manganese in shower water also puts people at risk. Manganese inhibits tyrosine hydroxylation, which is essential for the formation of dopamine. So manganese may cause Parkinson&apos;s disease by lowering dopamine levels.

</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Manganese</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Manganese</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Manganese-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Manganese-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Manganese toxicity can result in parkinsonism, though rest tremor is rare and there is often an associated dystonia. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Manganese-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Manganese-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mapk10tm1Flv</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Mapk10tm1Flv</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mapk9tm1Flv</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Mapk9tm1Flv</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Marti_and_Tolosa_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Marti_and_Tolosa_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Assessment of treatment efficacy in hemifacial spasm. It rates severity, frequency and functional impairment.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Marti_and_Tolosa_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Marti and Tolosa scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Medical_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth Jr, W. T., Swanson, P. D., &amp; Checkoway, H. (2006). Diabetes, smoking, and other medical conditions in relation to Parkinson&apos;s disease risk. Parkinsonism &amp; related disorders, 12(3), 185-189.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Medical_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The risks of PD associated with selected medical conditions.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Medical_risk_factor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Medical history factor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Melatonin</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Melatonin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Melatonin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Mercury_poisoning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Mercury_poisoning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mercury toxicity is a known cause of symptoms that mimic Parkinson&apos;s disease, especially tremor. One of the chief targets of the toxin is the enzyme pyruvate dehydrogenase (PDH). The enzyme is irreversibly inhibited by several mercury compounds, the lipoic acid component of the multienzyme complex binds mercury compounds tightly and thus inhibits PDH. However, the cause of the symptoms of Parkinson&apos;s disease is likely to be due to the fact that mercury potently causes the release of dopamine, thereby lowering dopamine levels. Mercury is found in a wide variety of sources: dietary fish intake, ethnic over-the-counter medications, occupational exposures to mercury vapour, possession of dental amalgam fillings, gold production, skin ointment, some soaps.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mercury_poisoning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mercury poisoning</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Metabolic_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Metabolic_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Metabolic biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Metallothionein</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Metallothionein</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Metallothionein</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Methanol</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Methanol</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Methanol</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Metoclopramide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Duvoisin, R. C., &amp; Sage, J. (2001). Parkinson&apos;s disease: A guide for patient and family. Wolters Kluwer Health.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Metoclopramide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Metoclopramide induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Metoclopramide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Metoclopramide-induced encephalopathy in Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Metoclopramide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Metoclopramide, commonly prescribed for various stomach disorders in the US, may induce parkinsonism and it does so in the same way the major transquilizers do by blocking the action of dopamine.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Metoclopramide-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Metoclopramide-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Micrographia</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Micrographia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Micrographia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Mini-mental_parkinson</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Larner, A. J. (2011). Mini-Mental Parkinson (MMP) as a Dementia Screening Test: Comparison with the Mini-Mental State Examination (MMSE). Current aging science.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mini-mental_parkinson</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MMP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Mini-mental_parkinson</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mini-Mental Parkinson (MMP), a derivative of the Mini-Mental State Examination (MMSE), was originally described as a cognitive screening instrument for use in Parkinson&apos;s disease. Its item content addresses some of the acknowledged shortcomings of the MMSE.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mini-mental_parkinson</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mini-mental parkinson</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Miscellaneous_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Miscellaneous_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Miscellaneous biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Mitochondrial_DNA_mutation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reeve, A. K., Krishnan, K. J. and Turnbull, D. (2008), Mitochondrial DNA Mutations in Disease, Aging, and Neurodegeneration. Annals of the New York Academy of Sciences, 1147: 21–29. doi: 10.1196/annals.1427.016</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mitochondrial_DNA_mutation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mitochondrial Dysfunction in Idiopathic Parkinson Disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mitochondrial_DNA_mutation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mutations in mitochondrial DNA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mitochondrial_DNA_mutation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">mitochondrial DNA mutations in early parkinson</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Mitochondrial_DNA_mutation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The mitochondrial dysfunction caused by mutations has been shown to be associated with signs of apoptosis and to cause cell loss. Mutations of the mitochondrial genome have also been shown to accumulate with age and in common neurodegenerative diseases, such as Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mitochondrial_DNA_mutation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mitochondrial DNA mutation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mitochondrial_DNA_polymerase_gamma_mutation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mitochondrial DNA polymerase gamma mutation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Mitochondrial_complex_I_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ramonet, D., Perier, C., Recasens, A., Dehay, B., Bové, J., Costa, V., ... &amp; Vila, M. (2012). Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death &amp; Differentiation, 20(1), 77-85.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mitochondrial_complex_I_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Loss of mitochondrial complex I activity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mitochondrial_complex_I_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mitochondrial complex I dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mitochondrial_complex_I_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mitochondrial dysfunction in Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mitochondrial_complex_I_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">decreased Complex I activity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Mitochondrial_complex_I_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mitochondrial complex I dysfunction has long been associated with Parkinson’s disease (PD). Recent evidence suggests that mitochondrial involvement in PD may extend beyond a sole respiratory deficit and also include perturbations in mitochondrial fusion/fission or ultrastructure. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mitochondrial_complex_I_deficiency</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Mitochondrial complex I deficiency</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Monoamines</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Monoamines</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Monoamines</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Monocycline</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Monocycline</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Monocycline</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Monogenic_forms_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Monogenic_forms_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">monogenetic forms of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Monogenic_forms_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">monogenic familial forms of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Monogenic_forms_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">monogenic forms of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Monogenic_forms_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">monogenic forms of parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Monogenic_forms_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A number of genes that cause, when mutated, mongenically inherited forms of Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Monogenic_forms_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Monogenic form of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Montgomery-Asberg_depression_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sampaio, C., Goetz, C. G., &amp; Schrag, A. (Eds.). (2012). Rating Scales in Parkinson&apos;s Disease: Clinical Practice and Research. Oxford University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Montgomery-Asberg_depression_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MADRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Montgomery-Asberg_depression_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The MADRS is an observer-rated scale and requires some clinical experience with depression. It covers all the DSM criteria of a major depressive episode.  </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Montgomery-Asberg_depression_rating_scale</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Montgomery-Asberg depression rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Morphological_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Morphological_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Biomarkers that indicate a change in morphology of affected brain regions in Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Morphological_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Morphological biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Motor_features</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">motor features</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">motor function</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">motor impairment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">motor symptoms</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Patients with PD may exhibit a number of secondary motor symptoms that may impact on their functioning at home, at work and while driving.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Motor symptom</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Motor_testing</IRI>
        <Literal datatypeIRI="&xsd;string">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Motor_testing</IRI>
        <Literal datatypeIRI="&xsd;string">motor test</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Motor_testing</IRI>
        <Literal datatypeIRI="&xsd;string">Testing abnormaities in speed of movement during target tracking and in control of direction.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Motor_testing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Motor testing</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Motorized_scooter</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Motorized scooter</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Mouse_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mouse_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">genetic PD mouse models</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mouse_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">genetic mouse model of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mouse_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">mouse models of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Mouse_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">rodent models for Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Mouse_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Models of basal ganglia injury and degeneration. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mouse_models_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mouse model of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Mucormycosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mucormycosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mucormycosis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Multidimensional_fatigue_inventory</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Elbers, R. G., van Wegen, E. E., Verhoef, J., &amp; Kwakkel, G. (2012). Reliability and structural validity of the Multidimensional Fatigue Inventory (MFI) in patients with idiopathic Parkinson&apos;s disease. Parkinsonism &amp; Related Disorders, 18(5), 532-536.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Multidimensional_fatigue_inventory</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MFI</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Multidimensional_fatigue_inventory</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The MFI is a self-report questionnaire that assesses five dimensions of fatigue (i.e. general fatigue (GF), physical fatigue (PF), reduced activity (RA), mental fatigue (MF) and reduced motivation (RM)).</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Multidimensional_fatigue_inventory</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Multidimensional fatigue inventory</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Multifocal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Multifocal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Multifocal dystonia involves two or more unrelated body parts.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Multifocal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Multifocal dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Multiple_system_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Multiple_system_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">MSA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Multiple_system_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson variant of multiple system atrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Multiple_system_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinson&apos;s disease and multiple system atrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Multiple_system_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A triad of coexisting NEURODEGENERATIVE disorders that manifest collective symptoms of autonomic, ataxic
(cerebellar), and extrapyramidal (parkinsonian) dysfunctions.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Multiple_system_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Multiple system atrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Muscle_action_potential</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Muscle_action_potential</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Muscle action potential</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Muscle_rigidity</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Muscle_rigidity</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Muscle rigidity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Mycoplasma_pneumonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Mycoplasma_pneumonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mycoplasma pneumonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Myectomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Truong, D. (2010). Living Well with Dystonia: A Patient Guide. Demos Medical Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Myectomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A surgical technique in which specific muscles are cut or removed in order to relieve dystonia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Myectomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Myotomy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Needle_electromyography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Needle electromyography</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuralgic_pain</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuralgic_pain</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuralgic pain</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuroacanthocytosis_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pahwa, R., Lyons, K. E., &amp; Lyons, K. E. (Eds.). (2013). Handbook of parkinson&apos;s disease. CRC Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroacanthocytosis_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">NA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroacanthocytosis_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neuro-acanthocytosis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neuroacanthocytosis_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">This is a rare cause of parkinsonism and typically presents with a hyperkinetic movement disorder, including chorea, tic-like features, and polyneuropathy.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuroacanthocytosis_syndrome</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Neuroacanthocytosis syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neurobehavioral_biomarkers</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neurobehavioral_biomarkers</IRI>
        <Literal datatypeIRI="&xsd;string">Neurobehavioral biomarkers can provide a wealth of basic information regarding PD progression and alleviation of typical symptoms which could induce deleterious consequences in a PD patient.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neurobehavioral_biomarkers</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neurobehavioral biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuroimaging_biomarkers_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neuroimaging_biomarkers_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Markers that use imaging techniques to follow the decline in neurotransmitter function, examine metabolic activity (using 18F-fluorodeoxyglucose) and monitor regional cerebral blood flow.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuroimaging_biomarkers_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuroimaging biomarker for Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tsai, L. (2001). Taking the Mystery Out of Medications in Autism/Asperger&apos;s Syndrome: A Guide for Parents and Non-Medical Professionals. Future Horizons.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuroleptic drug-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuroleptic-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuroleptic-induced tradive dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">antipsychotic induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neuroleptic drug-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neuroleptic-induced acute akathisia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neuroleptic-induced acute dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuroleptic-induced parkinsonism occurs at varying times after initiating neuroleptic therapy in approximately 20% to 40% of individuals treated with neuroleptic medications.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuroleptic-induced_parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Neuroleptic induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuromelanin</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuromelanin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuromelanin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuromelanin_Ab</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuromelanin_Ab</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuromelanin Ab</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuropathology_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neuropathology_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Clinical and pathological features of Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuropathology_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuropathology of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neurophysiological_testing</IRI>
        <Literal datatypeIRI="&xsd;string">Willow, M. J. (Ed.). (2005). Parkinson&apos;s Disease: New Research. Nova Publishers.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neurophysiological_testing</IRI>
        <Literal datatypeIRI="&xsd;string">Assessment of the functional mechanisms involved in the generation of certain symptoms or signs. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neurophysiological_testing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neurophysiological testing</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuroprotective_agent_for_parkinson</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroprotective_agent_for_parkinson</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neuroprotective therapies</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neuroprotective_agent_for_parkinson</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Treatment approaches and medications that attempt to prevent damage to neurons. In people with Parkinson’s disease, such therapies target preservation of the function of remaining dopaminergic neurons.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuroprotective_agent_for_parkinson</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuroprotective agent for parkinson</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuroprotective_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neuroprotective_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neuroprotective agent </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuroprotective_biomarker_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuroprotective biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neuropsychiatric_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neuropsychiatric_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A variety of alterations in mood, initiative, hedonistic tone, and cognitive functioning. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neuropsychiatric_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neuropsychiatric dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neurorestoration</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neurorestorative benefits</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neurorestorative effect</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neurorestorative properties</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neurorestorative strategies for Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">neurorestorative therapies</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">restorative therapy in Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A therapy that returns anatomical and functional integrity to the nigrostriatal dopamine system and reverses clinical symptoms and signs.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Neurorestorative_treatment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neurorestorative treatment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#New_York_University_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#New_York_University_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A scale for ssessing rigidity, tremor, bradykinesia, simultaneous movements, stance, postural stability, and gait including timed walking as well as 10 functional disability items, each on a 0-4 scale. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#New_York_University_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">New York University rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Nicotine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Nicotine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Nicotine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Nigral_glutathione_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Perry, T. L., Godin, D. V., &amp; Hansen, S. (1982). Parkinson&apos;s disease: a disorder due to nigral glutathione deficiency?. Neuroscience letters, 33(3), 305-310.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Nigral_glutathione_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Alterations in glutathione levels in Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Nigral_glutathione_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Glutathione depletion</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Nigral_glutathione_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">glutathione peroxidase deficiency in Parkinson&apos;s disease substantia nigra</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Nigral_glutathione_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">nigral GSH deficiency in PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Nigral_glutathione_deficiency</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reduced or absent glutathione (GSH) content in the substantia nigra of Parkinson&apos;s patients.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Nigral_glutathione_deficiency</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Nigral glutathione deficiency</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Nigrostriatal_dopaminergic_loss</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Drui, G., Carnicella, S., Carcenac, C., Favier, M., Bertrand, A., Boulet, S., &amp; Savasta, M. (2013). Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease. Molecular psychiatry.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Nigrostriatal_dopaminergic_loss</IRI>
        <Literal datatypeIRI="&xsd;string">ND dopaminergic loss</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Nigrostriatal_dopaminergic_loss</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) that is thought to cause the classical motor symptoms of Parkinson&apos;s disease. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Nigrostriatal_dopaminergic_loss</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Nigrostriatal dopaminergic loss</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Nocturia</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Nocturia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Nocturia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Non-kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hankey, G. J., &amp; Wardlaw, J. M. (2008). Clinical neurology. Manson publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Non-kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PNKD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Non-kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">nonkinesigenic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Non-kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">paroxysmal nonkinesigenic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Non-kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Spontaneous onset of attacks of abnormal involuntary movements.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Non-kinesigenic_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Non-kinesigenic dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Non-motor_features</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Non-motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">non-motor features</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Non-motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">non-motor impairment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Non-motor_features</IRI>
        <Literal datatypeIRI="&xsd;string">non-motor symptoms</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Non-motor_features</IRI>
        <Literal datatypeIRI="&xsd;string">pre-motor stage</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Non-motor_features</IRI>
        <Literal datatypeIRI="&xsd;string">premotor stage</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Non-motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Non-motor symptoms are a common and under appreciated feature of PD. These include autonomic dysfunction, cognitive/neurobehavioral disorders, and sensory and sleep abnormalities.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Non-motor_features</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Non-motor symptom</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Nonkinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Nonkinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PNKD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Nonkinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">non-kinesigenic dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Nonkinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An autosomal-dominant disorder characterized by paroxysms of hyperkinesias, which can include dystonia, dyskinesia, choreoathetosis, and ballism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Nonkinesigenic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Nonkinesigenic dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Normal_pressure_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Normal_pressure_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">NPH</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Normal_pressure_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">normal pressure hydrocephalus presenting as parkinson&apos;s syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Normal_pressure_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Those with communicating hydrocephalus can develop the NPH syndrome, in which gait dysfunction, cognitive decline, and urinary inconsistence are the predominant features.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Normal_pressure_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Normal pressure hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Northwestern_University_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Northwestern_University_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">NUDS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Northwestern_University_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">NUDS scores five types of activities of daily livingon 0-10 point scales, with descriptors for each score.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Northwestern_University_disability_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Northwestern University disability scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Nr4a2tm1Omc</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Nr4a2tm1Omc</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#OMICS_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#OMICS_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">The Omics analysis provides lots of data which can further establish the diagnosis and basic information regarding the genetic and environmental insult to PD patients.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#OMICS_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">OMICS biomarkers of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Obeso_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Obeso_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Obeso dyskinesia scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Obeso_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It assesses the intensity and duration of dyskinesia by combining historical and and motor examination data.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Obeso_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Obeso dyskinesia rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Obessive_behaviour</IRI>
        <Literal datatypeIRI="&xsd;string">Olanow, C. W., Stocchi, F., &amp; Lang, A. (Eds.). (2011). Parkinson&apos;s disease: non-motor and non-dopaminergic features. John Wiley &amp; Sons.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Obessive_behaviour</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">obsessive behavior</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Obessive_behaviour</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">obsessive-compulsive</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Obessive_behaviour</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">obsessive-compulsive stereotyped behavior</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Obessive_behaviour</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">obsessive-compulsive symptom</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Obessive_behaviour</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Obsessive–compulsive disorder (OCD) is characterized by complaints of persistent or repetitive thoughts (obsessions) or behaviors (compulsions).</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Obessive_behaviour</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Obsessive-compulsive behaviour</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Obstructive_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Obstructive_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism associated with obstructive hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Obstructive_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hydrocephalus secondary to obstruction within the ventricular system. Parkinsonism has rarely been reported as a feature of obstructive hydrocephalus.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Obstructive_hydrocephalus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Obstructive hydrocephalus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Occular_saccade_impairment</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Occular saccade impairment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ocular_surface_irritation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ocular surface irritation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Off-period_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pahwa, R., Lyons, K. E., &amp; Koller, W. (Eds.). (2003). Handbook of Parkinson&apos;s disease. CRC Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Off-period_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">&quot;off-period&quot; dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Off-period_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">off-period dystonias</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Off-period_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A late complication of levodopa therapy that tends to appear after at least four or five years of continuous administration.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Off-period_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Off-period dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Olfaction</IRI>
        <Literal datatypeIRI="&xsd;string">Doty, R., Golbe, L. I., McKeown, D. A., Stern, M. B., Lehrach, C., &amp; Crawford, D. (1993). Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson&apos;s disease. Neurology, 43(5), 962-962.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Olfaction</IRI>
        <Literal datatypeIRI="&xsd;string">olfactory testing</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Olfaction</IRI>
        <Literal datatypeIRI="&xsd;string">Olfactory dysfunction occurs in most patients with idiopathic Parkinson&apos;s disease and olfactory testing is a standardized test of odor identification ability. It can differentiate between progressive supranuclear palsy and idiopathic Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Olfaction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Olfaction testing</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Olfactory_dysfunction</IRI>
        <Literal datatypeIRI="&xsd;string">Barker, M. R., &amp; Rowe, F. D. (Eds.). (2010). Non-dopamine Lesions in Parkinson&apos;s Disease. Oxford University Press, USA.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Olfactory_dysfunction</IRI>
        <Literal datatypeIRI="&xsd;string">hyposmia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Olfactory_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Measurable smell loss that adversely impacts quality of life, the flavor and platability of foods and beverages, nutrition and safety. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Olfactory_dysfunction</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Olfactory dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Open_space_hesitation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Open space hesitation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Ophthalmological_measures</IRI>
        <Literal datatypeIRI="&xsd;string">neuro-ophthalmologic abnormalities</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ophthalmological_measures</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ophthalmological measure</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Oral_pain</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Oral_pain</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Oral pain</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Organophosphate</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Organophosphate</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Organophosphate</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Organotypic_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Organotypic_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Organotypic cultures combine features of cell culture and intact animals so that neurons are more easily accessible for pharmacology, gene transfer and repeated imaging than inside the intact animal. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Organotypic_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Organotypic culture</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Organotypic_slice_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Organotypic_slice_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">slice culture model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Organotypic_slice_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A culture system composed of postnatal rat substantia nigra pars compacta presenting postnatal dopaminergic neurons in their natural environment.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Organotypic_slice_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Organotypic slice culture</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Oromandibular_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Oromandibular_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Oromandibular dystonia is a focal dystonia characterized by forceful contractions of the face, jaw, and/or tongue causing difficulty in opening and closing the mouth and often affecting chewing and speech. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Oromandibular_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Oromandibular dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Oromandibular_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Oromandibular_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It includes a severity and a disability scale for roromandibular dystonia. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Oromandibular_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Oromandibular dystonia rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Other_essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Other_essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Idiopathic tremor syndromes are classified under this category by the Movement Disorder Society.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Other_essential_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Other essential tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK10_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK10_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK10 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK11_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK11_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK11 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK1_mutation_induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK1_mutation_induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">alpha-synuclein mutation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK1_mutation_induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK1 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK2_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK2_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK2 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK3_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK3_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinson&apos;s disease linked to Chromosome 2</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK3_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK3 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK4_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK4_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">alpha-synuclein duplication</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK4_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">alpha-synuclein triplication</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK4_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK4 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK5_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK5_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism associated with a mutation in the gene for ubiquitin hydrolase 1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK5_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ubiquitin C-terminal hydrolase L1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK5_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK5 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#BELcode"/>
        <IRI>#PARK6_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">##################################################################################
# Document Properties Section

SET DOCUMENT Name = &quot;Document name&quot;
SET DOCUMENT Description = &quot;Document description&quot;
SET DOCUMENT Version = &quot;1.0&quot;
SET DOCUMENT Copyright = &quot;Copyright (c) 2012, akodamullil. All Rights Reserved.&quot;
SET DOCUMENT Authors = &quot;akodamullil&quot;
SET DOCUMENT Licenses = &quot;Document license&quot;
SET DOCUMENT ContactInfo = &quot;your@email.com&quot;

##################################################################################
# Definitions Section

DEFINE NAMESPACE PFR AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-rat-protein-families.belns&quot;
DEFINE NAMESPACE MGI AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mgi-approved-symbols.belns&quot;
DEFINE NAMESPACE PFM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-mouse-protein-families.belns&quot;
DEFINE NAMESPACE MESHPP AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-biological-processes.belns&quot;
DEFINE NAMESPACE MESHCL AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-cellular-locations.belns&quot;
DEFINE NAMESPACE NCH AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-complexes.belns&quot;
DEFINE NAMESPACE CHEBI AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/chebi-names.belns&quot;
DEFINE NAMESPACE NCR AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-rat-complexes.belns&quot;
DEFINE NAMESPACE HGNC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/hgnc-approved-symbols.belns&quot;
DEFINE NAMESPACE SPAC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/swissprot-accession-numbers.belns&quot;
DEFINE NAMESPACE PFH AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-protein-families.belns&quot;
DEFINE NAMESPACE NCM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-mouse-complexes.belns&quot;
DEFINE NAMESPACE CHEBIID AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/chebi-ids.belns&quot;
DEFINE NAMESPACE RGD AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/rgd-approved-symbols.belns&quot;
DEFINE NAMESPACE MESHD AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-diseases.belns&quot;
DEFINE NAMESPACE GO AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-biological-processes-names.belns&quot;
DEFINE NAMESPACE SCHEM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-chemical-names.belns&quot;
DEFINE NAMESPACE EGID AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/entrez-gene-ids-hmr.belns&quot;
DEFINE NAMESPACE GOCCACC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-cellular-component-accession-numbers.belns&quot;
DEFINE NAMESPACE GOCCTERM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-cellular-component-terms.belns&quot;
DEFINE NAMESPACE HGU95AV2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u95av2.belns&quot;
DEFINE NAMESPACE HGU133P2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u133-plus2.belns&quot;
DEFINE NAMESPACE HGU133AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u133ab.belns&quot;
DEFINE NAMESPACE MGU74ABC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mg-u74abc.belns&quot;
DEFINE NAMESPACE MG430AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-moe430ab.belns&quot;
DEFINE NAMESPACE MG4302 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mouse430-2.belns&quot;
DEFINE NAMESPACE MG430A2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mouse430a-2.belns&quot;
DEFINE NAMESPACE RG230AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-rae230ab-2.belns&quot;
DEFINE NAMESPACE RG2302 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-rat230-2.belns&quot;

DEFINE ANNOTATION HemicAndImmuneSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-hemic-and-immune-system.belanno&quot;
DEFINE ANNOTATION UrogenitalSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-urogenital-system.belanno&quot;
DEFINE ANNOTATION FluidAndSecretion AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-fluid-and-secretion.belanno&quot;
DEFINE ANNOTATION CellStructure AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cell-structure.belanno&quot;
DEFINE ANNOTATION CellLine AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/atcc-cell-line.belanno&quot;
DEFINE ANNOTATION TextLocation AS  LIST {&quot;Abstract&quot;,&quot;Results&quot;,&quot;Legend&quot;,&quot;Review&quot;}
DEFINE ANNOTATION IntegumentarySystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-integumentary-system.belanno&quot;
DEFINE ANNOTATION DigestiveSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-digestive-system.belanno&quot;
DEFINE ANNOTATION MuskuloskeletalSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-musculoskeletal-system.belanno&quot;
DEFINE ANNOTATION Tissue AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-tissue.belanno&quot;
DEFINE ANNOTATION BodyRegion AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-body-region.belanno&quot;
DEFINE ANNOTATION Cell AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cell.belanno&quot;
DEFINE ANNOTATION NervousSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-nervous-system.belanno&quot;
DEFINE ANNOTATION SenseOrgan AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-sense-organ.belanno&quot;
DEFINE ANNOTATION Disease AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-disease.belanno&quot;
DEFINE ANNOTATION RespiratorySystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-respiratory-system.belanno&quot;
DEFINE ANNOTATION Species AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/species-taxonomy-id.belanno&quot;
DEFINE ANNOTATION CardiovascularSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cardiovascular-system.belanno&quot;
DEFINE ANNOTATION EndocrineSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-endocrine-system.belanno&quot;

##################################################################################
# Statements Section

SET STATEMENT_GROUP = &quot;Group 1&quot;

# Add statements below this comment

####################

SET Citation={&quot;PubMed&quot;,&quot;Neurobiol Dis. 2007 Nov;28(2):216-26. Epub 2007 Jul 17.&quot;,&quot;17707122&quot;}

SET Evidence=&quot;PINK1 mutants associated with recessive Parkinson&apos;s disease are defective in inhibiting\
 mitochondrial release of cytochrome c.Mutations in PTEN-induced kinase 1 (PINK1) gene cause recessive\
 familial type 6 of Parkinson&apos;s disease (PARK6). We investigated molecular mechanisms underlying PINK1\
 neuroprotective function and PARK6 mutation-induced loss of PINK1 function. Overexpression of wild-type\
 PINK1 blocked mitochondrial release of apoptogenic cytochrome c, caspase-3 activation and apoptotic cell\
 death induced by proteasome inhibitor MG132. N-terminal truncated PINK1 (NDelta35), which lacks\
 mitochondrial localization sequence, did not block MG132-induced cytochrome c release and cytotoxicity. \
Despite mitochondrial expression, PARK6 mutant (E240K), (H271Q), (G309D), (L347P), (E417G) and C-terminal\
 truncated (CDelta145) PINK1 failed to inhibit MG132-induced cytochrome c release and caspase-3 activation.\
 Overexpression of wild-type PINK1 blocked cytochrome c release and cell death caused by atractyloside,\
 which opens mitochondrial permeability transition pore (mPTP). PARK6 PINK1 mutants failed to inhibit\
 atractyloside-induced cytochrome c release. These results suggest that PINK1 exerts anti-apoptotic\
 effect by inhibiting the opening of mPTP and that PARK6 mutant PINK1 loses its ability to prevent\
 mPTP opening and cytochrome c release.&quot;
 
p(HGNC:PINK1) -- path(MESHD:&quot;Parkinson Disease&quot;)

#N
p(HGNC:PINK1) -| tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot; )
p(HGNC:PINK1) -| act(p(HGNC:CASP3))

#D

p(HGNC:PINK1, sub(E,240,K)) -&gt; tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot; )
p(HGNC:PINK1, sub(E,240,K)) -&gt; act(p(HGNC:CASP3))

p(HGNC:PINK1, sub(H,271,Q)) -&gt; tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot; )
p(HGNC:PINK1, sub(H,271,Q)) -&gt; act(p(HGNC:CASP3))

p(HGNC:PINK1, sub(G,309,D)) -&gt; tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot; )
p(HGNC:PINK1, sub(G,309,D)) -&gt; act(p(HGNC:CASP3))

p(HGNC:PINK1, sub(L,347,P)) -&gt; tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot; )
p(HGNC:PINK1, sub(L,347,P)) -&gt; act(p(HGNC:CASP3))

p(HGNC:PINK1, sub(E,417,G)) -&gt; tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot; )
p(HGNC:PINK1, sub(E,417,G)) -&gt; act(p(HGNC:CASP3))

SET Citation={&quot;PubMed&quot;,&quot;Exp Neurol. 2009 Sep;219(1):266-73. doi: 10.1016/j.expneurol.2009.05.027. Epub 2009 Jun 3.&quot;,&quot;19500570&quot;} 

SET Evidence =&quot;mutations of PINK1 cause abnormal mitochondrial morphology, bioenergetic function and \
oxidative metabolism in human tissues but suggest that the biochemical consequences may vary between \
mutations.&quot;

p(HGNC:PINK1, sub(E,240,K))  negativeCorrelation bp(GO:&quot; mitochondrion organization&quot;) 
p(HGNC:PINK1, sub(E,240,K))  negativeCorrelation bp(&quot;bioenergetic function&quot;)
p(HGNC:PINK1, sub(E,240,K))  negativeCorrelation bp(GO:&quot; cellular respiration&quot;)

p(HGNC:PINK1, sub(H,271,Q))  negativeCorrelation bp(GO:&quot; mitochondrion organization&quot;) 
p(HGNC:PINK1, sub(H,271,Q))  negativeCorrelation bp(&quot;bioenergetic function&quot;)
p(HGNC:PINK1, sub(H,271,Q))  negativeCorrelation bp(GO:&quot; cellular respiration&quot;)

p(HGNC:PINK1, sub(G,309,D))  negativeCorrelation bp(GO:&quot; mitochondrion organization&quot;) 
p(HGNC:PINK1, sub(G,309,D))  negativeCorrelation bp(&quot;bioenergetic function&quot;)
p(HGNC:PINK1, sub(G,309,D))  negativeCorrelation bp(GO:&quot; cellular respiration&quot;)

p(HGNC:PINK1, sub(L,347,P))   negativeCorrelation bp(GO:&quot; mitochondrion organization&quot;) 
p(HGNC:PINK1, sub(L,347,P))   negativeCorrelation bp(&quot;bioenergetic function&quot;)
p(HGNC:PINK1, sub(L,347,P))   negativeCorrelation bp(GO:&quot; cellular respiration&quot;)

p(HGNC:PINK1, sub(E,417,G))  negativeCorrelation bp(GO:&quot; mitochondrion organization&quot;) 
p(HGNC:PINK1, sub(E,417,G))  negativeCorrelation bp(&quot;bioenergetic function&quot;)
p(HGNC:PINK1, sub(E,417,G))  negativeCorrelation bp(GO:&quot; cellular respiration&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;PLoS Biol. 2007 Jul;5(7):e172. Epub 2007 Jun 19.&quot;,&quot;17579517&quot;} 

SET Evidence =&quot;PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone \
TRAP1. Mutations in the PTEN induced putative kinase 1 (PINK1) gene cause an autosomal recessive form \
of Parkinson disease (PD). So far, no substrates of PINK1 have been reported, and the mechanism by \
which PINK1 mutations lead to neurodegeneration is unknown. Here we report the identification of TNF \
receptor-associated protein 1 (TRAP1), a mitochondrial molecular chaperone also known as heat shock \
protein 75 (Hsp75), as a cellular substrate for PINK1 kinase. PINK1 binds and colocalizes with TRAP1 \
in the mitochondria and phosphorylates TRAP1 both in vitro and in vivo. We show that PINK1 protects \
against oxidative-stress-induced cell death by suppressing cytochrome c release from mitochondria, \
and this protective action of PINK1 depends on its kinase activity to phosphorylate TRAP1. Moreover, \
we find that the ability of PINK1 to promote TRAP1 phosphorylation and cell survival is impaired by \
PD-linked PINK1 G309D, L347P, and W437X mutations. Our findings suggest a novel pathway by which \
PINK1 phosphorylates downstream effector TRAP1 to prevent oxidative-stress-induced apoptosis and \
implicate the dysregulation of this mitochondrial pathway in PD pathogenesis.&quot;

#N
p(HGNC:PINK1) -| bp(GO:&quot; response to oxidative stress&quot;)
kin(p(HGNC:PINK1)) -&gt; p(HGNC:TRAP1,pmod(P)) 
p(HGNC:TRAP1,pmod(P))  -| bp(GO:&quot; response to oxidative stress&quot;)

p(HGNC:PINK1) -| tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot;)

#D
p(HGNC:PINK1, sub(G,309,D)) -&gt; bp(GO:&quot; response to oxidative stress&quot;)
bp(GO:&quot; response to oxidative stress&quot;) -&gt; bp(GO:apoptosis)
p(HGNC:PINK1, sub(G,309,D)) -| p(HGNC:TRAP1,pmod(P))
p(HGNC:PINK1, sub(G,309,D)) -&gt; tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot;)

p(HGNC:PINK1, sub(L,347,P)) -&gt; bp(GO:&quot; response to oxidative stress&quot;)
p(HGNC:PINK1, sub(L,347,P)) -| p(HGNC:TRAP1,pmod(P))
p(HGNC:PINK1, sub(L,347,P)) -&gt; tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot;)

p(HGNC:PINK1, sub(W,437,X)) -&gt; bp(GO:&quot; response to oxidative stress&quot;)
p(HGNC:PINK1, sub(W,437,X)) -| p(HGNC:TRAP1,pmod(P))
p(HGNC:PINK1, sub(W,437,X)) -&gt; tloc(p(HGNC:CYC1),MESHCL:&quot;Mitochondrial Membranes&quot;, MESHCL:&quot;Cytoplasm&quot;)

####################

SET Citation={&quot;PubMed&quot;,&quot;Mov Disord. 2008 Apr 30;23(6):881-5. doi: 10.1002/mds.21960.&quot;,&quot;18307263&quot;}

SET Evidence=&quot;Both mutations (p.A244G and p.V317I) were found to abolish the protective effect of \
wild-type PINK1 against staurosporine-induced apoptosis. These findings further expand the clinical \
spectrum of PINK1-related parkinsonism to include late onset, typical PD, and underline the existing \
difficulties in discriminating between mendelian parkinsonism and idiopathic PD.&quot;

p(HGNC:PINK1, sub(A,244,G)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:PINK1, sub(V,317,I)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;Parkinsonism Relat Disord. 2012 Jun;18(5):651-3. doi: 10.1016/j.parkreldis.2011.08.017. Epub 2011 Sep 17.&quot;,&quot;21925922&quot;} 

SET Evidence =&quot;Mutations in the PINK1 gene represent the second most frequent cause of early-onset \
Parkinson&apos;s disease (EOPD). One or two mutated alleles were also reported in some sporadic or familial\
 patients suffering from late-onset Parkinson&apos;s disease (LOPD). We aimed at assessing the frequency of \
mutations in this gene in our population. We performed a sequence analysis of PINK1 in 115 patients \
diagnosed with Parkinson&apos;s disease (PD) from southern Italy, including 93 sporadic cases with EOPD, \
9 familial cases with EOPD, and 13 familial cases with LOPD. Three known homozygous mutations \
(Q456X, W437X, Q126P), corresponding to a 2.6% of all cases, were found. In particular, one\
 mutation was detected among the sporadic cases (1.0%), one mutation among the familial \
early-onset patients (11.1%) and one mutation among the familial late-onset patients (7.7%). \
In addition, we found two heterozygous mutations (E476K, R207Q) among the sporadic patients. \
Only one mutation (R207Q) had not been previously described. Our results assess the role played by \
PINK1 in EOPD in southern Italy and illustrate the existence of mutations in this gene also in the \
late-onset form of the disease.&quot;

p(HGNC:PINK1, sub(Q,456,X)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:PINK1, sub(W,437,X)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:PINK1, sub(Q,126,P)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

p(HGNC:PINK1, sub(E,476,K)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:PINK1, sub(R,207,Q)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;Neurosci Lett. 2006 Dec 20;410(2):121-5. Epub 2006 Nov 7.&quot;,&quot;17084972&quot;} 

SET Evidence =&quot;Our results yielded significant evidence for disease association between PINK1 A340T\
 and PD with later onset (OR 1.55, 95% CI 1.04-2.32, p=0.0393), thus suggesting that PINK1 A340T \
variant may contribute to the risk for late-onset PD in Chinese.Recent studies have demonstrated\
 that mutations in PINK1 (PARK6 locus) gene, encoding PTEN-induced kinase 1, are associated with \
both familial recessive and sporadic early onset parkinsonism.&quot;

p(HGNC:PINK1, sub(A,340,T)) -- path(MESHD:&quot;Parkinson Disease 6, Autosomal Recessive Early-Onset&quot;)
path(MESHD:&quot;Parkinson Disease 6, Autosomal Recessive Early-Onset&quot;) isA path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;Ann Neurol. 2006 Oct;60(4):414-9.&quot;,&quot;16969854&quot;} 

SET Evidence =&quot;We demonstrate an enrichment of heterozygous mutations in sporadic PD patients \
compared with matched control subjects (1.2% in PD vs 0.4% in control subjects). Furthermore, we show \
that they adversely affect DeltaPsim in a similar way to the familial G309D mutation. Although it \
remains difficult to conclusively demonstrate the pathogenicity of heterozygous mutations, the \
results of this study and the previously reported subclinical nigrostriatal dysfunction in carriers \
of heterozygous PINK1 mutations suggest the possibility that these heterozygous mutations are a \
significant risk factor in the development of later onset PD.&quot;

p(HGNC:PINK1, sub(G,309,D)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;Rinsho Shinkeigaku. 2005 Nov;45(11):899-901.&quot;,&quot;16447757&quot;} 

SET Evidence =&quot;The deposition of alpha-synuclein (aS), a product of pathogenic gene for dominantly \
inherited familial Parkinson&apos;s disease (PD; park1), as fibrillary aggregates like Lewy bodies (LB), \
is a hallmark lesion of a set of neurodegenerative disorders termed synucleinopathies, including \
sporadic PD and dementia with Lewy bodies (DLB). We found that aS is the major component of LBs and \
further identified a specific phosphorylation of Ser129 of insoluble aS by mass spectrometric analysis. \
The roles of DJ-1 and PINK-1, products of pathogenic genes for autosomal recessive forms of early-onset \
parkinsonism, have subsequently been examined. Overexpression of DJ-1 conferred cultured cells \
resistance to oxidative stress, suggesting an antioxidant function of DJ-1. We also confirmed the \
anti-PTEN function of DJ-1 that may promote cell survival, showing decreased phosphorylation of Akt \
through upregulation of PTEN activity upon siRNA knockdown for DJ-1. PINK-1, that had been identified \
as a gene upregulated by PTEN overexpression, turned out to be a protein kinase localized in \
mitochondria. Collectively, information derived from studies on pathogenic genes for familial PD \
will open up the way toward the clarification of the pathogenesis of PD, underscoring the roles of \
protein aggregation, proteolysis, oxidative stress and protein phosphorylation in PD.&quot;

#N
p(HGNC:PARK7) -| bp(GO:&quot;response to oxidative stress&quot;)
p(HGNC:PARK7) -&gt; bp(GO:&quot;cytokine activity&quot;)

#D
p(HGNC:PARK7) -- path(MESHD:&quot;Parkinson Disease&quot;)

UNSET STATEMENT_GROUP

</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK6_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK6_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PINK1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK6_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK6 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#BELcode"/>
        <IRI>#PARK8_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">##################################################################################
# Document Properties Section

SET DOCUMENT Name = &quot;Document name&quot;
SET DOCUMENT Description = &quot;Document description&quot;
SET DOCUMENT Version = &quot;1.0&quot;
SET DOCUMENT Copyright = &quot;Copyright (c) 2012, akodamullil. All Rights Reserved.&quot;
SET DOCUMENT Authors = &quot;akodamullil&quot;
SET DOCUMENT Licenses = &quot;Document license&quot;
SET DOCUMENT ContactInfo = &quot;your@email.com&quot;

##################################################################################
# Definitions Section

DEFINE NAMESPACE PFR AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-rat-protein-families.belns&quot;
DEFINE NAMESPACE MGI AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mgi-approved-symbols.belns&quot;
DEFINE NAMESPACE PFM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-mouse-protein-families.belns&quot;
DEFINE NAMESPACE MESHPP AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-biological-processes.belns&quot;
DEFINE NAMESPACE MESHCL AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-cellular-locations.belns&quot;
DEFINE NAMESPACE NCH AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-complexes.belns&quot;
DEFINE NAMESPACE CHEBI AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/chebi-names.belns&quot;
DEFINE NAMESPACE NCR AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-rat-complexes.belns&quot;
DEFINE NAMESPACE HGNC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/hgnc-approved-symbols.belns&quot;
DEFINE NAMESPACE SPAC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/swissprot-accession-numbers.belns&quot;
DEFINE NAMESPACE PFH AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-protein-families.belns&quot;
DEFINE NAMESPACE NCM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-mouse-complexes.belns&quot;
DEFINE NAMESPACE CHEBIID AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/chebi-ids.belns&quot;
DEFINE NAMESPACE RGD AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/rgd-approved-symbols.belns&quot;
DEFINE NAMESPACE MESHD AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-diseases.belns&quot;
DEFINE NAMESPACE GO AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-biological-processes-names.belns&quot;
DEFINE NAMESPACE SCHEM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-chemical-names.belns&quot;
DEFINE NAMESPACE EGID AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/entrez-gene-ids-hmr.belns&quot;
DEFINE NAMESPACE GOCCACC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-cellular-component-accession-numbers.belns&quot;
DEFINE NAMESPACE GOCCTERM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-cellular-component-terms.belns&quot;
DEFINE NAMESPACE HGU95AV2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u95av2.belns&quot;
DEFINE NAMESPACE HGU133P2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u133-plus2.belns&quot;
DEFINE NAMESPACE HGU133AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u133ab.belns&quot;
DEFINE NAMESPACE MGU74ABC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mg-u74abc.belns&quot;
DEFINE NAMESPACE MG430AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-moe430ab.belns&quot;
DEFINE NAMESPACE MG4302 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mouse430-2.belns&quot;
DEFINE NAMESPACE MG430A2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mouse430a-2.belns&quot;
DEFINE NAMESPACE RG230AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-rae230ab-2.belns&quot;
DEFINE NAMESPACE RG2302 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-rat230-2.belns&quot;

DEFINE ANNOTATION HemicAndImmuneSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-hemic-and-immune-system.belanno&quot;
DEFINE ANNOTATION UrogenitalSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-urogenital-system.belanno&quot;
DEFINE ANNOTATION FluidAndSecretion AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-fluid-and-secretion.belanno&quot;
DEFINE ANNOTATION CellStructure AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cell-structure.belanno&quot;
DEFINE ANNOTATION CellLine AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/atcc-cell-line.belanno&quot;
DEFINE ANNOTATION TextLocation AS  LIST {&quot;Abstract&quot;,&quot;Results&quot;,&quot;Legend&quot;,&quot;Review&quot;}
DEFINE ANNOTATION IntegumentarySystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-integumentary-system.belanno&quot;
DEFINE ANNOTATION DigestiveSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-digestive-system.belanno&quot;
DEFINE ANNOTATION MuskuloskeletalSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-musculoskeletal-system.belanno&quot;
DEFINE ANNOTATION Tissue AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-tissue.belanno&quot;
DEFINE ANNOTATION BodyRegion AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-body-region.belanno&quot;
DEFINE ANNOTATION Cell AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cell.belanno&quot;
DEFINE ANNOTATION NervousSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-nervous-system.belanno&quot;
DEFINE ANNOTATION SenseOrgan AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-sense-organ.belanno&quot;
DEFINE ANNOTATION Disease AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-disease.belanno&quot;
DEFINE ANNOTATION RespiratorySystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-respiratory-system.belanno&quot;
DEFINE ANNOTATION Species AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/species-taxonomy-id.belanno&quot;
DEFINE ANNOTATION CardiovascularSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cardiovascular-system.belanno&quot;
DEFINE ANNOTATION EndocrineSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-endocrine-system.belanno&quot;

##################################################################################
# Statements Section

SET STATEMENT_GROUP = &quot;Group 1&quot;

# Add statements below this comment

########################

SET Citation={&quot;PubMed&quot;,&quot;Neurology. 2008 Sep 23;71(13):1021-6. doi: 10.1212/01.wnl.0000326575.20829.45.&quot;,&quot;18809839&quot;} 

SET Evidence =&quot;Mutations in PARK8 (LRRK2) are associated with autosomal dominant parkinsonism and Parkinson disease \
(PD). The mean UPSIT score in G2019S parkinsonian carriers was lower than that in healthy controls (p &lt; 0.001) and \
similar to that found in patients with PD (p &gt; 0.999).&quot;

p(HGNC:LRRK2,sub(G,2019,S)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;J Biomed Sci. 2008 Sep;15(5):661-7. doi: 10.1007/s11373-008-9260-0. Epub 2008 Jun 4.&quot;,&quot;18523869&quot;} 

SET Evidence =&quot; The clinical phenotypes and [(18)F]-dopa PET findings for subjects with R1441H or G2385R resembled \
those of patients with idiopathic PD. Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) cause \
autosomal-dominant familial Parkinson&apos;s disease (PD).&quot;

p(HGNC:LRRK2,sub(R,1441,H)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:LRRK2,sub(G,2385,R)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;Mov Disord. 2006 Aug;21(8):1144-7.&quot;,&quot;16671078&quot;} 

SET Evidence =&quot;We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative \
process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD.&quot;

p(HGNC:LRRK2,sub(G,2019,S)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;Exp Cell Res. 2007 Oct 1;313(16):3658-70. Epub 2007 Jul 19.&quot;,&quot;17706965&quot;} 

SET Evidence =&quot;The PD-associated mutation, R1441C, located within the Roc domain, leads to an increase in LRRK2 \
kinase activity and a decrease in the rate of GTP hydrolysis, compared to the wild-type protein, in an in vitro \
assay. This finding suggests that the R1441C mutation may help stabilize an activated state of LRRK2. \
Additionally, LRRK2-mediated phosphorylation is stimulated upon binding of non-hydrolyzable GTP analogs, \
suggesting that LRRK2 is an MAPKKK-activated intramolecularly by its own GTPase. Since GTPases and MAPKKKs \
are upstream regulators of multiple signal transduction cascades, LRRK2 may play a central role in integrating \
pathways involved in neuronal cell signaling and the pathogenesis of PD.&quot;

p(HGNC:LRRK2,sub(R,1441,C)) -&gt; kin(p(HGNC:LRRK2))
p(HGNC:LRRK2,sub(R,1441,C)) -| bp(GO:&quot;cell-cell signaling&quot;) 
p(HGNC:LRRK2,sub(R,1441,C)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;Hum Mol Genet. 2006 Jan 15;15(2):223-32. Epub 2005 Dec 1.&quot;,&quot;16321986&quot;} 

SET Evidence =&quot;The disease-associated I2020T mutant shows a significant increase in autophosphorylation of \
approximately 40% in comparison to wild-type protein in vitro. This suggests that the pathology of PD \
caused by the I2020T mutation is associated with an increase rather than a loss in LRRK2 kinase activity.&quot;

p(HGNC:LRRK2,sub(I,2020,T)) -&gt; kin(p(HGNC:LRRK2))
kin(p(HGNC:LRRK2)) -&gt; p(HGNC:LRRK2,pmod(P))

########################

SET Citation={&quot;PubMed&quot;,&quot;J Neurochem. 2009 May;109(4):959-68. doi: 10.1111/j.1471-4159.2009.06024.x. Epub 2009 Mar 3.&quot;,&quot;19302196&quot;} 

SET Evidence =&quot; Therefore, we addressed the question if LRRK2 exhibits MAPKKK activity by systematically \
testing MAPKKs as candidate substrates, in vitro. We demonstrate that LRRK2 variants phosphorylate \
mitogen-activated protein kinase kinases (MAPKK), including MKK3 -4, -6 and -7. MKKs act upstream of \
the MAPK p38 and JNK mediating oxidative cell stress, neurotoxicity and apoptosis. The disease-associated \
LRRK2 G2019S and I2020T mutations show an increased phosphotransferase activity towards MKKs correlating \
with the activity shown for its autophosphorylation. Our findings present evidence of a new class of \
molecular targets for mutant LRRK2 that link to neurotoxicity, cellular stress, cytoskeletal dynamics \
and vesicular transport.&quot;

p(HGNC:LRRK2,sub(G,2019,S)) -&gt; kin(p(HGNC:LRRK2))
p(HGNC:LRRK2,sub(I,2020,T)) -&gt; kin(p(HGNC:LRRK2))
kin(p(HGNC:LRRK2)) -&gt; p(HGNC:MAP2K3,pmod(P))
kin(p(HGNC:LRRK2)) -&gt; p(HGNC:MAP2K4,pmod(P))
kin(p(HGNC:LRRK2)) -&gt; p(HGNC:MAP2K6,pmod(P))
kin(p(HGNC:LRRK2)) -&gt; p(HGNC:MAP2K7,pmod(P))

########################

SET Citation={&quot;PubMed&quot;,&quot;Hum Genet. 2007 Feb;120(6):857-63. Epub 2006 Sep 30.&quot;,&quot;17019612&quot;} 

SET Evidence =&quot; In transfection studies, we demonstrated that both the wild type and Gly2385Arg variant \
LRRK2 protein localize to the cytoplasm and form aggregates. However, under condition of oxidative \
stress, the Gly2385Arg variant was more toxic and associated with a higher rate of apoptosis. Our \
study lends support to the contention that the Gly2385Arg is a common risk factor for PD in the \
Chinese population. Our bioinformatics and in-vitro studies also suggest that the Gly2385Arg variant \
is biologically relevant and it might act through pro-apoptotic mechanisms.&quot;

p(HGNC:LRRK2,sub(G,2019,R)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:LRRK2,sub(G,2019,R)) -&gt;  bp(GO:apoptosis)

########################

SET Citation={&quot;PubMed&quot;,&quot;J Neurosci. 2008 Mar 26;28(13):3384-91. doi: 10.1523/JNEUROSCI.0185-08.2008.&quot;,&quot;18367605&quot;} 

SET Evidence =&quot;The substitution of serine for glycine at position 2019 (G2019S) in the kinase \
domain of LRRK2 represents the most prevalent genetic mutation in both familial and apparently \
sporadic cases of PD. Because mutations in LRRK2 are likely associated with a toxic gain of function, \
destabilization of LRRK2 may be a novel way to limit its detrimental effects. Here we show that LRRK2 \
forms a complex with heat shock protein 90 (Hsp90) in vivo and that inhibition of Hsp90 disrupts the \
association of Hsp90 with LRRK2 and leads to proteasomal degradation of LRRK2. Hsp90 inhibitors may therefore \
limit the mutant LRRK2-elicited toxicity to neurons. As a proof of principle, we show that Hsp90 inhibitors \
rescue the axon growth retardation caused by overexpression of the LRRK2 G2019S mutation in neurons. Therefore, \
inhibition of LRRK2 kinase activity can be achieved by blocking Hsp90-mediated chaperone activity and Hsp90 \
inhibitors may serve as potential anti-PD drugs.&quot;

p(HGNC:LRRK2,sub(G,2019,S)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
complex(p(HGNC:HSP90AA1),p(HGNC:LRRK2)) -| bp(GO:axonogenesis)

########################

SET Citation={&quot;PubMed&quot;,&quot;Hum Mol Genet. 2007 Sep 1;16(17):2031-9. Epub 2007 Jun 20.&quot;,&quot;17584768&quot;} 

SET Evidence =&quot;Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant \
and certain cases of sporadic Parkinson&apos;s disease (PD). The G2019S substitution in LRRK2 is the most common \
genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the \
activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, \
and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve \
reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how \
the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These \
findings have important implications for therapeutic strategies in PD.&quot;

p(HGNC:LRRK2,sub(G,2019,S)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:LRRK2,sub(G,2019,S)) -&gt; (kin(p(HGNC:LRRK2)) -&gt; p(HGNC:LRRK2,pmod(P)))

########################

SET Citation={&quot;PubMed&quot;,&quot;J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010. Epub 2008 Mar 19.&quot;,&quot;18353371&quot;} 

SET Evidence =&quot;In this brain bank-based series, LRRK2 G2019S mutation occurred in patients with parkinsonism \
associated with either typical brainstem LB pathology or non-specific nigral degeneration.&quot;

p(HGNC:LRRK2,sub(G,2019,S)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;J Neurochem. 2009 Sep;110(5):1514-22. doi: 10.1111/j.1471-4159.2009.06235.x. Epub 2009 Jun 22.&quot;,&quot;19545277&quot;} 

SET Evidence =&quot;These findings suggest that LRRK2(G2019S)-induced neurodegeneration in Parkinsonian brains \
may be partly mediated by increased phosphorylation of tubulin-beta and constraining of microtubule dynamics.&quot;

p(HGNC:LRRK2,sub(G,2019,S)) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:LRRK2,sub(G,2019,S)) -&gt; p(HGNC:TUBB,pmod(P))

UNSET STATEMENT_GROUP

</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PARK8_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK8_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">LRRK2</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PARK8_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsonism caused by mutations in the gene for Leucine-Rich Repeat Kinase 2</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PARK8_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK8 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PC12</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#PC12</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cell lines originated from rat neuroblastoma and presenting DAT, D2R, DA, TH, vesicles and DA release phenotypes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PC12</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">PC12</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PET_biomarker</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PET_biomarker</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PET biomarker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PET_imaging_biomarker</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PET imaging biomarker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#BELcode"/>
        <IRI>#PINK7_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">##################################################################################
# Document Properties Section

SET DOCUMENT Name = &quot;Document name&quot;
SET DOCUMENT Description = &quot;Document description&quot;
SET DOCUMENT Version = &quot;1.0&quot;
SET DOCUMENT Copyright = &quot;Copyright (c) 2012, akodamullil. All Rights Reserved.&quot;
SET DOCUMENT Authors = &quot;akodamullil&quot;
SET DOCUMENT Licenses = &quot;Document license&quot;
SET DOCUMENT ContactInfo = &quot;your@email.com&quot;

##################################################################################
# Definitions Section

DEFINE NAMESPACE PFR AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-rat-protein-families.belns&quot;
DEFINE NAMESPACE MGI AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mgi-approved-symbols.belns&quot;
DEFINE NAMESPACE PFM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-mouse-protein-families.belns&quot;
DEFINE NAMESPACE MESHPP AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-biological-processes.belns&quot;
DEFINE NAMESPACE MESHCL AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-cellular-locations.belns&quot;
DEFINE NAMESPACE NCH AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-complexes.belns&quot;
DEFINE NAMESPACE CHEBI AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/chebi-names.belns&quot;
DEFINE NAMESPACE NCR AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-rat-complexes.belns&quot;
DEFINE NAMESPACE HGNC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/hgnc-approved-symbols.belns&quot;
DEFINE NAMESPACE SPAC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/swissprot-accession-numbers.belns&quot;
DEFINE NAMESPACE PFH AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-protein-families.belns&quot;
DEFINE NAMESPACE NCM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-named-mouse-complexes.belns&quot;
DEFINE NAMESPACE CHEBIID AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/chebi-ids.belns&quot;
DEFINE NAMESPACE RGD AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/rgd-approved-symbols.belns&quot;
DEFINE NAMESPACE MESHD AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/mesh-diseases.belns&quot;
DEFINE NAMESPACE GO AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-biological-processes-names.belns&quot;
DEFINE NAMESPACE SCHEM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-chemical-names.belns&quot;
DEFINE NAMESPACE EGID AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/entrez-gene-ids-hmr.belns&quot;
DEFINE NAMESPACE GOCCACC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-cellular-component-accession-numbers.belns&quot;
DEFINE NAMESPACE GOCCTERM AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/go-cellular-component-terms.belns&quot;
DEFINE NAMESPACE HGU95AV2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u95av2.belns&quot;
DEFINE NAMESPACE HGU133P2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u133-plus2.belns&quot;
DEFINE NAMESPACE HGU133AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-hg-u133ab.belns&quot;
DEFINE NAMESPACE MGU74ABC AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mg-u74abc.belns&quot;
DEFINE NAMESPACE MG430AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-moe430ab.belns&quot;
DEFINE NAMESPACE MG4302 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mouse430-2.belns&quot;
DEFINE NAMESPACE MG430A2 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-mouse430a-2.belns&quot;
DEFINE NAMESPACE RG230AB AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-rae230ab-2.belns&quot;
DEFINE NAMESPACE RG2302 AS URL &quot;http://resource.belframework.org/belframework/1.0/namespace/affy-rat230-2.belns&quot;

DEFINE NAMESPACE dbSNP AS URL &quot;file:///C:/Users/testuser/Desktop/BEL/BEL Workspace/Namespaces/SNP.belns&quot;

DEFINE ANNOTATION HemicAndImmuneSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-hemic-and-immune-system.belanno&quot;
DEFINE ANNOTATION UrogenitalSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-urogenital-system.belanno&quot;
DEFINE ANNOTATION FluidAndSecretion AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-fluid-and-secretion.belanno&quot;
DEFINE ANNOTATION CellStructure AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cell-structure.belanno&quot;
DEFINE ANNOTATION CellLine AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/atcc-cell-line.belanno&quot;
DEFINE ANNOTATION TextLocation AS  LIST {&quot;Abstract&quot;,&quot;Results&quot;,&quot;Legend&quot;,&quot;Review&quot;}
DEFINE ANNOTATION IntegumentarySystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-integumentary-system.belanno&quot;
DEFINE ANNOTATION DigestiveSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-digestive-system.belanno&quot;
DEFINE ANNOTATION MuskuloskeletalSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-musculoskeletal-system.belanno&quot;
DEFINE ANNOTATION Tissue AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-tissue.belanno&quot;
DEFINE ANNOTATION BodyRegion AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-body-region.belanno&quot;
DEFINE ANNOTATION Cell AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cell.belanno&quot;
DEFINE ANNOTATION NervousSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-nervous-system.belanno&quot;
DEFINE ANNOTATION SenseOrgan AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-sense-organ.belanno&quot;
DEFINE ANNOTATION Disease AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-disease.belanno&quot;
DEFINE ANNOTATION RespiratorySystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-respiratory-system.belanno&quot;
DEFINE ANNOTATION Species AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/species-taxonomy-id.belanno&quot;
DEFINE ANNOTATION CardiovascularSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-cardiovascular-system.belanno&quot;
DEFINE ANNOTATION EndocrineSystem AS  URL &quot;http://resource.belframework.org/belframework/1.0/annotation/mesh-endocrine-system.belanno&quot;

##################################################################################
# Statements Section

SET STATEMENT_GROUP = &quot;Group 1&quot;

# Add statements below this comment

########################

SET Citation={&quot;PubMed&quot;,&quot;Rinsho Shinkeigaku. 2005 Nov;45(11):899-901.&quot;,&quot;21532868&quot;} 

SET Evidence =&quot;The deposition of alpha-synuclein (aS), a product of pathogenic gene for dominantly \
inherited familial Parkinson&apos;s disease (PD; park1), as fibrillary aggregates like Lewy bodies (LB), \
is a hallmark lesion of a set of neurodegenerative disorders termed synucleinopathies, including \
sporadic PD and dementia with Lewy bodies (DLB). We found that aS is the major component of LBs \
and further identified a specific phosphorylation of Ser129 of insoluble aS by mass spectrometric \
analysis. The roles of DJ-1 and PINK-1, products of pathogenic genes for autosomal recessive forms \
of early-onset parkinsonism, have subsequently been examined. Overexpression of DJ-1 conferred \
cultured cells resistance to oxidative stress, suggesting an antioxidant function of DJ-1. We \
also confirmed the anti-PTEN function of DJ-1 that may promote cell survival, showing decreased \
phosphorylation of Akt through upregulation of PTEN activity upon siRNA knockdown for DJ-1. PINK-1, \
that had been identified as a gene upregulated by PTEN overexpression, turned out to be a protein \
kinase localized in mitochondria. Collectively, information derived from studies on pathogenic \
genes for familial PD will open up the way toward the clarification of the pathogenesis of PD, \
underscoring the roles of protein aggregation, proteolysis, oxidative stress and protein \
phosphorylation in PD.&quot;

p(HGNC:PARK7) -- path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:PINK1) -- path(MESHD:&quot;Parkinson Disease&quot;)
p(HGNC:PARK7) -| bp(GO:&quot;response to oxidative stress&quot;)
p(HGNC:PARK7) -&gt; bp(GO:&quot;cytokine activity&quot;)

########################

SET Citation={&quot;PubMed&quot;,&quot;Clin Genet. 2010 Feb;77(2):183-8. doi: 10.1111/j.1399-0004.2009.01310.x. Epub 2009 Nov 23.&quot;,&quot;19968671&quot;} 

SET Evidence =&quot;When we considered a three-marker sliding window, we found a highly significant association \
between the disease and the haplotypes including markers rs17523802, Ins/Del, and rs3766606 (p = 0.0007) \
and markers Ins/Del, rs3766606 and rs7517357 (p = 0.0054). Our results indicate that polymorphisms located \
in a region spanning 3535 bp from the promoter to the intron 2 of the DJ-1 gene confer risk to sporadic PD \
in southern Italy.&quot;

g(HGNC:PARK7) -&gt; p(HGNC:PARK7)
g(HGNC:PARK7) -- g(dbSNP:rs17523802)
g(HGNC:PARK7) -- g(dbSNP:rs3766606)
g(HGNC:PARK7) -- g(dbSNP:rs7517357)

g(dbSNP:rs17523802) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
g(dbSNP:rs3766606) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)
g(dbSNP:rs7517357) -&gt; path(MESHD:&quot;Parkinson Disease&quot;)

UNSET STATEMENT_GROUP

</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#PINK7_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PINK7_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DJ-1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#PINK7_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PINK7</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#PINK7_mutation_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PARK7 mutation parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pallidal_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gross, C., Rougier, A., Guehl, D., Boraud, T., Julien, J., &amp; Bioulac, B. (1997). High-frequency stimulation of the globus pallidus internalis in Parkinson&apos;s disease: a study of seven cases. Journal of neurosurgery, 87(4), 491-498.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pallidal_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">globus pallidus pars interna stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pallidal_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pallidal DBS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pallidal_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pallidus stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pallidal_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">stimulation of the globus pallidus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Pallidal_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">High frequency stimulation of the globus pallidus internalis which leads to alleviation of akinesia and rigidity and improvement of gait and speech disturbances. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pallidal_stimulation</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Pallidal stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pallidotomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Pallidotomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A surgical treatment for Parkinson’s disease in which targeted areas of neurons in the PALLIDUM, one of the BRAIN structures that control movement, are destroyed. This process interrupts the flow of nerve signals the globus pallidus sends to the motor cortex, which in turn controls the muscles, reducing many of the symptoms of Parkinson’s such as TREMORS, BRADYKINESIA, DYSTONIA, and other DYSKINESIA.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pallidotomy</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Pallidotomy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Paraquat</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://viartis.net/parkinsons.disease/toxic.causes.htm</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Paraquat</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Paraquat is a quaternary ammonium herbicide. Other members of this class include diquat, cyperquat, diethamquat, difenzoquat and morfamquat. Pesticides are known to be associated with an increased rate of Parkinson&apos;s Disease. Paraquat structurally resembles MPTP and its metabolite MPP+. MPTP and MPP+ are neurotoxic chemicals, that induce Parkinson&apos;s Disease in exposed humans. Paraquat might therefore might, as do MPTP and MPP+ inhibit tyrosine hydroxylation, which is essential for the formation of dopamine.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Paraquat</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Paraquat</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Paresthesia</IRI>
        <Literal datatypeIRI="&xsd;string">Duvoisin, R. C., &amp; Sage, J. (2001). Parkinson&apos;s disease: A guide for patient and family. Wolters Kluwer Health.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Paresthesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sensations, usually unpleasant, arising spontaneously in a limb or other part of the body and variously experienced as pins and needles or a feeling of warmth or coldness (thermal paresthesias).</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Paresthesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Paresthesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Park2tm1Ccs</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Park2tm1Ccs</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Park2tm1Roo</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Park2tm1Roo</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Park2tm1Shn</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Park2tm1Shn</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Park2tm1Tmd</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Park2tm1Tmd</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Park2tm1Ykt</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Park2tm1Ykt</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Park7tm1Cai</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Park7tm1Cai</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Park7tm1Shn</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Park7tm1Shn</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Park7tm1Xz</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Park7tm1Xz</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Parkin</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Parkinson-Plus_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinson-Plus_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">atypical Parkinson&apos;s syndromes</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinson-Plus_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">atypical parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Parkinson-Plus_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A group of diverse, relatively uncommon and obscure neurodegenerative disorders that may masquerade as PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkinson-Plus_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson-Plus syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Parkinson_disease_dyskinesia_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinson_disease_dyskinesia_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PDYS-26</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Parkinson_disease_dyskinesia_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">This scale aims at quantifying the impact of dyskinesias on patient functioning and comprises of 26 items rated on a 4-point scale.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkinson_disease_dyskinesia_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson disease dyskinesia scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Parkinson_fatigue_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Brown, R. G., Dittner, A., Findley, L., &amp; Wessely, S. C. (2005). The Parkinson fatigue scale. Parkinsonism &amp; related disorders, 11(1), 49-55.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinson_fatigue_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PFS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinson_fatigue_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PFS-16</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Parkinson_fatigue_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The PFS-16 scale was designed to tap a single construct encompassing the physical aspects fatigue and their impact on the patient’s daily function. The scale deliberately excludes emotional and cognitive features that may occur as part of the fatigue experience but which may also occur independently in Parkinsonism. The scale has good intrinsic properties and satisfactory test-retest reliability. It shows reasonable associations with other measures of fatigue and is able to identify patients who self-report the presence of fatigue, and particularly those in whom fatigue is a problem.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkinson_fatigue_scale</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Parkinson fatigue scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Parkinson_psychosis_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Friedberg, G., Zoldan, J., Weizman, A., &amp; Melamed, E. (1998). Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson&apos;s disease. Clinical neuropharmacology, 21(5), 280-284.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinson_psychosis_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PPRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Parkinson_psychosis_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PPRS is a relevant, reliable, valid, and easily-administered instrument for measuring the severity of parkinsonian psychosis. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkinson_psychosis_rating_scale</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Parkinson psychosis rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Parkinsoniam_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinsoniam_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinson tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Parkinsoniam_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Any kind of tremor presented by most patients with PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkinsoniam_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsonian tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinsons_disease_cognitive_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PD-CRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkinsons_disease_cognitive_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsons disease cognitive rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Parkinsons_disease_dementia-short_screen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Aarsland, D., Cummings, J., Weintraub, D., &amp; Chaudhuri, K. R. (Eds.). (2013). Neuropsychiatric and Cognitive Changes in Parkinson&apos;s Disease and Related Movement Disorders: Diagnosis and Management. Cambridge University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinsons_disease_dementia-short_screen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PDD-SS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Parkinsons_disease_dementia-short_screen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The PDD-SS was designed and validated as a PD-specific brief cognitive test for screening dementia in PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkinsons_disease_dementia-short_screen</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsons disease dementia-short screen</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Parkinsons_disease_questionnaire-39</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Parkinsons_disease_questionnaire-39</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PDQ-39</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Parkinsons_disease_questionnaire-39</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A 39-item questionnaire aimed at assessing numerous areas of health-related quality of life. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Parkinsons_disease_questionnaire-39</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsons disease questionnaire-39</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Paroxymal_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti K. &amp; Metman L. V. (2010) The Encyclopedia of Movement Disorders. Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Paroxymal_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">paroxysmal dyskinesias</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Paroxymal_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A heterogeneous group of disorders characterized by intermittent attacks of hyperkinetic involuntary movements.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Paroxymal_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Paroxysmal dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Paroxysmal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Paroxysmal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Episodic movement disorder in which abnormal movements are only present during attacks.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Paroxysmal_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Paroxysmal dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pathological_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Pathological_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">The pathological biomarkers are the molecular hallmarks of PD diagnosis and its final confirmation. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pathological_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pathological biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pathological_gambling</IRI>
        <Literal datatypeIRI="&xsd;string">Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A., &amp; Ahlskog, J. E. (2005). Pathological gambling caused by drugs used to treat Parkinson disease. Archives of Neurology, 62(9), 1377.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Pathological_gambling</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pathological gambling is a rare potential complication related to treatment of Parkinson disease (PD).</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pathological_gambling</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pathological gambling</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Peak_dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Albanese, A., &amp; Jankovic, J. (Eds.). (2012). Hyperkinetic movement disorders: differential diagnosis and treatment. John Wiley &amp; Sons.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Peak_dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dopa-induced peak dose dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Peak_dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">inter-dose dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Peak_dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">on period dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Peak_dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">peak-dose L-Dopa-induced dyskinesias</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Peak_dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">peak-dose dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Peak_dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Peak-dose dyskinesia occurs when dopaminergic activity levels are high and when patients are experiencing good clinical benefit from levodopa.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Peak_dose_dyskinesia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Peak dose dyskinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Peripheral_surgery</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Peripheral_surgery</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Procedures that target parts of the body other than the brain and they have been useful primarily in blepharospasm and cervical dystonia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Peripheral_surgery</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Peripheral surgery</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Persistent_depression</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Persistent_depression</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Persistent depression</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pharmacological_management_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pharmacological_management_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pharmacotherapeutic management of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pharmacological_management_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pharmacotherapy for Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pharmacological_management_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pharmacotherapy of parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Pharmacological_management_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pharmacotherapy involves managing multiple medications to relieve specific symptoms, as well as monitoring drug interactions, side effects, and complications. The primary therapeutic approach for Parkinson’s disease is pharmacotherapy, with LEVODOPA and dopamine agonists as its mainstays.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pharmacological_management_of_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pharmacological management of parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Physiological_biomarkers_od_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Physiological_biomarkers_od_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">neurophysiological biomarker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Physiological_biomarkers_od_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string"> Biomarkers used to describe phenotypes resulting from disease of the basal ganglia or pathological changes outside the basal ganglia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Physiological_biomarkers_od_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Physiological biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pink1tm1Aub</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Pink1tm1Aub</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pink1tm1Shn</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Pink1tm1Shn</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pittsburgh_sleep_quality_index</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pittsburgh_sleep_quality_index</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PSQI</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Pittsburgh_sleep_quality_index</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is recommended to assess insomnia and quality of nighttime sleep.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pittsburgh_sleep_quality_index</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pittsburgh sleep quality index</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Plasma_homocysteine</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Plasma_homocysteine</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Plasma homocysteine</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Platelet_complex-1_activity</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Platelet_complex-1_activity</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Platelet complex-1 activity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Poliomyelitis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Poliomyelitis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Poliomyelitis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://emedicine.medscape.com/article/1188764-overview</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PSG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Polysomnographic sleep measure</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">nocturnal polysomnography</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">polysomnographic architecture</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">polysomnographic recordings</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">polysomnographic study</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Nocturnal, laboratory-based polysomnography (PSG) is the most commonly used test in the diagnosis of obstructive sleep apnea syndrome (OSAS). It is often considered the criterion standard for diagnosing OSAS, determining the severity of the disease, and evaluating various other sleep disorders that can exist with or without OSAS. PSG is used to evaluate abnormalities of sleep and/or wakefulness and other physiologic disorders that have an impact on or are related to sleep and/or wakefulness. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Polysomnography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Polysomnography</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Position-specific_postural_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Position-specific_postural_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A rare variant of postural tremor.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Position-specific_postural_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Position-specific postural tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Position_specific_writing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Position_specific_writing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">type B tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Position_specific_writing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Position-specific tremor occurs when the hand position used in writing is adopted.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Position_specific_writing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Position specific tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PTP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dementia pugilistica</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism and traumatic brain injury</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">post-traumatic movement disorder</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">post-traumatic parkinson syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">post-traumatic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">post-traumatic tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Repeated concussive head injury, such as experienced by boxers, can result in parkinsonism, ataxia, dementia, and personality change.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Post-traumatic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Posttraumatic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Postencephalic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Postencephalic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Post-encephalitic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Postencephalic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">postencephalitic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Postencephalic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Postencephalitic parkinsonism develops as a result of damage to the brain after infection with a viral form of encephalitis called encephalitis lethargica.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Postencephalic_parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Postencephalic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Postural_instability</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Postural_instability</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PI</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Postural_instability</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Postural instability due to loss of postural reflexes is generally a manifestation of the late stages of PD and usually occurs after the onset of other clinical features.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Postural_instability</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Postural instability</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Postural_irregularity</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Postural_irregularity</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Postural irregularity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Postural_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Postural_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Postural tremor is present while voluntarily maintaining a position against gravity.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Postural_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Postural tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Power_wheelchair</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Power wheelchair</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pramipexole</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pramipexole</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pramipexole</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Primary_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Primary_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It describes a case in which the dystonia is the only neurological disorder that the person has. Primary dystonias include some genetic forms (such as DYT1 dystonia in which a gene has been identified) and forms for which a cause is not usually found. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Primary_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Primary dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Primary_immature_dopaminergic_neuron</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Primary_immature_dopaminergic_neuron</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Midbrain dopamine neurons cultured in the context of their physiological neighbors.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Primary_immature_dopaminergic_neuron</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Primary immature dopaminergic neuron</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Primary_midbrain_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Primary_midbrain_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A culture system originated from E13 rodent embryo midbrain presenting with 5-10% dopaminergic neurons.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Primary_midbrain_culture</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Primary midbrain culture</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Primary_orthostatic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Primary_orthostatic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A unique tremor syndrome that has been observed until now only in patients over 40 years old and is characterized by a subjective feeling of unsteadiness during stance but only in severe cases during gait.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Primary_orthostatic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Primary orthostatic tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Primary_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Adler, C. H., &amp; Ahlskog, J. E. (Eds.). (2000). Parkinson&apos;s disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Springer.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Primary_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">primary symptoms of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Primary_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsonism occuring as a neurodegenrative disorder with a definite cause. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Primary_parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Primary parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Primary_writing_tremot</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Primary_writing_tremot</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tremor during writing without other manifestations of tremor or other neurological disease is called primary writing tremor.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Primary_writing_tremot</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Primary writing tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Prochlorperazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Grosset, D., Grosset, K. A., Okun, M. S., &amp; Fernandez, H. H. (2009). Parkinson’s Disease: Clinician’s Desk Reference.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Prochlorperazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">prochlorperazine induced acute parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Prochlorperazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An anti-nausea agent which induces secondary parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Prochlorperazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Prochlorperazine-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Progressive_pallidal_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fernandez-Alvarez, E., Aicardi, J., &amp; Bathien, N. (2001). Movement disorders in children. Cambridge University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Progressive_pallidal_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">primary atrophy of the pallidal system</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Progressive_pallidal_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">progressive atrophy of the globus pallidus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Progressive_pallidal_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A selective atrophy of the motor neurons of the globus pallidus leading to progressive parkinsonian signs and dystonic features with intact intellect.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Progressive_pallidal_atrophy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Progressive pallidal atrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Progressive_supranuclear_palsy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Progressive_supranuclear_palsy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">PSP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Progressive_supranuclear_palsy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">progressive supra-nuclear palsy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Progressive_supranuclear_palsy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A rare neurodegenerative disease with symptoms that are similar to those of Parkinson’s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Progressive_supranuclear_palsy</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Progressive supranuclear palsy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Promethazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hardiman O. (2011) Neurodegenerative Disorders: A Clinical Guide. Springer</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Promethazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A neuroleptic agent that induces secondary parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Promethazine-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Promethazine-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Proteinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Walker, L. C., &amp; LeVine 3rd, H. (2002). Proteopathy: the next therapeutic frontier?. Current opinion in investigational drugs (London, England: 2000), 3(5), 782-787.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Proteinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">proteopathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Proteinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The abnormal conformation and assembly of proteins, which is a probable cause of many degenerative diseases of old age.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Proteinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">protein misfolding</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Proteinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Proteinopathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Proteomic_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Proteomic_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Proteomic biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Psychosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Psychosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A condition of mental dysfunction in which a person loses contact with reality. DELUSIONS, HALLUCINATIONS, CONFUSION, DISORIENTATION, and PARANOIA are common in psychosis. In the person with Parkinson’s disease, psychosis can develop as a separate disease entity, as a manifestation of the brain deterioration taking place as a result of the Parkinson’s, or as a side effect of ANTIPARKINSON’S MEDICATIONS.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Psychosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Psychosis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ptstm1Ich</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Ptstm1Ich</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pulsion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Pulsion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">antepulsion</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Pulsion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">pulsion is the tendency to step forward when bumped or bumping into an object.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pulsion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pulsion</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Punding</IRI>
        <Literal datatypeIRI="&xsd;string">Evans, A. H., Katzenschlager, R., Paviour, D., O&apos;Sullivan, J. D., Appel, S., Lawrence, A. D., &amp; Lees, A. J. (2004). Punding in Parkinson&apos;s disease: its relation to the dopamine dysregulation syndrome. Movement disorders, 19(4), 397-405.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Punding</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Punding is a term that was coined originally to describe complex prolonged, purposeless, and stereotyped behaviour in chronic amphetamine users.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Punding</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Punding</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Pyridoxal_kinase</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Pyridoxal_kinase</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pyridoxal kinase</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Quantitative_tremor_analysis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Quantitative_tremor_analysis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mathematical analysis of the accelerogram and EMG of hand tremor with spectral analysis to assess the frequency and amplitude of tremor during standardized maneuvers.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Quantitative_tremor_analysis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Quantitative tremor analysis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Ramisectomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Ramisectomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Extradural sectioning of the posterior primary division of the cervical nerve roots. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ramisectomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ramisectomy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Rapid-onset_dystonia-parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schapira H.V.A. (2010) parkinson&apos;s Disease. Oxford University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rapid-onset_dystonia-parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">RDP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rapid-onset_dystonia-parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">rapid-onset dystonia parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rapid-onset_dystonia-parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">rapid-onset dystonia with parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rapid-onset_dystonia-parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">rapid-onset of dystonia parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Rapid-onset_dystonia-parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An autosomal-dominant coordination in which affected individuals have the onset of dystonia and parkinsonism over hours to days. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Rapid-onset_dystonia-parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Rapid onset dystonia parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Rapid_eye_movement_sleep_behaviour_disorder</IRI>
        <Literal datatypeIRI="&xsd;string">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rapid_eye_movement_sleep_behaviour_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">RBD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rapid_eye_movement_sleep_behaviour_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">REM sleep behavior disorder</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rapid_eye_movement_sleep_behaviour_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">rapid eye movement (REM) sleep behavior disorder</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Rapid_eye_movement_sleep_behaviour_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The stage in which dreams primarily take place is called rapid eye movement (REM). In people with Parkinson’s, this mechanism becomes dysfunctional and the body acts out dreams, sometimes with great physical energy expressed through kicking, thrashing, swinging of the arms, and other actions that can actually be harmful to the person or to a partner who is sharing the bed.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Rapid_eye_movement_sleep_behaviour_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rapid eye movement sleep behaviour disorder</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Recessive_early-onset_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Recessive_early-onset_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">parkinsonism linked to chromosome 1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Recessive_early-onset_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">recessive form of early-onset parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Recessive_early-onset_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">recessive, early onset parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Recessive_early-onset_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">recessive, early-onset PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Recessive_early-onset_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Relatively high proportion of patients with early-onset parkinsonism have been found to be caused by recessive mutations in several genes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Recessive_early-onset_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Recessive early-onset parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Reduced_CSF_gluthatione-SH</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Reduced_CSF_gluthatione-SH</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reduced CSF gluthatione-SH</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Reserpine_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Reserpine_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Reserpine-induced model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Reserpine_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The first animal model for PD using rabbits treated with reserpine, a catecholamine-depleting agent that blocks vesicular storage of monoamines.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Reserpine_model</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Reserpine model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Rest_tremor</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Rest_tremor</IRI>
        <Literal datatypeIRI="&xsd;string">Tremors are unilateral, occur at a frequency between 4 and 6 Hz, and almost always are prominent in the distal part of an extremity. Hand tremors are described as supination–pronation (“pill-rolling”) tremors that spread from one hand to the other. Rest tremor in patients with PD can also involve the lips, chin, jaw and legs but, unlike essential tremor, rarely involves the neck/head or voice. Thus a patient who presents with head tremor most likely has essential tremor, cervical dystonia, or both, rather than PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Rest_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rest tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Resting_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Resting_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Type II tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Resting_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Resting tremor occurs in a body part that is not voluntarily activatedand is completely supported against gravity.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Resting_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Resting tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Restless_legs_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Restless_legs_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">RLS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Restless_legs_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">leg restlessness</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Restless_legs_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A condition in which the legs twitch involuntarily usually when sitting or lying quietly at rest. It may be mild, with occasional tingling and small areas of twitching, or severe enough that the legs appear to be walking or running of their own volition.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Restless_legs_syndrome</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Restless legs syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Retropulsion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Retropulsion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Retropulsion is the tendency to step back.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Retropulsion</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Retropulsion</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Rigidity</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Rigidity</IRI>
        <Literal datatypeIRI="&xsd;string">Rigidity is characterised by increased resistance, usually accompanied by the “cogwheel” phenomenon, particularly when associated with an underlying tremor, present throughout the range of passive movement of a limb (flexion, extension or rotation about a joint). It may occur proximally (eg, neck, shoulders, hips) and distally (eg, wrists, ankles).</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Rigidity</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rigidity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Risk_factors_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gorell, J. M., Peterson, E. L., Rybicki, B. A., &amp; Johnson, C. C. (2004). Multiple risk factors for Parkinson&apos;s disease. Journal of the neurological sciences, 217(2), 169-174.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Risk_factors_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">risk factors for PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Risk_factors_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">risk factors for Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Risk_factors_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">risk factors in Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Risk_factors_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">risk factors of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Risk_factors_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Occupational, environmental lifestyle and, likely, genetic factors, individually and collectively, play a significant role in the etiology of the Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Risk_factors_for_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Risk factors for Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Rotenon_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">LeDoux, M. S. (Ed.). (2005). Movement Disorders: Genetics and Models. Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rotenon_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rotenon</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Rotenon_model</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A model used by researchers for rotenone exposure to model the systemic defect in complex I reported in PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Rotenon_model</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Rotenone model</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Rotenone</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://viartis.net/parkinsons.disease/toxic.causes.htm</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Rotenone</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rotenone is an insecticide that has the potential to cause Parkinson&apos;s disease. Insecticides are also known to affect well water. Rotenone is commonly used in powdered form to treat parasitic mites on chickens and other fowl, and so can be found in poultry. Rotenone is produced by extraction from the roots, seeds, and leaves of certain tropical legumes. Rotenone inhibits tyrosine hydroxylation, which is essential for the formation of dopamine. So rotenone could cause Parkinson&apos;s disease by lowering dopamine levels. When given intravenously to mice, rotenone has been demonstrated to cause a model of Parkinson&apos;s disease. Rotenone toxicity is also caused by complex I inhibition, depletion of cellular and oxidative damage. These processes cause loss of midbrain dopaminergic neurons, leading to depletion of dopamine in the brain.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Rotenone</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rotenone</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Rural_living</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Priyadarshi, A., Khuder, S. A., Schaub, E. A., &amp; Priyadarshi, S. S. (2001). Environmental risk factors and Parkinson&apos;s disease: a metaanalysis. Environmental research, 86(2), 122-127.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rural_living</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">exposure to rural environmental factors</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rural_living</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">rural living</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rural_living</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">rural residency</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Rural_living</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The association of rural living with PD, which may be related to exposure to potential neurotoxins present in pesticides, well water, or spring water.  </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Rural_living</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to rural living</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Rush_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Rush_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">RDRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Rush_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It rates patients during activities of daily living such as drinking, dressing, and walking.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Rush_dyskinesia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Rush dyskinesia rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#SCOPA-COG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Fisher, A., Hanin, I., Poewe, W., &amp; Windisch, M. (Eds.). (2007). Alzheimer&apos;s and Parkinson&apos;s Diseases (Vol. 4). Karger Publishers.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#SCOPA-COG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SCOPA-COG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#SCOPA-COG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">scales for outcomes of Parkinson&apos;s disease-cognition</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#SCOPA-COG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SCOPA-COG is a simple, sensitive, validated test, which should be incorporated in the tests for the evaluation of PD patients. The SCOPA-COG consists of 10 items with a maximum score of 43, with higher scores reflecting better performance.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#SCOPA-COG</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Scales for outcomes of Parkinson&apos;s disease-cognition</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#SH-SY5Y</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Falkenburger, B. H., &amp; Schulz, J. B. (2006). Limitations of cellular models in Parkinson’s disease research. In Parkinson’s Disease and Related Disorders (pp. 261-268). Springer Vienna.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#SH-SY5Y</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SH-SY5Y</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#SH-SY5Y</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Cell lines originated from the human neuroblastoma and presenting DAT, D2R, DA, TH, vesicles and DA release phenotypes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#SH-SY5Y</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">SH SY5Y</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#SPECT_biomarker</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#SPECT_biomarker</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SPECT biomarker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#SPECT_imaging_biomarker</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SPECT imaging biomarker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Saint_Luis_encephalitis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Saint_Luis_encephalitis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Saint Luis encephalitis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Saliva_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Saliva_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">In vitro diagnostic biomarkers that can be estimated from saliva samples of a PD patient.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Saliva_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Saliva biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Salsolinol</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Salsolinol</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Salsolinol</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Scales_for_outcomes_in_Parkinsons_disease-Motor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Scales_for_outcomes_in_Parkinsons_disease-Motor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SCOPA-Motor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Scales_for_outcomes_in_Parkinsons_disease-Motor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">This seeks to assess motor signs, functional ability and motor complications in PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Scales_for_outcomes_in_Parkinsons_disease-Motor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Scales for outcomes in Parkinsons disease-Motor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Schwab_and_England_activities_of_daily_living_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Schwab_and_England_activities_of_daily_living_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schwab and England disability scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Schwab_and_England_activities_of_daily_living_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schwab and England scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Schwab_and_England_activities_of_daily_living_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is a questionnaire that measures the patient&apos;s perception of functional independence. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Schwab_and_England_activities_of_daily_living_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schwab and England activities of daily living scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Secondary_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Secondary_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">acquired dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Secondary_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Secondary dystonia results from environmental or other damage to the brain, or from exposure to certain types of medications.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Secondary_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Secondary dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Secondary_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Adler, C. H., &amp; Ahlskog, J. E. (Eds.). (2000). Parkinson&apos;s disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Springer.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Secondary_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">secondary to parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Secondary_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">symptomatic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Secondary_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsonism that has been induced by a specific and potentially identifiable cause, such as drugs, toxins, or trauma.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Secondary_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Secondary parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Segmental_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Segmental_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Segmental dystonia affects two or more adjacent parts of the body.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Segmental_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Segmental dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Selective_peripheral_denervation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Truong, D. (2010). Living Well with Dystonia: A Patient Guide. Demos Medical Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Selective_peripheral_denervation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A surgical technique in which the motor nerve branches to specific muscles are cut in order to relieve dystonia. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Selective_peripheral_denervation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Selective peripheral denervation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sensory_symptom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sensory_symptom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sensory symptoms are part of PD in the earliest clinical descriptions of the disorder and are reported in 40%-50% of patients.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sensory_symptom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sensory symptom</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Shapiro_tourette_syndrome_severity_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Shapiro_tourette_syndrome_severity_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">STSSS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Shapiro_tourette_syndrome_severity_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is a composite clinician rating of severity comprising 5 factors.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Shapiro_tourette_syndrome_severity_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Shapiro tourette syndrome severity scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Short_parkinsons_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Short_parkinsons_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SPES</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Short_parkinsons_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">short parkinson&apos;s rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Short_parkinsons_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Similar to UPDRS, it assesses mental function, activities of daily living, motor findings, and complications of therapy. It uses a 0-3 rating and involves approximately 7-10 minutes. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Short_parkinsons_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Short parkinsons rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Shuffling_gait</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Shuffling_gait</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Walking stooped forward with short, shuffling steps is perhaps the most distinctive gait disturbance of Parkinson’s. In this gait, the person’s feet barely clear the surface when walking, or one or both feet may drag.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Shuffling_gait</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Shuffling gait</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Shy_Drager_syndrom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Shy_Drager_syndrom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SDS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Shy_Drager_syndrom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Shy-Drager syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Shy_Drager_syndrom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Neurological syndrome characterized by severe autonomic failure combined with parkinsonism, cerebellar and pyramidal signs.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Shy_Drager_syndrom</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Shy Drager syndrom</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sialorrhoea</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sialorrhoea</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">drooling</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sialorrhoea</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Excessive saliva production and drooling.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sialorrhoea</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sialorrhoea</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Simple_kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Simple_kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Occurs during voluntary movements that are not goal directed. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Simple_kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Simple kinetic tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Slc6a3tm1(cre)Lrsn</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Slc6a3tm1(cre)Lrsn</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sleep_EEG</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sleep_EEG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sleep EEG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sleep_attack</IRI>
        <Literal datatypeIRI="&xsd;string">Schapira, A. H. (2000). Sleep attacks (sleep episodes) with pergolide. The Lancet, 355(9212), 1332-1333.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sleep_attack</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The terms sleep attack implies abrupt and uncontrollable onset of sleep, which seems to be always preceded by a prodrome of sleepness.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sleep_attack</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sleep attack</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sleep_disorder</IRI>
        <Literal datatypeIRI="&xsd;string">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sleep_disorder</IRI>
        <Literal datatypeIRI="&xsd;string">sleep disorder</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sleep_disorder</IRI>
        <Literal datatypeIRI="&xsd;string">Problems in falling or staying asleep in people with Parkinson’s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sleep_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sleep disturbance</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sleep_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sleep_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">disturbed sleep</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sleep_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">sleep problems</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sleep_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Problems in falling or staying asleep are common in people with Parkinson’s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sleep_disturbance</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sleep disturbance</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Slowness_of_movement</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Slowness_of_movement</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">bradykinesia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Slowness_of_movement</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Slowness of movement</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sncatm1Nbm</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Sncatm1Nbm</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sncatm1Rosl</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Sncatm1Rosl</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sncatm1Sud</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Sncatm1Sud</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sporadic_OPCA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Noggle C.A., Dean R.S., Horton A.M.Jr. (2012) The Encyclopedia of Neuropsychological Disorders. Springer Publishing Company.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sporadic_OPCA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SOPCA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sporadic_OPCA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">sporadic olivopontocerebellar atrophy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sporadic_OPCA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The sporadic type of OPCA is considered by many to be a subgroup of multiple system atrophy. Generally OPCAs are progressive neurodegenerative conditions and the typical age of onset for the sporadic form is 49 years. The etiology of OPCA is not well-known, but the sporadic forms have been shown to involve abnormalities of alpha-synuclein. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sporadic_OPCA</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sporadic OPCA</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sporadic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sporadic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A case of dystonia that is genetic or presumed to be genetic when the affected person does not have a history of dystonia in the family.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sporadic_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sporadic dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sporadic_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sporadic_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">sPD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sporadic_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">sporadic PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sporadic_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">sporadic form of PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sporadic_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">sporadic parkinson&apos;s</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sporadic_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The most frequent synucleinopathy and neurodegenerative disorder of the human brain, which develops within multiple central and subdivisions of the human nervous system. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sporadic_parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sporadic parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Sporadic_tauopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Sporadic_tauopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">tauopathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Sporadic_tauopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sporadic tauopathies include Pick disease (PiD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), argyrophilic grain disease (AGD) and neurofibrillary tangle dementia. Classification is based on the cellular and anatomical distribution of tau-immunoreactive structures, the ultrastructure of tau filaments and the isoform profile of pathological tau bands.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Sporadic_tauopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sporadic tauopathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Start_hesitation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Start_hesitation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Start hesitation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Stem_cell_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Stem_cell_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">stem cell-based therapy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Stem_cell_therapy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Stem cell therapy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Striatal_iron</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Striatal_iron</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Striatal iron</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Striatonigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Striatonigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">SND</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Striatonigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">degeneration in the striatonigral</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Striatonigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A disease caused by the degeneration of the striatum and substantia nigra, clinically presenting as parkinsonism with or without some degree of autonomic and cerebellar dysfunction.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Striatonigral_degeneration</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Striatonigral degeneration</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Strict_diet</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Gao, X., Chen, H., Fung, T. T., Logroscino, G., Schwarzschild, M. A., Hu, F. B., &amp; Ascherio, A. (2007). Prospective study of dietary pattern and risk of Parkinson disease. The American journal of clinical nutrition, 86(5), 1486-1494.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Strict_diet</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">diet</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Strict_diet</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dietary</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Strict_diet</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dietary exposure</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Strict_diet</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">intake</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Strict_diet</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">nutrient intake</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Strict_diet</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Association between dietary patterns and PD risk.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Strict_diet</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dietary intake</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Structural_lesion-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Structural_lesion-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">lesion of the subthalamic nucleus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Structural_lesion-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">lesion responsible for parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Structural_lesion-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mass lesions of the midbrain, basal ganglia, or ventricular outflow pathways are an uncommon cause of parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Structural_lesion-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Structural lesion-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Subthalamic_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Benabid, A. L., Koudsié, A., Benazzouz, A., Fraix, V., Ashraf, A., Le Bas, J. F., ... &amp; Pollak, P. (2000). Subthalamic stimulation for Parkinson&apos;s disease. Archives of medical research, 31(3), 282-289.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Subthalamic_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">stimulation of the subthalamic nucleus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Subthalamic_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">subthalamic (STN) deep brain stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Subthalamic_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">subthalamic deep brain stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Subthalamic_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">subthalamic nucleus stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Subthalamic_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ventrolateral thalamic stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Subthalamic_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">High frequency stimulation of the brain that induces a jamming of sensory-motor loops in the subthalamic nucleus.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Subthalamic_stimulation</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Subthalamic stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Swallowing_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Miller, N., Noble, E., Jones, D., &amp; Burn, D. (2006). Hard to swallow: dysphagia in Parkinson’s disease. Age and ageing, 35(6), 614-618.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Swallowing_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">swallowing disturbance</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Swallowing_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">swallowing dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Swallowing_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Swallowing dysfunction occurs from the earliest stages of Parkinson’s disease (PD), even in asymptomatic cases. Changes range from drooling (despite indications of decreased salivary production in PD; food residues in the oral sulci long after meals; poor bolus formation; slowed oral transit; repeated tongue pumping for retropulsion of the bolus; delayed triggering of the pharyngeal swallow reflex; reduced diameter but prolonged opening of the upper oesophageal sphincter; to vallecular stasis, residue in the piriform sinuses with risk of aspiration and true aspiration.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Swallowing_disorder</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Swallowing disorder</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Symptom_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">www.medicalnewstoday.com</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Symptom_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral"> Symptom is something the patient feels and describes. Parkinson’s disease causes problems with movement, cognitive problems, neurobehavioral problems, as well as sensory and sleep difficulties. The signs and symptoms usually begin gradually, slowly and often randomly (in no set order).
</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Symptom_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Symptom of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Symptomatic_skin_response</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Symptomatic skin response</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Synucleinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">McCann, H., Stevens, C. H., Cartwright, H., &amp; Halliday, G. M. (2014). α-Synucleinopathy phenotypes. Parkinsonism &amp; related disorders, 20, S62-S67.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Synucleinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">alpha-synucleinopathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Synucleinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">α-Synucleinopathies are neurodegenerative diseases characterised by the abnormal accumulation of α-synuclein aggregates in neurons, nerve fibres or glial cells.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Synucleinopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Synucleinopathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Syphilis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Syphilis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Syphilis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Syphilitic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Frederick Tice, Tice&apos;s practice of medicine, volume 10. Hoeber Medical Division, Harper &amp; Row, 1968.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Syphilitic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">syphilic vascular parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Syphilitic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">syphilitic vascular parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Syphilitic_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Syphilitic involvement of the basal ganglia may sometimes produce a parkinsonian syndrome.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Syphilitic_parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Syphilitic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Targeted_gene</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Transgenic mouse model of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Task-specific_kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Task-specific_kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">May appear or become exacerbated during specific activities.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Task-specific_kinetic_tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Task-specific kinetic tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Task_specific_writing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Task_specific_writing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Type A tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Task_specific_writing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is characterized by tremor appearing only during writing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Task_specific_writing</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Task specific tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Tauopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dickson, D., &amp; Weller, R. O. (Eds.). (2011). Neurodegeneration: the molecular pathology of dementia and movement disorders. Wiley. com.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Tauopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">tauopathies</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Tauopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tauopathies are neurodegenerative diseases that are neuropathologically characterized by prominent intracellular accumulations of abnormal filaments of tau protein. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tauopathy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tauopathy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Testing_autonomic_nervous_system</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Testing autonomic nervous system</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tfamtm1Lrsn</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Tfamtm1Lrsn</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Thalamotomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Thalamotomy</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A surgical procedure that creates a LESION (scar) in the THALAMUS to disrupt the nerve signals between the BRAIN and the muscles.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Thalamotomy</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Thalamotomy</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Three-wheeled_walking_stabilizer</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Three-wheeled walking stabilizer</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Tightening_sensation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tightening_sensation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tightening sensation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Tingling_sensation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tingling_sensation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tingling sensation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tnfrsf1atm1Imx</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Tnfrsf1atm1Imx</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Tnfrsf1btm1Imx</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">http://www.informatics.jax.org/</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tnfrsf1btm1Imx</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Tnfrsf1btm1Imx</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Toluene</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Toluene</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Toluene is a solvent that has been shown to cause Parkinson&apos;s Disease, or that has been associated with people with Parkinson&apos;s disease. Toluene is used as an octane booster in fuel, as a solvent in paints, paint thinners, chemical reactions, rubber, printing, adhesives, lacquers, leather tanning, disinfectants, and to produce phenol and TNT (a component of explosives). It is also used as a raw material for toluene di-isocyanate, which is used in the manufacture of polyurethane foams. The precise means of toxicity of toluene is not known.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Toluene</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Toluene</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Toronto_western_spasmodic_torticollis_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Toronto_western_spasmodic_torticollis_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">TWSTRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Toronto_western_spasmodic_torticollis_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It consists of 3 subclasses and is used to assess motor severity, activities of daily living, and pain. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Toronto_western_spasmodic_torticollis_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Toronto western spasmodic torticollis scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Torsion_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Torsion_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Also known as dystonia musculorum deformans, is a disease characterized by painful muscle contractions resulting in uncontrollable distortions.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Torsion_dystonia</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Torsion dystonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Tourette_syndrome_global_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Tourette_syndrome_global_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">TSGS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Tourette_syndrome_global_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is a multidimensional scale of GTS symptoms and social functioning comprising 8 individually rated dimensions.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tourette_syndrome_global_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tourette syndrome global scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Toxin-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Toxin-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s disease induced by toxins</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Toxin-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsonian syndromes induced by other toxins</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Toxin-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">toxin-induced Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Toxin-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to toxins causing damage to the substantia nigra or basal ganglia can potentially result in irreversible parkinsonism. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Toxin-induced_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Toxin-induced parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Toxin_cause_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">1.Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Facts on Files, Inc.
2.Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Toxin_cause_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Poisons, typically chemicals, that can cause illness, injury and disease, a number of which have been considered or implicated as possible causes of Parkinson&apos;s disease.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Toxin_cause_of_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Toxin cause of parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Toxoplasma</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Toxoplasma</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Toxoplasma</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Transcranial_magnetic_stimulation</IRI>
        <Literal datatypeIRI="&xsd;string">Kobayashi, M., &amp; Pascual-Leone, A. (2003). Transcranial magnetic stimulation in neurology. The Lancet Neurology, 2(3), 145-156.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Transcranial_magnetic_stimulation</IRI>
        <Literal datatypeIRI="&xsd;string">The electrical stimulation of neural tissue, including cerebral cortex, spinal roots, and cranial and peripheral nerves.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Transcranial_magnetic_stimulation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Transcranial magnetic stimulation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Transcranial_ultrasound_biomarker</IRI>
        <Literal datatypeIRI="&xsd;string">Michell, A. W., Lewis, S. J. G., Foltynie, T., &amp; Barker, R. A. (2004). Biomarkers and Parkinson&apos;s disease. Brain, 127(8), 1693-1705.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Transcranial_ultrasound_biomarker</IRI>
        <Literal datatypeIRI="&xsd;string">Using a temporal bone acoustic window, it is possible to use ultrasound to determine the echogenicity of the substantia nigra (Becker and Berg, 2001). In Parkinson&apos;s disease this tends to be increased bilaterally, whereas in non-extrapyramidal neurological disorders it is often normal, although in ∼30% of cases this examination could not distinguish these two groups</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Transcranial_ultrasound_biomarker</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Transcranial ultrasound biomarker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Transgenic_Drosohila_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Duty, S., &amp; Jenner, P. (2011). Animal models of Parkinson&apos;s disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology, 164(4), 1357-1391.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Transgenic_Drosohila_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A multicellular model organism with mutations in a number of conserved human genes including those implicated in PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Transgenic_Drosohila_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Drosohila model of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Transgenic_mouse_model_of_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Pfeiffer R.E., Wszolek Z.K., Ebadi M. (2013) Parkinson&apos;s Disease-Second Ed. CRC Press. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Transgenic_mouse_model_of_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">These transgenic models are developed by manipulating genes of interest identified through familial studies of PD or by identification of genes whose potential role in basal ganglia development, dopamine function, or cell death has been hypothesized to participate in PD.   </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Transgenic_mouse_model_of_Parkinsons_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Transgenic mouse model of Parkinsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Treatment_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hely, M. A., Fung, V. S., &amp; Morris, J. G. (2000). Treatment of Parkinson&apos;s disease. Journal of clinical neuroscience, 7(6), 484-494.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Treatment_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">treatment for Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Treatment_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">treatment of early Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Treatment_of_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Amelioration of the symptoms of Parkinson&apos;s disease while seeking to lessen the potential development of late levodopa complications. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Treatment_of_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Treatment of Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tremor is a rhythmic oscillation of at least one functional body region.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tremor</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tremor</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Tremor-predominant_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Facts on Files, Inc.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Tremor-predominant_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tremor-predominant Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Tremor-predominant_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">tremor predominant parkinson&apos;s</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Tremor-predominant_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">tremor-predominant PD</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Tremor-predominant_Parkinson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A presentation of PD in which the primary and obvious symptom is tremor.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tremor-predominant_Parkinson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Tremor predominant Parkinsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Tuberculosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Tuberculosis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Tuberculosis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Turn_hesitation</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Turn hesitation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Turning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley, A. D., Romaine, D. S., &amp; Samii, A. (2010). The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Turning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">changing direction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Turning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Changing direction, or turning, becomes a challenge for many people with Parkinson’s and is a function of movement during which the risk for falling is high. The person with Parkinson’s attempts to accommodate
the loss of these abilities by using small, shuffling steps to move in an arc when changing direction.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Turning</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Turning</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Type_2_diabetes</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., &amp; Tuomilehto, J. (2007). Type 2 diabetes and the risk of Parkinson&apos;s disease. Diabetes care, 30(4), 842-847.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Type_2_diabetes</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">diabetes mellitus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Type_2_diabetes</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Type 2 diabetes is associated with an increased risk of Parkinson&apos;s disease. Surveillance bias might account for higher rates in diabetes. The mechanism behind this association between diabetes and Parkinson&apos;s disease is not known. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Type_2_diabetes</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Type 2 diabetes</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#U-shaped_walking_stabilizer</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">U-shaped walking stabilizer</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Ubiquinone_NADH_oxidoreductase</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ubiquinone_NADH_oxidoreductase</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ubiquinone NADH oxidoreductase</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Ubiquitin</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ubiquitin</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ubiquitin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Ultrasonography</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Ultrasonography</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Ultrasonography</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Unified_Parkinson_s_disease_rating_scale</IRI>
        <Literal datatypeIRI="&xsd;string">Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 79(4), 368-376.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Unified_Parkinson_s_disease_rating_scale</IRI>
        <Literal datatypeIRI="&xsd;string">UPDRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Unified_Parkinson_s_disease_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">UPDRS assessment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Unified_Parkinson_s_disease_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Unified Parkinson&apos;s disease rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Unified_Parkinson_s_disease_rating_scale</IRI>
        <Literal datatypeIRI="&xsd;string">UPDRS is the most well established scale for assessing disability and impairment and is used to track the progression of PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Unified_Parkinson_s_disease_rating_scale</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Unified Parkinsons disease rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Unified_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Unified_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It is intended to address the potential limitations of the F-M scale by subdeviding body regions and separately assessing a duration factor measuring the time dystonia was present during the examination.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Unified_dystonia_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Unified dystonia rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Unified_myoclonus_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Unified_myoclonus_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It assesses myoclonus severity, characteristics, and disability using 73 items.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Unified_myoclonus_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Unified myoclonus rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#University_of_California_Los_Angeles_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#University_of_California_Los_Angeles_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It measures 14 signs and symptoms and seven activities of daily living each on a 0-2 scale. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#University_of_California_Los_Angeles_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">University of California Los Angeles scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Urinary_8-OH-2dG</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Urinary_8-OH-2dG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Urinary 8-OH-2dG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Urine_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Urine_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&xsd;string">In vitro diagnostic bimarkers that can be estimated from urine samples of a PD patient.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Urine_biomarkers_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Urine biomarker of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Vascular_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Anthony Schapira. Parkinson&apos;s Disease. Oxford University Press, 2010</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Vascular_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">cerebral vascular disease and parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Vascular_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">multiinfarct state</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Vascular_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">vascular ischemic parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Vascular_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Acute ischemic infarction of the caudate, putamen, globus pallidus, or brain stem can result in parkinsonism.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Vascular_parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Vascular parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Vesical_sphincter_EMG</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Vesical sphincter EMG</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Visiospatial_and_color_discrimination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Bertrand, J. A., Bedetti, C., Postuma, R. B., Monchi, O., Génier Marchand, D., Jubault, T., &amp; Gagnon, J. F. (2012). Color discrimination deficits in Parkinson&apos;s disease are related to cognitive impairment and white‐matter alterations. Movement Disorders, 27(14), 1781-1788.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Visiospatial_and_color_discrimination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Color discrimination deficit is a common nonmotor manifestation of Parkinson&apos;s disease (PD). However, the pathophysiology of this dysfunction remains poorly understood. Although retinal structure changes found in PD have been suggested to cause color discrimination deficits, the impact of cognitive impairment and cortical alterations remains to be determined.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Visiospatial_and_color_discrimination</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Color discrimination deficit</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Visiospatial_deficit</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Sandyk, R. (1995). Reyersal of a Visuospatial Deficit on the Clock Drawing Test in Parkinson&apos;s Disease by Reatment with Weak Electromagnetic Fields. International Journal of Neuroscience, 82(3-4), 255-268.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Visiospatial_deficit</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Visuospatial dysfunction</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Visiospatial_deficit</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Visuospatial function</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Visiospatial_deficit</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Visuospatial impairment</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Visiospatial_deficit</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Visuospatial memory deficits</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Visiospatial_deficit</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Visuospatial deficits are among the most frequently encountered abnormalities in neuropsychological testing of patients with Parkinson&apos;s disease, being present in up to 90% of cases. Clinically, impairment of visuospatial functions may not be noted by Parkinsonian patients but may contribute to various functional disabilities including frequent falls, difficulties operating a vehicle, ambulating, and dressing. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Visiospatial_deficit</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Visuospatial deficit</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Vitamin_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Etminan, M., Gill, S. S., &amp; Samii, A. (2005). Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson&apos;s disease: a meta-analysis. The Lancet Neurology, 4(6), 362-365.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Vitamin_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dietary folate</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Vitamin_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">dietary vitamin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Vitamin_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">intake of vitamin</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Vitamin_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Dietary vitamin E may have a neuroprotective effect attenuating the risk of PD.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Vitamin_intake</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Vitamin intake</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Walking_difficulty</IRI>
        <Literal datatypeIRI="&xsd;string">Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., ... &amp; Ebadi, M. (2013). Biomarkers in Parkinson’s Disease (Recent Update). Neurochemistry International.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Walking_difficulty</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Walking difficulty</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Wearing-off_questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Kompoliti, K., &amp; Verhagen, L. (2010). Encyclopedia of Movement Disorders (Vol. 1). Academic Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Wearing-off_questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It captures wearing-off symptoms and has three versions.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Wearing-off_questionnaire</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Wearing-off questionnaire</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Webster_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s Disease. Second Edition. Edited by Manuchair Ebadi and Ronald F . Pfeiffer. CRC Press 2013.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Webster_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">The Webster scale scores nine impairment items and one disability item, each on a scale of 0-3, with 3 indicating more severe. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Webster_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Webster scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Well-water_drinking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Priyadarshi, A., Khuder, S. A., Schaub, E. A., &amp; Priyadarshi, S. S. (2001). Environmental risk factors and Parkinson&apos;s disease: a metaanalysis. Environmental research, 86(2), 122-127.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Well-water_drinking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">ground water use</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Well-water_drinking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">well water drinking</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Well-water_drinking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">An increased risk of getting PD in people who drink well water has been found. The risk of PD is assumed to be due to some form of contamination from pesticides, volatile organic compounds, and other chemicals with neurotoxic properties.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Well-water_drinking</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Exposure to well water</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#West_Nile_virus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#West_Nile_virus</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">West Nile virus</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Western_equine_encephalitis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Western_equine_encephalitis</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Western equine encephalitis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Wheeled_walker</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">rollator</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Wheeled_walker</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">roller walker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Wheeled_walker</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Wheeled walker</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Wilson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schapira H.V.A. (2010) parkinson&apos;s Disease. Oxford University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Wilson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Wilson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Wilson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Wilson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Wilson_s_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A rare, autosomal-reccssive inborn error of metabolism presenting in the second and third decades and resulting in deficient biliary excretion of copper. Motor symptoms can include resting or action tremor, dysarthria, slowed saccades, dystonia, rigidity, and bradykinesia. </Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Wilson_s_disease</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">Wilsons disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Writers_cramp_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Writers_cramp_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">WCRS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Writers_cramp_rating_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Writers cramp rating scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#X-linked_dystonia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Schapira H.V.A. (2010) parkinson&apos;s Disease. Oxford University Press.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#X-linked_dystonia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">DYT3</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#X-linked_dystonia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lubag</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#X-linked_dystonia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">XDP</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#X-linked_dystonia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">x-linked dystonia parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#X-linked_dystonia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">x-linked dystonia-parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#X-linked_dystonia_parkinsonism</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Lubag is an X-linked recessive disorder of Filipino males that can present with either parkinsonism or dystonia. Patients initially presenting with dystonia inevitably develop parkinsonism as the disease progresses.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#X-linked_dystonia_parkinsonism</IRI>
        <Literal xml:lang="en" datatypeIRI="&rdf;PlainLiteral">X linked dystonia parkinsonism</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Yale_global_tic_severity_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <IRI>#Yale_global_tic_severity_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">YGTSS</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Yale_global_tic_severity_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">It includes separate rating of severity for motor and phonic tics along five dimensions.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Yale_global_tic_severity_scale</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Yale global tic severity scale</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#Zebrafish_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Duty, S., &amp; Jenner, P. (2011). Animal models of Parkinson&apos;s disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology, 164(4), 1357-1391.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#Zebrafish_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A genetic model of PD made by inactivation or knockdown of a variety of PD-related genes.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Zebrafish_model_of_Parkinson_disease</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Zebrafish model of Parkinson disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <IRI>#n-hexane</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Jankovic, J. J. T. E., &amp; Tolosa. (2007). Parkinson&apos;s disease and movement disorders. E. Tolosa (Ed.). Lippincott Williams &amp; Wilkins.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <IRI>#n-hexane</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">N-hexane, a constituent of solvents has been shown to cause parkinsonism. Most of the n-hexane used in industry is mixed with similar chemicals called solvents. The major use for solvents containing n-hexane is to extract vegetable oils from crops such as soybeans. These solvents are also used as cleaning agents in the printing, textile, furniture, and shoe making industries, and also by chemists. Certain glues used in the roofing, and shoe and leather industries also contain n-hexane. Several consumer products contain n-hexane, such as gasoline, spot removers, quick-drying glues, and also rubber cement.  The means of toxicity of n-hexane is still unknown.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#n-hexane</IRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">n-hexane</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#Reference"/>
        <AbbreviatedIRI>owl:Thing</AbbreviatedIRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Mosley A.D., Romaine D.S. &amp; Samii A. (2010) The Encyclopedia of Parkinson&apos;s Disease. Infobase Publishing.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <AbbreviatedIRI>owl:Thing</AbbreviatedIRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinson&apos;s disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty IRI="#synonyms"/>
        <AbbreviatedIRI>owl:Thing</AbbreviatedIRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsonian syndromes</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <AbbreviatedIRI>owl:Thing</AbbreviatedIRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">A noun that describes a constellation of EXTRAPYRAMIDAL SYMPTOMS that resemble those of Parkinson’s disease but may result from other causes or conditions. These generally result from either Parkinson’s or damage to the same areas of the BRAIN Parkinson’s disease affects.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <AbbreviatedIRI>owl:Thing</AbbreviatedIRI>
        <Literal datatypeIRI="&rdf;PlainLiteral">Parkinsonism</Literal>
    </AnnotationAssertion>
</Ontology>



<!-- Generated by the OWL API (version 3.3.1957) http://owlapi.sourceforge.net -->

